Non-Invasive Venous Thrombus Composition and Therapeutic Response by Multiparametric MRI by Palmer, Olivia
Non-Invasive Venous Thrombus Composition and Therapeutic Response by Multiparametric MRI 
 
by 
 
Olivia Ruth Palmer 
A dissertation submitted in partial fulfillment 
 of the requirements for the degree of  
Doctor of Philosophy  
(Biomedical Engineering) 
in the University of Michigan 
2019 
Doctoral Committee: 
 
Assistant Research Professor José A. Díaz, Co-Chair  
Assistant Professor Joan M. Greve, Co-Chair 
Professor Thomas Chenevert 
Professor J. Brian Fowlkes 
 
 
  
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Olivia Ruth Palmer 
  
opalmer@umich.edu  
  
ORCID iD: 0000-0002-6195-8613 
 
  
  
  
© Olivia Ruth Palmer 2019 
 
 
 ii 
Dedication 
 
To my mother, Dione Palmer, who in every way made this dream possible. And to my 
grandfather, Robert Palmer, who lost his life to complications from deep vein thrombosis just a 
few months before I began my graduate work.    
 iii 
Acknowledgements 
 I would like to express my sincerest gratitude to all those who contributed—scientifically 
and personally—to helping me complete this work. First, I am incredibly grateful to the people 
who helped me believe I could succeed in this program in the first place. My advisor Joan Greve 
saw potential in me when I didn’t think I could reasonably pursue a PhD. With minimal research 
experience and completely disparate research interests ranging from optics and environmental 
engineering to imaging, I was far from an obvious candidate. While I had been told that UM was 
too much of a “reach” school, Joan went out of her way on the visit weekend to make me feel 
that I belonged at Michigan. My friend and physics professor Danielle Berg supported and 
encouraged me through every self-doubt in the decision process. Her pivotal words at that time 
continue to motivate me: “If you’re not scared, then you’re not pushing yourself to reach your 
full potential. People like you and me don’t settle for the comfortable path, and that’s what 
separates a good life from an extraordinary life. Do you have the courage to embrace an 
extraordinary opportunity?” 
 Joan has supported me in every endeavor, from my research ideas to taking time away for 
an industry co-op and many extracurricular activities. I am grateful for her unending enthusiasm, 
genuine care for my wellbeing, and dedication to helping students succeed. I am a better 
communicator and more confident scientist because of her. This work would also not have been 
possible if not for Jose Diaz. Beyond teaching me the art of microsurgery, Jose showed me how 
keep the patient at the heart of basic science research, and perhaps more importantly, how to 
transform challenges and failure into motivation. And of course, Jose’s meticulously polished 
 iv 
PowerPoint presentations inspired my PowerPoint masterpieces that are now visible in several 
journals. His boundless humility and servant leadership inspires a fierce work ethic in his 
students, myself included. I am thankful for his tremendous support and guiding example; I 
would not be the scientist and leader I am today if not for him. I would also like to thank my 
committee members Tom Chenevert and Brian Fowlkes, for their guidance and support 
throughout this process. Their expert questions and feedback have been incredibly valuable in 
the completion of this work.  
 I have been fortunate to mentor and work with several people on this project. This work 
would not have been possible if not for the efforts of Calvin Chiu, Grey Braybrooks, Ulrich 
Scheven, Amos Cao, Paige Castle, Jie Ma, Vijay Vobbilisetty, and Mac Morris. Calvin endured 
the endless frustration of inserting tail veins for the dobutamine studies in my first paper, along 
with helping with many hours of imaging and analysis including work on projects that didn’t 
make it into this dissertation. Grey worked largely independently on the collateral project, 
troubleshooting the meticulous process of building geometric models of small tortuous collateral 
veins and completing all the imaging for the collaterals paper. Uli and Amos developed highly 
valuable tools for data analysis. Beyond being a supportive friend, Paige spent her last month in 
the lab writing the code to apply a Gaussian Mixture Model to my thrombus composition data, 
adapting work that Jie had done using k-means clustering. I was thrilled when Vijay graciously 
took over the unhappy task of cleaning mouse poop off running wheels for my exercise study. 
Vijay also took over most of the imaging in my final exercise studies and spent hours doing 
tedious thrombus boundary tracing on over 150 data sets. Mac hit the ground running, accepting 
my challenge to submit an abstract in his first two weeks. I am incredibly grateful for his 
 v 
willingness to help me tackle a very challenging problem and provide valuable scientific 
contributions to the thrombus classification work.  
 I am grateful to the members of Jose’s lab who taught me all the bench techniques 
required for this research. Maxim Shaydakov patiently taught me the entire q-RT PCR process 
(starting with the basics of pipetting). Josh Rainey took time away from his project to help with 
data collection for Maxim’s and my EIM update paper. Melanie Flaherty walked me through the 
ELISA process, and deeply inspired me with her dedication and passion for basic science 
research. Mel is one of the greatest scientists I’ve ever met, and our brief time working together 
left a lasting impression. Cathy Luke taught me how to do immunohistochemistry and was a 
tremendous help as I worked through staining over 300 slides. 
 At the end of my 3rd year, I took a leap into a completely unfamiliar area and became a 
Technology Transfer Fellow. This 10 hour/week position exposed me to innovations from over 
12 different industries. In the 48 invention disclosures I reviewed, I learned how to quickly get 
up to speed on the technical details in completely new fields, a skill that proved highly valuable 
for future job prospects. I am grateful to my Tech Transfer supervisor, Anne Juggernauth, for 
pushing me outside my comfort zone with projects ranging from chemical engineering to 
autonomous vehicle technology.  
 The Graduate Society of Women Engineers (GradSWE) has offered a backbone of 
support and community throughout my graduate work. I served as Activities Co-Chair, then 
Professional Development Co-Chair, and then Media Officer—roles which connected me to 
many hardworking and talented people along with other great campus organizations and centers. 
I simply would not have made it through the hardest periods of my PhD work without this 
supportive community and many of the friendships that came from it. I am especially grateful to 
 vi 
my lab mate and amazing friend Colleen Crouch. Nothing beats a hard day of research like one 
of our pool breaks, camping trips, or even just a walk around north campus. 
I would like to acknowledge my funding sources – the Rackham Merit Fellowship (RMF) 
and the Graduate Assistance in Areas of National Need fellowship. Through RMF I was able to 
start research the summer before my first semester, which gave me enough traction to be able to 
submit a conference abstract in my very first semester. The RMF community has provided a 
supportive environment and plenty of extremely beneficial write-ins. I also would like to thank 
the Rackham Graduate School for providing financial assistance with attendance to conferences 
in Toronto, Tampa, and Berlin. Additionally, the College of Engineering Co-Curricular Grant 
allowed me to attend a week-long Biotech professional development workshop through the 
American Society for Cell Biology.  
Lastly and most importantly, I would like to thank my extraordinary mother, Dione 
Palmer. My mom made tremendous sacrifices to carve a loving and stable path for me. She never 
pushed education; she supported my unusual path through a performing arts high school, and 
partnered with me in strengthening every essay, project, and presentation. My mom is selfless, 
compassionate, faithful, and full of astounding strength. She is the source of my tenacity, 
enthusiasm, communication skills, financial acumen, writing ability, determination, and so much 
more. This achievement is as much hers as it is my own.  
 vii 
Preface 
 
This dissertation summarizes research that I have conducted over the past five years 
while working in Dr. Joan Greve’s and Dr. José Diaz’s laboratories. Sections of this thesis have 
been previously published and are presented here with some modifications as outlined below. 
Chapter 2 is work that has been previously published as follows: Palmer OR, Chiu CB, 
Cao A, Scheven UM, Diaz JA, Greve JM. In Vivo Characterization of the Murine Venous 
System Before and During Dobutamine Stimulation: Implications for Preclinical Models of 
Venous Disease. Annals of Anatomy, Sept 1, 2017;214:43-52, PMID 28865773.  
Parts of Chapter 3 and Appendix 1 have been adapted from work that has been previously 
published as follows: Diaz JA, Saha P, Cooley B, Palmer OR, Grover SP, Mackman N, 
Wakefield TW, Henke PK, Smith A, Lal BK; Choosing a Mouse Model of Venous Thrombosis: 
A Consensus Assessment of Utility and Application, Dual Publication in Arteriosclerosis 
Thrombosis and Vascular Biology and Journal of Thrombosis and Haemostasis, endorsed by the 
ATVB Council and ISTH. PMID: 30786739. 
Chapter 4 is work that has been previously published as follows: Palmer OR, Shaydakov 
ME, Rainey JP, Lawrence DA, Greve JM, Diaz JA. Update on the Electrolytic IVC Model for 
Pre-Clinical Studies of Venous Thrombosis. Research and Practice in Thrombosis and 
Haemostasis. 2018; 2: 266-273, PMID 30046728.  
Chapter 5 is work that has been submitted for publication as follows: Palmer OR, 
Braybrooks G, Cao A, Diaz JA, Greve JM. Multiple Overlapping Thin Slap Acquisitions Reveal 
 viii 
Collateral Vein Pathways in Mouse Models of Venous Thrombosis Consistent with Humans. 
Journal of Magnetic Resonance Imaging 2019. (Under Review) 
  
 ix 
 
 
 
 
 
Table of Contents 
 
 
Dedication ..................................................................................................................................ii 
Acknowledgements ................................................................................................................... iii 
Preface ...................................................................................................................................... vii 
List of Tables ........................................................................................................................... xiv 
List of Figures ........................................................................................................................... xv 
List of Appendices ................................................................................................................. xxiv 
List of Abbreviations .............................................................................................................. xxv 
Abstract ............................................................................................................................... xxviii 
 Introduction ................................................................................................................ 1 
1.1 Overview of Deep Vein Thrombosis................................................................................ 1 
1.2 Treatment History and Standard Practice ......................................................................... 2 
1.3 Thrombus Composition ................................................................................................... 4 
1.4 Clinical Thrombus Imaging ............................................................................................. 6 
1.5 Preclinical Models of DVT .............................................................................................. 7 
1.6 Thesis Overview.............................................................................................................. 8 
 In Vivo Characterization of the Murine Venous System Before and During 
Dobutamine Stimulation: Implications for Preclinical Models of Venous Disease ..................... 10 
2.1 Abstract ......................................................................................................................... 10 
 x 
2.2 Introduction ................................................................................................................... 11 
2.3 Methods ........................................................................................................................ 13 
2.3.1 Mice ....................................................................................................................... 13 
2.3.2 Magnetic Resonance Imaging ................................................................................. 14 
2.3.3 Dobutamine Administration ................................................................................... 14 
2.3.4 Image Quantification .............................................................................................. 15 
2.3.5 Statistical Analysis ................................................................................................. 16 
2.4 Results .......................................................................................................................... 17 
2.4.1 3D Maximum Intensity Projections Allowed Consistent Slice Planning Orthogonal 
to Veins .................................................................................................................. 17 
2.4.2 Influences of Age and Sex on Vein Area Differ by Location .................................. 18 
2.4.3 Veins Show Minimal Circumferential Deformation Across the Cardiac Cycle........ 20 
2.4.4 Veins Demonstrate Ovular Shapes In Vivo ............................................................. 22 
2.4.5 Dobutamine Has a Small Impact on the Venous System ......................................... 23 
2.4.6 Dobutamine Effect on Cross-Sectional Area ........................................................... 24 
2.4.7 Dobutamine Effect on Maximum Cyclic Strain ...................................................... 25 
2.4.8 Dobutamine Effect on Circularity ........................................................................... 27 
2.5 Discussion ..................................................................................................................... 28 
 Mouse Models of Venous Thrombosis: Research-Based Model-Selection Algorithm 37 
3.1 Common Mouse Models of Venous Thrombosis ........................................................... 37 
3.1.1 Ligature Based IVC Models ................................................................................... 41 
3.1.2 Free Radical Thrombosis Models ........................................................................... 44 
3.1.3 Recurrent Model of Venous Thrombosis ................................................................ 46 
3.1.4 Comparison and Critique of the Models ................................................................. 47 
3.1.5 Choosing a Model Based on the Research Question ............................................... 48 
3.2 Importance of Interrupting Side Branches ...................................................................... 51 
 A Cost-Effective Flexible Pre-Clinical Tool for Studying the Fibrinolytic System in 
Venous Thrombosis: An Update on The Electrolytic IVC Model (EIM).................................... 55 
4.1 Abstract ......................................................................................................................... 55 
4.2 Introduction ................................................................................................................... 56 
4.3 Methods ........................................................................................................................ 57 
 xi 
4.3.1 Mice and EIM Surgical Procedure .......................................................................... 57 
4.3.2 EIM Equipment ...................................................................................................... 59 
4.3.3 Validation and Characterization ............................................................................. 59 
4.3.4 Thrombus Weight .................................................................................................. 60 
4.3.5 Thrombus Volume Assessment by MRI (in vivo) ................................................... 60 
4.3.6 Quantitative Real-Time Polymerase Chain Reaction .............................................. 61 
4.3.7 Immunohistochemistry ........................................................................................... 61 
4.3.8 PAI-1 Activity Assay ............................................................................................. 62 
4.3.9 Statistical Analysis ................................................................................................. 62 
4.4 Results .......................................................................................................................... 63 
4.4.1 Voltage-to-current circuit provides cost-effective system for performing EIM ........ 63 
4.4.2 Thrombus Size in EIM is both Current and Time Dependent .................................. 64 
4.4.3 The Fibrinolytic System is Suppressed in Acute VT ............................................... 65 
4.5 Discussion ..................................................................................................................... 66 
 Collateral Vein Pathways of C57BL/6 Mice: Comparative Analysis with Human 
Anatomy ................................................................................................................................... 72 
5.1 Abstract ......................................................................................................................... 72 
5.2 Introduction ................................................................................................................... 73 
5.3 Materials and Methods .................................................................................................. 75 
5.3.1 MOTSA Optimization ............................................................................................ 75 
5.3.2 Mouse Models........................................................................................................ 76 
5.3.3 MRI ....................................................................................................................... 77 
5.3.4 Statistical Analysis ................................................................................................. 78 
5.4 Results .......................................................................................................................... 78 
5.4.1 Multiple overlapping thin slice acquisition reveals collateral vein pathways ........... 78 
5.4.2 Collateral pattern is influenced by pre-existing vascular anatomy ........................... 83 
5.4.3 Collateral veins correlate with degree of stenosis.................................................... 84 
5.5 Discussion ..................................................................................................................... 85 
 Thrombus Composition by Multiparametric MRI...................................................... 89 
6.1 Introduction ................................................................................................................... 89 
6.2 Study Design ................................................................................................................. 90 
 xii 
6.2.1 Mouse Models........................................................................................................ 90 
6.2.2 Multiparametric MRI Methods ............................................................................... 91 
6.2.3 Histology ............................................................................................................... 92 
6.3 Analysis Methods & Preliminary Findings .................................................................... 93 
6.3.1 Manual Thresholding of MP-MRI .......................................................................... 93 
6.3.2 Unsupervised Classification ................................................................................... 94 
6.4 Results .......................................................................................................................... 98 
6.5 Conclusions ................................................................................................................. 101 
 Effects of Spontaneous Exercise on Murine Model of Venous Thrombosis ............. 102 
7.1 Introduction ................................................................................................................. 102 
7.2 Methods ...................................................................................................................... 103 
7.2.1 Experimental Groups and Spontaneous Exercise .................................................. 103 
7.2.2 Magnetic Resonance Imaging ............................................................................... 104 
7.2.3 Histology and Immunohistochemistry .................................................................. 105 
7.2.4 Circulating Inflammatory Cytokines..................................................................... 105 
7.3 Results ........................................................................................................................ 106 
7.3.1 Exercise Reduces Thrombus Size ......................................................................... 106 
7.3.2 Impact of Exercise on Thrombus Composition ..................................................... 107 
7.3.3 Impact of Exercise on Circulating Inflammatory Cytokines .................................. 111 
7.4 Discussion ................................................................................................................... 112 
 Conclusions ............................................................................................................ 115 
8.1 Scientific Contributions ............................................................................................... 115 
8.1.1 First In Vivo Characterization of the Murine Venous System ................................ 115 
8.1.2 First Model Selection Algorithm .......................................................................... 115 
8.1.3 Improvements to VT Model Surgical Equipment and Characterization ................. 116 
8.1.4 Foundational Methodology for Determining Thrombus Composition ................... 117 
8.1.5 First Basic Science Study of Exercise in VT ......................................................... 117 
8.2 Future Directions ......................................................................................................... 118 
8.3 Translational Potential ................................................................................................. 120 
Appendices…... ...................................................................................................................... 121 
 xiii 
Bibliography ........................................................................................................................... 133 
 xiv 
List of Tables 
 
 
Table 1 Summary of main findings by in vivo MRI investigation of the murine venous system. ­ 
indicates increase, ¯ indicates decrease. .................................................................................... 21 
Table 2 Effects of dobutamine on cyclic strain and circularity. Results are presented as mean ± 
SEM. Bold text indicates values that are significantly (p<0.05) different from baseline. Baseline 
measurements: young male n=15, old male n=15, young female n=10, old female n=10; 
dobutamine measurements n=5 across all groups. ..................................................................... 26 
Table 3 A listing of the Well-Characterized Murine DVT Models, Guidelines for Surgical 
Validation, and Their Advantages and Disadvantages ............................................................... 39 
Table 4 Equipment required and price ranges for the previously described system compared to 
the VIC. Sample product numbers are provided for each component for reference. References: 
VIC – voltage to current converter. ........................................................................................... 63 
 xv 
List of Figures 
 
Figure 1.1 Post thrombotic femoral vein showing intraluminal synechia and thickening of the 
vein wall. Adapted from Perrin 2014 [23]. .................................................................................. 6 
Figure 1.2 DVT composition changes over time, transforming from a jelly-like consistency 
(acute) to a strong scar-like tissue (chronic), which is not responsive to thrombolytic therapies. .. 8 
Figure 2.1 Representative maximum intensity projections (MIPs), axial images, and analyzed 
regions of five locations in the murine venous system. Slice planning (dashed line) is shown over 
coronal and sagittal MIPs. Arrows indicate vein of interest. Arrowheads in axial slices indicate 
corresponding artery. Venous boundaries in the analyzed regions are outlined, with the minimum 
and maximum axes of the vessel demarcated. Typical numbers of voxels across each vessel 
were: jugular=50, suprarenal IVC=62, infrarenal IVC=51, iliac=34, femoral=23. Scale bars in 
axial images represent 3 mm. IVC: Inferior Vena Cava. ............................................................ 18 
Figure 2.2 Average cross-sectional area across the cardiac cycle (mean ± SEM) at five locations 
in the venous system of C57BL/6 mice (left), and area adjusted to individual gram (g) body 
weight (right). Significant age differences denoted by *, and sex differences by †, p<0.05; young 
male n=15, old male n=15, young female n=10, old female n=10. IVC: Inferior Vena Cava. .... 19 
Figure 2.3 Cyclic strain values in the venous system typically remained below 10% across the 
cardiac cycle. (A) Representative data from n=15 young male jugular veins. (B) Maximum 
cyclic strain (mean ± SEM) is plotted at each location. There were no significant sex differences. 
 xvi 
Age differences denoted by *, and location differences by ¥, p<0.05; young male n=15, old male 
n=15, young female n=10, old female n=10. IVC: Inferior Vena Cava. ..................................... 20 
Figure 2.4 (A) Murine veins imaged in vivo tend to have oblong or irregular shapes. (A) 
Representative images from young and old (arrows = vein of interest, filled arrowhead = 
concomitant artery, open arrowhead in infrarenal IVC = artery-vein proximity difference with 
age). (B) Circularity (mean ± SEM), defined as the ratio of the minimum and maximum axes 
lengths of the vein, is plotted for each vessel location. Significant age differences denoted by *, 
and sex differences by †, p<0.05; young male n=15, old male n=15, young female n=10, old 
female n=10. Scale bars in A represent 1 mm. IVC: Inferior Vena Cava. .................................. 23 
Figure 2.5 Representative images of the suprarenal IVC at baseline (A and B-light) and the same 
slice during dobutamine infusion (C and B-dark) from an old male mouse. When the two images 
are superimposed, a slight increase in area and circularity is apparent (B). IVC: Inferior Vena 
Cava. ........................................................................................................................................ 24 
Figure 2.6 Change in area (mean ± SEM) due to dobutamine infusion is plotted for each location 
across age and sex. Significant changes in area under cardiac stress denoted by #, age differences 
in area response to dobutamine denoted by *, location differences in dobutamine response 
denoted by ¥, p<0.05; baseline measurements: n=5 across all groups. IVC: Inferior Vena Cava 25 
Figure 3.1 Choosing a Mouse Model of Venous Thrombosis. Representative schematic overview 
of common mouse models of venous thrombosis....................................................................... 38 
Figure 3.2 Model Selection Algorithm. This flow chart may serve as a starting point for 
considerations in model selection. No single model is adequate to capture the complexity of VT; 
thus, we recommend alternatives and secondary model options below each model. Mouse strain 
and sex should also be considered in model selection, as induction rates are strain dependent in 
 xvii 
stenosis models, and lateral branches draining into the IVC (common in mice from a C57 
background) may not be interrupted in female mice. ................................................................. 50 
Figure 3.3 Thrombus length and volume (measured by MRI) and thrombus weight (IVC + 
thrombus) 2 days following IVC ligation in IB and OB mice. * indicates p<0.05. ..................... 52 
Figure 3.4 Sagittal MRI slices with saturation bands placed to saturate either outflow (veins 
bright) or inflow (outflow bright). Back branches flowing into the IVC prior to thrombus 
induction (A and B) reversed direction 2 days following IVC ligation when branches were left 
uninterrupted (C and D). ........................................................................................................... 53 
Figure 3.5 Schematic representation of blood flow reversal in branching vessels. None of the 
mice in this study had left branches. Four mice had right branches, in which two reversed blood 
flow direction. All mice had two back branches; all distal back branches reversed blood flow 
direction, three of five proximal back branches reversed blood flow direction. .......................... 53 
Figure 4.1 A) Schematic representation of the EIM. Any lateral branches draining into the IVC 
distal to the left renal vein are ligated, and a 250 µA current is applied to a copper wire placed 
within the IVC against the anterior wall. The right lymph node, consistently located near the 
bifurcation, serves as an anatomical reference for placement of the 25-gauge needle containing 
the copper wire. B) Gross anatomy images of the thrombus and vein wall at day 2 harvest; line 
markings denote mm. References: EIM – electrolytic inferior vena cava model, IVC – inferior 
vena cava. ................................................................................................................................. 56 
Figure 4.2 The EIM was developed using a square wave stimulator and constant current unit (C, 
Grass Technologies), both of which are discontinued. Construction of a standard voltage-to-
current converter (VIC) – circuit diagram shown in A and constructed circuit with standard DC 
power supply shown in B – provide a cost-effective alternative. The VIC was validated on the 
 xviii 
benchtop and then in vivo by thrombus weights at days 2, 6, and 11 to the Grass S48 system (n=5 
per group, mean ± SEM, D). References: EIM – electrolytic inferior vena cava model, VIC – 
voltage to current converter, DC – direct current, NS – not statistically significant. ................... 58 
Figure 4.3 A) Contiguous axial MR images were used to quantify thrombus volume. Axial 
sections at the approximate midpoint of the thrombus at day 2 are shown for each group. Blood 
flow is visible surrounding the thrombus in all groups. The IVC is outlined in blue, the thrombus 
in green, and the aorta in red. Schematic representation of the thrombus is shown to the right of 
the MR images to highlight the thrombus size at day 2. B) Modifications to the model 
demonstrate the current and time dependency of thrombus size (n=3 per group, mean ± SEM) in 
the EIM, as measured by MRI. Time points were compared across groups, *p<0.05. References: 
MR(I) – magnetic resonance imaging, IVC – inferior vena cava. .............................................. 64 
Figure 4.4 A) Representative composite longitudinal images of thrombus stained for 
plasminogen at days 2, 6, and 11 post thrombus induction. B) Analysis for positive staining as a 
percentage of total thrombus area. ............................................................................................. 65 
Figure 4.5 Dynamics of fibrinolytic system markers tissue plasminogen activator (t-PA), 
urokinase plasminogen activator (u-PA), and plasminogen activator inhibitor 1 (PAI-1) from the 
vein wall were assessed by qRT-PCR (left axis). Active circulating PAI-1 was assessed by 
ELISA (right axis). Data presented as mean ± SEM. TC – true controls (naïve animals). 
References: TC – true control (surgically naïve mice), qRT-PCR – quantitative real time 
polymerase chain reaction. ........................................................................................................ 66 
Figure 5.1 2D axial slices from single slab 3D-TOF acquisitions the tail artery of a naïve mouse 
were used to optimize repetition time (A) and flip angle (B). Asterisks represent the chosen 
parameter. ................................................................................................................................. 79 
 xix 
Figure 5.2 Representative coronal MIPs from MOTSA of two mice at days 2, 6, 14, and 21 
following A) inferior vena cava ligation (total IVC occlusion) or B) electrolytic induced IVC 
stenosis (partial IVC occlusion). Green arrowheads: superficial epigastric veins; white 
arrowheads: internal epigastric veins; orange arrows: gonadal veins; red arrows: periureteric 
veins. Vertebral veins not visible in coronal images. C) Number of collateral veins over time 
following two models of caval thrombosis. ............................................................................... 80 
Figure 5.3 Schematic representation of the superficial (green), intermediate (purple), and deep 
(dark blue) collateral vein pathways in C57BL/6 mice following inferior vena cava obstruction.
 ................................................................................................................................................. 81 
Figure 5.4 Number of collaterals in each collateral pathway with corresponding MOTSA data, 
inverted color scale for clarity: deep collaterals (A), ascending lumbar veins noted by black 
arrowhead, white arrowhead denoting the rejoining with the IVC through the lumbar vein; 
intermediate collaterals (B) with gonadal (blue arrows) and periureteral (red arrows) veins; and 
superficial collaterals (C) with superficial (green arrowheads) and internal (teal arrows) 
epigastric veins. ........................................................................................................................ 82 
Figure 5.5 Representative coronal MIPs from MOTSA showing collateral vessel patterns in mice 
6 days post thrombus induction grouped by anatomical patterns of branches draining into the 
IVC, which are interrupted during thrombus induction. ............................................................. 83 
Figure 5.6 Representative axial time-of-flight image at baseline (A), saturating arterial flow to 
show venous collaterals (B), and saturating venous flow to show arteries (C). D) Collateral vein 
cross-sectional area from a cross-section taken 6 mm proximal to the iliac bifurcation. * denotes 
difference from the same model at day 6, p<0.05. ..................................................................... 85 
 xx 
Figure 5.7 Collateral cross-sectional area correlates with the degree of vessel occlusion (R2 = 
0.64, p<0.0001). Data is from two models of inferior vena cava thrombosis (partial or total 
occlusion) at days 2, 6, 14, and 21 following thrombus induction. ............................................. 85 
Figure 6.1 A: Representative MR images of the same location. Dotted white line – thrombus; 
solid line – aorta (A). B: Following imaging, mice were harvested, the thrombus was fixed, and 5 
µm sections from 3 blocks were used for histology. .................................................................. 91 
Figure 6.2 A: Contiguous axial slices were acquired using T2* and T2 MRI. Thrombi (dashed 
line), shown adjacent to the aorta (‘A’, solid line) displayed heterogeneity in signal intensity. B 
& C: Representative gross anatomy images for each model are shown in the center. For each 
axial slice along the thrombus, the area of low signal intensity in T2* MRI (left) and high signal 
intensity in T2 MRI (right) was measured by thresholding techniques for both the stasis model 
(B) and the blood flow model (C). Time points were compared using two-way ANOVA, * 
p<0.05. ..................................................................................................................................... 94 
Figure 6.3 Representative T2* and T2 MR images (windowed and leveled individually) used for 
classification in two murine models of venous thrombosis at day 2 post induction. Thrombus – 
green, aorta – white dashed line, scale bar 1 mm. ...................................................................... 96 
Figure 6.4 Akaike information criterion (AIC) parameter search scores for the first 15 clusters to 
reduce the relative information lost in the Gaussian mixture model. The circle indicates good 
options for minimizing AIC without overfitting the model. ....................................................... 97 
Figure 6.5 Schematic representation of GMM workflow. Voxels are classified using a GMM and 
mapped back to the thrombus to form a classified tissue map for each axial slice. 3D stacks of 
2D images for the ligation model at days 2, 6, and 14 are shown at the right. ............................ 98 
 xxi 
Figure 6.6 Representative MP-MRI and resulting GMM with paired MSB histology for each 
time point.................................................................................................................................. 99 
Figure 6.7 Ligation and EIM correlation of GMM with histological staining for RBCs (A, D), 
fibrin (B, E) and collagen (C, F). ............................................................................................. 100 
Figure 6.8 Schematic of treatment options. Currently, the thrombus age is inferred from the 
patient’s recollection of symptom onset. Treatment selection based on thrombus composition 
would reduce the risk to the patient. ........................................................................................ 101 
Figure 7.1 Schematic representation of experimental groups. Exercising mice (EC and EH) had 
continuous access to an in-cage running wheel beginning 2 weeks prior to and continuously 
following VT induction by EIM. Mice with pharmacological intervention (EH and CH) received 
subcutaneous injections of low molecular weight heparin (LMWH). Within each experimental 
group, mice were separated into three time points of interest (day 2, 6, and 14 following VT 
induction, n=5 each). Day 2 and 6 mice were imaged on days 2 and 6, respectively, prior to 
harvest. Day 14 mice were imaged at days 2, 4, 6, 11, and 14 prior to harvest. At harvest, blood 
was collected via exsanguination, and the IVC with surrounding tissue was collected for 
histology. ................................................................................................................................ 104 
Figure 7.2 Average daily exercise activity in 31 mice before and following VT induction. ...... 106 
Figure 7.3 Thrombus volume measured by MRI. AT day 11, thrombus volume was significantly 
reduced with exercise, p<0.05. CC – true control; EC – exercise; CH – low molecular weight 
heparin (LMWH); EH – exercise + LMWH. Day 2, 11, and 14 have n=5 per group; days 2 and 6 
have n=10 per group. .............................................................................................................. 107 
Figure 7.4 Neutrophil content as measured by Ly6g immunohistochemistry (IHC) with 
representative IHC and binary image of positive staining from each group. Binary images are 
 xxii 
enhanced for clarity – positive stain regions appear larger than the true amount. CC – true 
control; EC – exercise; CH – low molecular weight heparin (LMWH); EH – exercise + LMWH. 
* = p<0.05. ............................................................................................................................. 108 
Figure 7.5 Day 2 percent fibrin (A) and red blood cell (B) content as measured from Martius 
Scarlet Blue stain and representative histology images from each group. Fibrin is stained pink, 
RBCs yellow, and collagen blue. CC – true control; EC – exercise; CH – low molecular weight 
heparin (LMWH); EH – exercise + LMWH. * = p<0.05. ........................................................ 109 
Figure 7.6 Day 6 percent fibrin (A) and red blood cell (B) content as measured from Martius 
Scarlet Blue stain and representative histology images from each group. Fibrin is stained pink, 
RBCs yellow, and collagen blue. CC – true control; EC – exercise; CH – low molecular weight 
heparin (LMWH); EH – exercise + LMWH. * = p<0.05. ........................................................ 109 
Figure 7.7 Percent collagen content in thrombus and vein wall (A, D) or thrombus only (C, F) 
with representative histology images from each group (B, E) at days 6 and 14 as measured from 
Masson’s Trichrome stain (collagen = blue). CC – true control; EC – exercise; CH – low 
molecular weight heparin (LMWH); EH – exercise + LMWH. * = p<0.05, *** = p<0.001. .... 110 
Figure 7.8 Fibroblast content as measured by immunohistochemistry (IHC) for FSP-1 at day 6 
(A) and 14 (B) with representative IHC from each group. CC – true control; EC – exercise; CH – 
low molecular weight heparin (LMWH); EH – exercise + LMWH. * = p<0.05, *** = p<0.001.
 ............................................................................................................................................... 111 
Figure 7.9 A) Circulating tumor necrosis factor alpha (TNFα) was elevated with exercise at day 
2, but showed a decreasing trend with exercise at day 6 in both control and LMWH treatment 
groups and the LMWH group at day 14. B) Circulating C reactive protein (CRP) was not 
significantly different between groups at any time point. C) Interleukin-6 (IL-6) was significantly 
 xxiii 
reduced with administration of LMWH but was not significantly different with exercise. CC – 
true control; EC – exercise; CH – low molecular weight heparin (LMWH); EH – exercise + 
LMWH. * = p<0.05. Significance bars only shown comparing exercise group to its treatment 
control group (i.e. CC vs EC and CH vs EH); all other comparisons denoted with asterisk colored 
by group of comparison. ......................................................................................................... 112 
Figure 7.10 Picture of a mouse using the in-cage running wheel. White line shows curvature of 
the spine required to use the wheel, which increases tension on incision site. .......................... 113 
Figure 8.1 An aged mouse (over 1 year old) checking out the in-cage running wheel. Aged mice 
become too large to be able to fit onto an in-cage running wheel. ............................................ 119 
 Figure A.1 Multiple 1 mm contiguous axial slices were acquired to encompass the calf region (A 
and B) using a fast spin-echo sequence. A 180° inversion preparation RF pulse was used to 
highlight fluid accumulation, measured using a threshold of three standard deviations above 
mean muscle signal intensity (C, blue). ………………………………………………………..131 
Figure A.2 Murine calf edema (bar) and total calf volume (line) as measured by MRI before 
surgery, and days 1, 2, 4, 7, and 14 following induction of VT using the IVC ligation model 
(n=5; mean, standard deviation; * denotes differences from pre-surgical volume of p<0.05)…132 
 
 xxiv 
List of Appendices 
 
Appendix 1: Detailed Surgical Procedures .......................................................................... 121 
1.1 Surgical Preparation and Approach.............................................................................. 121 
1.2 Ligation Model ............................................................................................................ 121 
1.3 EIM. ............................................................................................................................ 122 
1.3a Supplies Needed .......................................................................................................... 122 
1.3b Surgical Preparation .................................................................................................... 124 
1.3c Surgical Procedure ...................................................................................................... 124 
Appendix 2: Harvest Procedures......................................................................................... 127 
2.1 Harvest for Histology .................................................................................................. 127 
2.2 Harvest for Thrombus Weight ..................................................................................... 128 
Appendix 3: Note on Leg Edema in Murine Models ........................................................... 130 
 
 xxv 
List of Abbreviations 
In Order of Appearance 
Deep Vein Thrombosis        DVT 
Magnetic Resonance Imaging       MRI 
Pulmonary Embolism         PE 
Post Thrombotic Syndrome        PTS 
Venous Thromboembolism        VTE 
Venous Thrombosis         VT 
Interleukin          IL 
Low Molecular Weight Heparin       LMWH 
Vitamin K Antagonist         VKA 
Catheter Directed Thrombolysis       CDT 
Percutaneous Mechanical Thrombectomy      PMT 
Red Blood Cell         RBC 
Von Willebrand Factor        vWF 
Neutrophil Extracellular Traps       NETs 
Deoxyribose Nucleic Acid        DNA 
Computed Tomography        CT 
Magnetic Resonance Direct Thrombus Imaging     MR-DTI 
Inferior Vena Cava         IVC 
Electrocardiogram         ECG 
 xxvi 
Proportional Integral Derivative       PID 
Standard Error of the Mean        SEM 
Analysis of Variance         ANOVA 
Analysis of Covariance        ANCOVA 
Maximum Intensity Projection       MIP 
Time of Flight          TOF 
Enzyme-Linked Immunosorbent Assay      ELISA 
Ferric Chloride         FeCl3 
Electrolytic IVC Model        EIM 
Thrombus Weight         TW 
Interrupted Branches         IB 
Open Branches         OB 
Plasminogen Activator Inhibitor-1       PAI-1 
Voltage to Current Converter        VIC 
Direct Current          DC 
Polymerase Chain Reaction        PCR 
True Controls          TC 
Diaminobenzidine         DAB 
Tissue Plasminogen Activator       t-PA 
Urokinase Plasminogen Activator       u-PA 
Not Significant         NS 
Pharmacomechanical Catheter Directed Thrombolysis    PCDT 
Multiple Overlapping Thin Slab Acquisition      MOTSA 
 xxvii 
Radiofrequency         RF 
Repetition Time         TR 
Echo Time          TE 
Flip Angle          FA 
Contrast to Noise Ratio        CNR 
Region of Interest         ROI 
Number of Excitations        NEX 
Magnetic Resonance Venography       MRV 
Apparent Diffusion Coefficient       ADC 
Multiparametric MRI         MP-MRI 
Martius Scarlet Blue         MSB 
Gaussian Mixture Model        GMM 
Akaike Information Criterion        AIC 
True Control VT Group        CC 
Exercise Control Group        EC 
Control Heparin Group        CH 
Exercise + Heparin Group        EH 
Tumor Necrosis Factor α        TNFα 
C Reactive Protein         CRP 
 xxviii 
Abstract 
 
Deep vein thrombosis (DVT), or a blood clot in a deep vein (commonly the legs), is 
known as the silent killer—there may be few or no symptoms, yet a section of the thrombus 
could break free and travel to the lungs causing a potentially fatal pulmonary embolism. DVT 
and its complications affect 900,000 people in the U.S. each year, with one third of cases 
resulting in fatality. Anticoagulants (the standard treatment) pose serious bleeding risks and rely 
on the patient’s fibrinolytic system to break up the thrombus, which is often incapable of doing 
so thus leading to post thrombotic syndrome (PTS) in almost 50% of patients. Removing the 
DVT completely via thrombolytic treatments may improve quality of life by reducing PTS. 
However, thrombolysis is only effective on acute thrombi. Impaired success with thrombolytic 
treatment is due to heterogeneity in the thrombus (old clot, which is unable to be broken up, 
intermixed with fresh clot, which can easily be broken up). This problem is largely overlooked 
based on an inability to determine thrombus composition.  
Currently, the only method for determining disease stage is the patient’s recollection of 
when their symptoms began, which is inherently unreliable and could put the patient at risk. 
Further, thrombi of the same chronological age may organize at different rates in different 
people. Magnetic resonance imaging (MRI) has the potential to provide information about 
thrombus composition (clot age), and thus inform patient-specific treatment planning.  
Since there are several limitations to studying DVT in humans, animal models are key 
tools for understanding the disease. Mouse models are the most commonly used, providing a 
unique biological environment to study disease progression and treatment. Any model requires 
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rigorous characterization and standardization to ensure reproducibility between studies. Our first 
objective was to quantify structural and functional changes in the healthy venous system of 
young and aged mice of both sexes, at rest and under conditions which simulate exercise. 
Second, we assessed the endogenous response to two models of DVT mimicking the two 
possible clinical scenarios: total or partial occlusion.  
Following the necessary model characterization, we developed a multiparametric MRI 
approach to probe thrombus composition without the need for contrast agents. Our results show 
imaging correlation with known composition by histology. This method provides a novel 
approach to study thrombus composition, and could eventually be used clinically to provide 
patient-specific treatment planning for DVT.  
Additionally, we investigated the impact of exercise, an emerging therapeutic option, on 
thrombus composition. Using an in-cage running wheel, our results show that spontaneous 
exercise – both alone and in combination with standard treatment – reduces initial thrombus size 
and contributes to thrombus resolution. We found that exercise increases acute fibrin content, 
attenuates local inflammation, and decreases sub-chronic collagen content in pharmacologically 
treated mice.  
 This work provides 1) the first in vivo characterization of the murine venous system in 
health and disease, 2) a foundational methodology to determine thrombus composition by MRI, 
and 3) insights on the impact of exercise on DVT. This research can help DVT investigators 
from the animal model perspective, and provides a step forward in characterizing thrombus 
composition for patient-specific DVT treatment planning.  
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Introduction 
1.1 Overview of Deep Vein Thrombosis 
Deep vein thrombosis (DVT), or a blood clot in a deep vein, is the third most common 
cardiovascular disease. When considering blood clots, most people think of heart attack and 
stroke for their imminent and life-threatening outcomes. Conversely, DVT may have few or no 
symptoms, yet the risk lies in the potential for a portion of the thrombus to break free from its 
origin—perhaps in the femoral vein of the leg or the ilio-caval veins in the abdomen—travel 
through the heart and become lodged in the first small vessels it encounters in the lungs. This 
event is known as a pulmonary embolism (PE), which is fatal in roughly 10% of patients [1]. 
Thus, DVT is sometimes referred to as the “silent killer.” Even in less dire circumstances 
(absence of PE), chronic DVT leads to the post thrombotic syndrome (PTS), characterized by 
severe pain and swelling of the affected leg. This condition can be so uncomfortable that patients 
with PTS have quality of life scores worse than patients living with chronic heart, lung, and 
musculoskeletal conditions [2], [3]. PTS can lead to ulcers and may require amputation. 
DVT and PE are collectively referred to as venous thromboembolism (VTE), which 
affects an estimated 900,000 people in the United States each year [4]. As staggering as this 
number may be, it is likely an underestimate, as the only prevalence data available is from 2005. 
Age and obesity are both risk factors for DVT, and with rapid growth in the aging population and 
an obesity pandemic, the number of people affected by VTE is projected to double by 2050 [4]. 
Even with standard treatment, one third of patients die of complications from DVT, and nearly 
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half develop PTS [4], [5]. Further, DVT recurrence is a huge problem, affecting 10-30% of DVT 
patients in 2-5 years [5].  
1.2 Treatment History and Standard Practice 
Biologically, DVT is a combination of runaway coagulation, sterile inflammation, and a 
suppressed fibrinolytic system. Most treatments target coagulation to slow or stop the 
progression of thrombogenesis, known as anticoagulants. Anti-inflammatory approaches are of 
growing interest but not yet used clinically. Preclinical studies of anti-inflammatory targets have 
shown promise as a potential DVT therapy without bleeding risk; p-selectin inhibition promoted 
thrombus resolution and prevented vein wall fibrosis better than anticoagulants in a baboon 
model [6], and neutralizing interleukin(IL)-6 decreased vein wall intimal thickness and fibrosis 
in a mouse model [7]. Thrombolytic treatments promote fibrinolysis to get rid of the existing 
thrombus. Some drugs such as statins have been shown to have pleiotropic effects; statins have 
been shown to be anti-inflammatory and pro-fibrinolytic. The beneficial role of statins in DVT 
arose in 2009 from the JUPITER trial, where the rate of DVT was significantly smaller in 
patients receiving rosuvastatin therapy versus a placebo control [8]. While statins have shown to 
have prophylactic effects, their potential as a therapeutic remains in question. 
Anticoagulant treatment for at least 6 months is the gold standard of treatment in DVT, 
commonly paired with graduated compression stockings to assist in PTS prevention [9]. 
Anticoagulation typically includes initial heparin or low molecular weight heparin (LMWH) 
followed by a vitamin K antagonist (VKAs) such as warfarin. Heparin’s use in humans began in 
1935, and with its rapid adoption the mortality from PE among symptomatic DVT patients 
dropped from 18% to 0.4% [10]. The development of VKAs, however, came from a very 
different source. In the 1920s, Canadian veterinarians discovered that cattle were bleeding to 
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death after consuming spoiled sweet clover hay, which they termed “sweet clover disease” [11]. 
Further investigations in 1948 uncovered the anticoagulant agent, which Wisconsin researchers 
Karl Link and his student Eugen Wilhelm Schoeffel developed into a rat poison that 
revolutionized the rodenticide field: warfarin. Clinical usefulness had long been suspected, yet 
physicians were wary to use rat poison on patients until 1951, when a marine inductee was 
admitted to the hospital for a failed suicide attempt. The marine had consumed 567 mg of 
warfarin, prompting hemorrhage that was fully treated by Vitamin K administration at the 
hospital. This event prompted warfarin’s development into Coumadin Sodium, and the standard 
treatment pairing was established. 
Despite limited success, the standard treatment of anticoagulants has remained unchanged 
since the 1950s [10]. By targeting the coagulation cascade, anticoagulants stop the progression of 
thrombogenesis, but rely on the body’s natural fibrinolytic system (which is often dysfunctional 
or suppressed in unprovoked DVT) to break up the existing thrombus. Thus, while 
anticoagulants do prevent pulmonary embolism and thrombus progression during administration, 
they fail to prevent PTS [12]. More importantly, anticoagulants carry significant risk of major 
bleeding events, including intracranial hemorrhage. If anticoagulants are contraindicated, vena 
cava filters may be implanted in an attempt to prevent PE, however this does nothing towards 
clearing the DVT or mitigating symptoms in the affected leg. In patients with PTS, stents may be 
placed to promote recanalization in chronically occluded vessels.  
Thrombolytic therapies seek to do what anticoagulants cannot: dissolve the existing 
thrombus. Systemic administration of thrombolytic agents was found to have unacceptably high 
rates of bleeding complications with only mild thrombus clearance [9], thus localized therapy via 
catheter directed thrombolysis (CDT) is more commonly used—alone or in combination with 
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percutaneous mechanical thrombectomy (PMT). Anticoagulant therapy is still used before and 
after thrombolytic treatment. If venous patency remains insufficient (typically <50%) following 
CDT, a stent is placed to open the vessel.  
Although the use of thrombolytic agents for myocardial infarction dates back to the 1950’s 
[13], its use in DVT treatment is complicated. While several small clinical trials have shown 
significantly improved venous patency and reduced PTS in patients treated with thrombolytics 
compared to anticoagulation alone [14], the recent multicenter ATTRACT trial concluded that 
CDT did not reduce PTS or improve quality of life, and worse, increased the risk of major 
bleeding [15]. A primary factor confounding the use of CDT is its indication for acute DVT. 
Two weeks is traditionally thought of as the cut-off for the acute phase, yet CDT trials have 
varied in recruitment cut-off from 10 days to 21 days. This timeline is built from a timeline of 
symptoms reported by the patient, which is inherently unreliable. Would the results of the 
ATTRACT trial proved as dismal if physicians had had a way to verify acute phase by MRI? 
1.3 Thrombus Composition 
The effectiveness of thrombolytic treatment and its indication for acute DVT is directly 
tied to the evolution of thrombus composition. Thrombogenesis is thought to originate in the 
valve pockets or at a site of endothelial damage [16]. DVT is sometimes referred to as a “red 
clot” due to the predominance of red blood cells (RBCs) as opposed to the platelet rich “white” 
arterial clot. RBCs are entrapped by three structures in DVT: fibrin, von Willebrand factor 
(vWF) strands, and neutrophil extracellular traps (NETs).  
Activated endothelial cells release weibel palade bodies containing P-selectin and von 
Willebrand factor (vWF). vWF strands assemble into 3D web-like structures [17] that entrap 
RBCs, and this erythrocyte adhesion is further enhanced under stasis conditions—common in the 
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onset of thrombogenesis [18]. At the same time, the adhesion molecule P-selectin facilitates 
polymorphonuclear neutrophil recruitment. Inflammatory signals then stimulate neutrophil 
apoptosis, launching the release of neutrophil extracellular traps (NETs) and extracellular DNA. 
Extracellular DNA further enhances the coagulation cascade and promotes fibrin formation [19], 
which is concurrently formed by the coagulation cascade. Activated endothelial cells also 
express tissue factor, a potent pro-coagulant molecule involved in the cascade of events leading 
to thrombin production, which activates platelets and converts fibrinogen to fibrin.  
Together, the vWF strands, NETs, and cross-linked fibrin form traps for RBCs. Thus, the 
acute thrombus is an amorphous laminar structure composed of RBCs entrapped in layers of 
fibrin and platelet aggregates. At this stage, the thrombus is a jelly-like consistency, easily 
probed by a guidewire for CDT. Its instability also makes the acute thrombus more likely to 
dislodge or have a section dislodge causing a PE. As the fibrin meshwork assembles, platelet 
aggregates accumulate in a twisted scaffold-like pattern through the brick-and-mortar structure 
of fibrin and RBCs. Moving into the chronic stage, fibrin is gradually replaced by collagen in a 
radially inward remodeling process [20]. With the progression of fibrosis, intraluminal synechia 
develop (Figure 1.1), increasing resistance within the vessel and creating a potentially un-
navigable path for a guidewire. This process can permanently damage the valve leaflets leading 
to dysfunction and reflux. Any attempts at thrombolytic therapy on these chronic segments will 
be unsuccessful and put the patient at increased bleeding risk [21]. Similarly, anticoagulants will 
have no effect, leaving stenting as the only option for recanalization to relieve symptoms.  
To further complicate matters, most thrombi are not cohesively “acute” or “chronic,” but 
rather an intertwined combination of phases, with older thrombus closer to the site of 
thrombogenesis. Additionally, the same chronologically aged thrombus in one patient may have 
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a very different degree of organization compared to another patient, depending on the location 
and patient characteristics [22]. 
 
Figure 1.1 Post thrombotic femoral vein showing intraluminal synechia and thickening of the vein wall. Adapted from Perrin 
2014 [23]. 
1.4 Clinical Thrombus Imaging 
Ultrasound is the standard imaging modality for diagnosing DVT, however currently 
practiced compression ultrasound requires manual compression, making it difficult or impossible 
to perform on vessels above the inguinal ligament, in obese patients (endemic disease in our 
country), in patients with an excess of swelling, pregnant women, and patients in casts or other 
immobilization devices [24].  Ultrasound elastography has shown some preliminary promise in 
discriminating between acute and chronic DVT (thrombi >8 months old have decreased strain 
magnitude and increased echo amplitude compared to thrombi <14 days old) [25], however the 
clinical problem of importance is discerning the transition from acute to chronic, such as a ~10 
day old thrombus from a ~18 day old thrombus. Further, ultrasound approaches are operator 
dependent and are limited in reproducibility [26].   
If ultrasound or contrast venography is inconclusive or contraindicated, computed 
tomography (CT) or MRI may be used. MRI use has mainly been limited to diagnosis in such 
cases. However, the vast information readily attainable by MRI has the potential to provide 
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patient specific information regarding thrombus composition and thus inform treatment 
approaches. Currently in the MRI research setting, thrombus is typically imaged using either fast 
imaging with steady state precession, in which contrast depends on the T2/T1 ratio and the 
thrombus appears dark relative to flowing blood [27], or a T1-weighted fast spoiled gradient 
echo sequence with magnetization preparation known as direct thrombus imaging (MR-DTI), in 
which thrombi rich in methemoglobin appear bright [28]–[31]. MR-DTI may be beneficial in 
avoiding incorrect diagnosis of recurrent VT because chronic (3 and 6 months post diagnosis) 
DVT appears dark whereas fresh thrombi is bright [29], [32]. Beyond these extreme 
acute/chronic ages, however, MR-DTI is incapable of aging the thrombus specifically enough to 
inform treatment planning.  
1.5 Preclinical Models of DVT 
The need for improvement in the standard of care is self-evident, and this impetus requires 
basic science investigations on the evolution of DVT in preclinical models. Unfortunately, there 
are several limitations to studying DVT in humans: thrombogenesis is unpredictable, patients 
become symptomatic when the clot is already several days or weeks old, and the only way to get 
a biopsy of the thrombus-vein wall interface is post mortem or post amputation. Additionally, 
thrombi develop under complex and continually changing flow conditions, making in vitro 
experiments insufficient for a total understanding of VTE. Thus, animal models are key tools for 
investigating this complex disease. Murine models provide a unique biological environment to 
study disease progression and treatment, with the added availability of genetically manipulated 
strains to give insight to molecular pathways.  
 8 
 
Figure 1.2 DVT composition changes over time, transforming from a jelly-like consistency (acute) to a strong scar-like tissue 
(chronic), which is not responsive to thrombolytic therapies. 
1.6 Thesis Overview 
Developing methods to assess thrombus composition and treatment response by MRI 
begins with understanding the preclinical venous system under both healthy conditions and the 
two possible disease scenarios of DVT: total or partial occlusion. Most studies prior to this work 
were focused on ex vivo characterization. Our limited understanding of venous biology 
emphasizes the need to first understand the healthy state to provide a foundation for investigating 
developing pathology. Thus, my first objective was to quantify structural and functional changes 
in the healthy venous system of young and aged mice of both sexes, at rest and under conditions 
which simulate exercise (Chapter 2). Understanding the healthy state of the animal model 
provides the foundation for investigating DVT in mice.  
Following the first in vivo characterization of the murine venous system, my second 
objective was to uncover the best practices in the mouse models of venous thrombosis given 
some of the controversies and problems in the field. Towards this aim, I developed the first 
model selection algorithm as a tool for researchers and reviewers to select the most appropriate 
primary and secondary VT model depending on the research question at hand (Chapter 3). 
Importantly, using MRI techniques I proved the hypothesis that thrombus size variability if 
branching vessels are left uninterrupted is due to blood flow reversal (Section 3.2). Additionally, 
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on discovering that the original equipment used in the only true blood flow model of VT had 
been discontinued, I developed an equipment alternative that reduced costs by 90% and provided 
a critical update on this model to the field (Chapter 4). Vascular obstruction prompts 
venogenesis, an understudied phenomenon that had previously been noted in animal models. 
However, the relevance of the most common preclinical model to the human condition was 
unclear. Thus, I performed a comparative analysis of collateral vein pathways between mice and 
humans in two mouse models of VT, demonstrating for the first time that mice develop collateral 
pathways consistent with humans (Chapter 5). 
The thorough characterization of the healthy murine venous system, best practices in 
various VT models, and understanding of the endogenous response to VT provided the necessary 
foundation to develop imaging methods to advance the treatment paradigm in DVT. My third 
objective was to develop MRI methods to non-invasively reveal thrombus composition, and thus 
inform patient-specific treatment planning (Chapter 6). This work showed that multiparametric 
MRI can discern heterogeneities within the thrombus and thus characterize composition changes 
both along the thrombus and over time.  
Non-invasive determination of thrombus composition provides a platform to investigate 
how composition changes in response to different therapeutics. Specifically, we were interested 
in looking at the systemic effects of exercise and its interactions with the current standard 
pharmacological therapeutic (LMWH). Thus, my fourth objective was to determine whether 
exercise – alone and coupled with the standard treatment of anticoagulants – correlates to 
changes in thrombus composition and resolution (Chapter 7).  
 10 
 
In Vivo Characterization of the Murine Venous System Before and During Dobutamine 
Stimulation: Implications for Preclinical Models of Venous Disease 
2.1 Abstract 
Although widely used as a preclinical model for studying venous diseases, there is a 
scarcity of in vivo characterization of the naïve murine venous system. Additionally, previous 
studies on naïve veins (ex vivo) have not included the influence of surrounding structures and 
biomechanical forces. Using MRI, we noninvasively quantified the cross-sectional area, cyclic 
strain, and circularity of the venous system in young and old, male and female C57BL/6 mice. 
We investigated the most common venous locations used to perform venous disease research: the 
common jugular vein, suprarenal inferior vena cava (IVC), infrarenal IVC, common iliac vein, 
and common femoral vein. Our results elucidate age-dependent changes in venous cross-
sectional area, which varied by location. Maximum cyclic strain, a parameter of lumen 
expansion, showed 10% change across the cardiac cycle, approximately half the magnitude of 
arteries. Veins demonstrated noncircular shapes, particularly in the core vasculature. The 
cardiovascular stressor dobutamine had only a small impact on the venous system. Also, our data 
demonstrate that the peripheral veins tend to decrease in cross-sectional area and circularity with 
age. Conversely, the IVC tends to increase in size and circularity with age, with males exhibiting 
larger variability in response to dobutamine compared to females. This work provides a 
foundation for drawing age and sex comparisons in disease models, and represents the first in 
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vivo characterization of the murine venous system at rest and during the application of a 
pharmacological exercise surrogate. 
2.2 Introduction 
Venous diseases have been designated a national priority by the Surgeon General (Leavitt, 
2008) and the Center for Disease Control [33]. The troubling statistics on the prevalence of 
venous disease and data suggesting sub-optimal treatment [34]–[36] emphasize the critical need 
for a more comprehensive understanding of the venous system, including the geometric and 
biomechanical characteristics of veins in the animal models so commonly used to investigate 
disease progression and therapeutic options. While the arterial system has been well studied in 
health and disease [37], [38], there are far fewer studies regarding venous disease, including a 
paucity of in vivo investigations of the healthy venous system of murine models. 
Blood volume, flow, and pressure dictate vessel shape, in conjunction with vessel wall 
contents. As such, abnormal vein shape can be indicative of an underlying pathology in the vein 
lumen, such as thrombosis, or an extraluminal structure deforming a vein, such as a tumor [39]–
[41]. Alterations in geometry can lead to changes in biomechanical forces, which play a primary 
role in the location, initiation, and progression of cardiovascular disease [42]. Thus, 
understanding the geometry and biomechanics of the healthy venous system establishes the 
baseline for investigating disease, enabling better interpretation of research results.  
Most geometric and biomechanical investigations of the venous system have acquired 
data ex vivo [20], [43]–[45]. Such experiments provide valuable information on material 
properties and the stress-strain response of the vessel wall. However, ex vivo studies are 
inherently limited to a single time-point and subject to misinterpretations. Non-physiological 
pressures coupled with a lack of blood flow, external tethering from surrounding anatomical 
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structures, and circumferential and axial stresses—all of which influence vessel structure and 
function—may alter results. While many intuit the relatively motionless nature of veins 
compared to arteries, ex vivo testing may confound some perspectives on the actual motion of 
veins in vivo, potentially compromising research on the venous system. There is little to no data 
quantifying cyclic strain of the venous system in humans or the preclinical models often used as 
surrogates. 
Murine models are the most commonly used preclinical model for investigating venous 
diseases. Mice provide a unique biological environment to study disease progression and 
treatment in a highly controlled manner, with the added availability of genetically manipulated 
strains to uncover molecular pathways. Recently, the NIH has addressed concerns over lack of 
sex diversity in preclinical experiments [46]. In addition, some venous diseases disproportionally 
affect the older population [4], [47], [48]. Thus, it is imperative to understand the naïve venous 
system that considers age and sex differences, as outlined in this work.  
Dobutamine is a β1-receptor agonist that increases cardiac output. As such, it is used 
clinically in the treatment of acute heart failure and as one of the most widely available 
pharmacological stress testing agents [49], [50]. Pharmacologically induced stress testing is used 
to diagnose cardiovascular disease in patients presenting with the inability to complete a 
treadmill test. Preclinically, dobutamine has been used in a similar manner [51], [52] and to 
reveal subtle phenotypic differences in conditional knockout mice [53]. The high field magnetic 
resonance imaging (MRI) used in this work allowed us to non-invasively characterize murine 
vasculature in both baseline and physiologically stressed conditions in vivo, with high spatial and 
temporal resolution.  
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Herein, we present in vivo quantification of the healthy venous system of murine models 
in the most common veins used to perform venous disease research: the common jugular vein, 
suprarenal inferior vena cava (IVC), infrarenal IVC, common iliac vein, and common femoral 
vein. Using MRI, we analyzed cross-sectional area, cyclic strain, and vessel circularity across 
age and sex. Additionally, we administered the cardiac stressor dobutamine to evaluate the 
venous response. These novel data provide foundational knowledge in the characterization of the 
naïve murine venous system. 
2.3 Methods 
All experiments were performed at the University of Michigan with approval from the 
University of Michigan’s animal care and use committee. 
2.3.1 Mice 
Adult male and female C57BL/6 mice aged either 3-4 months or 15-18 months were used 
in this study. These ages are the human equivalent of a young adult or adult over the age of 50, 
respectively [54]. Data was acquired in 50 mice: n=15 young males, n=15 old males, n=10 
young females, and n=10 old females; within this cohort, dobutamine was administered in n=5 
mice per group. For imaging procedures, mice were anesthetized using 2% isoflurane, 1 L/min 
O2 carrier gas. Heart rate and respiration were monitored with ECG electrodes and a respiratory 
pillow, respectively (SA Instruments, Inc., NY). A PID controller was used to maintain the 
animal’s temperature at 37±1ºC via warm air circulation through the bore of the magnet. Mean 
total imaging time was 1.5 hours, or 2.5 hours when administering dobutamine (approximately 1 
hour with dobutamine). 
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2.3.2 Magnetic Resonance Imaging 
Imaging was performed on a 7 Tesla horizontal bore magnet using a Direct Drive console 
(Agilent Technologies, Santa Clara, CA). All animals were imaged supine with the legs taped 
into an extended position. 3D time-of-flight (TOF) gradient echo sequences were used to acquire 
volumes at each of five locations: common jugular, suprarenal IVC, infrarenal IVC, iliac vein, 
and femoral vein (repetition time/echo time [TR/TE] 20/2 ms, field of view [FOV] 30 x 30 x 30 
mm, flip angle [α] 20º, matrix 128 x 64 x 64 zero-filled to 256 x 128 x 128, number of 
excitations [NEX] 2, slab thickness 12 mm, imaging time 3 minutes). Coronal and sagittal 
maximum intensity projections (MIPs) of the venograms were used to plan cardiac-gated 2D 
TOF slices perpendicular to each vessel location (TR equal to the period of the cardiac cycle—
approximately 180 ms, TE 6 ms, FOV (25.6 mm)2, α 30º, matrix 512 x 256 zero-filled to 5122, 
resolution 50 x 50 µm, slice thickness 1 mm, NEX 6, imaging time 6 minutes per location). 
These parameters resulted in approximately 25 voxels across the jugular vein, 31 across the 
suprarenal IVC, 25 across the infrarenal IVC, 17 across the iliac, and 12 across the femoral vein. 
The imaging parameters were chosen to enhance signal in moving blood, while maintaining a 
flip angle adequate to prevent saturation of the slower venous blood flow at the edge of the 
vessel. Twelve CINE frames were acquired across the cardiac cycle to quantify lumen expansion 
for each location. 
2.3.3 Dobutamine Administration 
In a subset of n=20 mice (5 of each sex and age group), a 30-gauge needle connected to a 
polyethylene catheter (PE10; Braintree Scientific) initially filled with saline was inserted into the 
tail vein for dobutamine infusion. Dobutamine infusion was initiated following acquisition of 
baseline (i.e. resting heart rate) CINE images at each of the five locations. A dosage of 40 µg/kg 
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of body weight was infused by the tail vein catheter at a rate of 2 µL/min. Once the increased 
heart rate reached a steady state, CINE images were acquired using the same slice planning as 
the baseline acquisitions. 
2.3.4 Image Quantification 
Each of the five locations was analyzed for cross-sectional area, cyclic strain, and 
circularity using a semi-automated in-house MATLAB script. The k-space data acquired at 512 x 
256 and zero-filled to 512 x 512 points in the frequency and phase encode direction were 
multiplied by a broad Gaussian weighting function to produce slight image blurring with a k-
space attenuation chosen to have a root mean squares width of 0.8 voxels (voxel = three-
dimensional pixel). This blurring step served to reduce random noise at a small cost of spatial 
resolution, due to the sub-voxel spatial width of our filter. The filtered data was then Fourier 
transformed, and the blurred image was up-sampled to obtain an image with 1024 x 1024 voxels 
for improved threshold searches. The added up-sampling step (implemented in MATLAB using 
2D interpolation of the image) introduces information about the local derivative of voxel 
intensities at a vessel boundary, to better constrain the spatial location of a point identified to be 
on the vessel boundary by the thresholding algorithm.  
To produce a reference image at a given vessel location, the 12 images acquired over the 
cardiac cycle were averaged. Then, a region of interest containing the vessel was defined and the 
voxel of maximum signal intensity was identified, allowing for 50% of the maximum signal 
intensity within the ROI to be used as a cutoff threshold in that frame. Starting at the maximum 
intensity voxel, an iterative radial search, subject to the thresholding condition, was used to find 
a connected patch of voxels surrounding the brightest voxel. The patch of voxels delineated the 
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mean vessel shape. We then averaged the intensity of the patch, thus defining a reference 
intensity for the subsequent frame-by-frame analysis.  
Each CINE frame was then examined individually, again using a 50% thresholding 
criterion to find the vessel, its center, and the coordinates of the voxels lying on the edge of the 
vessel—used to calculate vessel perimeter. The boundary coordinates were transformed to polar 
coordinates, taking the center found for the time-averaged image as our polar origin. Finally, the 
boundary data were fitted to the first 8 terms of a Fourier series, and the fit was used to calculate 
the area and center coordinates of the vessel by polar integration for each frame.  
Green-Lagrange circumferential cyclic strain waveforms were calculated using 
𝜀" = 12 &' 𝑃"𝑃)"*+,- − 1/ × 100%	𝑤𝑖𝑡ℎ	𝑖 → 1 − 12																																												(1)	
where Pi is the perimeter at a given frame in the cardiac cycle (i varying between 1 and 12), and 
Pdias is the minimum perimeter of the vessel across the cardiac cycle. It is worth noting that the 
Green-Lagrange circumferential strain measures changes in area, provided the vessel's expansion 
preserves its shape. In this case, a cyclic strain value of 50% corresponds to a doubling cross-
sectional area. Circularity of the vessel was measured as a ratio of the average minimum and 
maximum axes lengths of the vessel across the cardiac cycle.  
2.3.5 Statistical Analysis 
All data are plotted as mean ± standard error (SEM). For location differences, groups were 
treated as categorical and repeated measures one-way ANOVA with Tukey’s post hoc test was 
used to determine differences between locations. ANCOVA was used for comparisons between 
linear regression fits on cross-sectional area of veins distal to the heart. To determine group 
effects (age and sex) for baseline measurements and the effects of dobutamine, linear mixed 
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effects modeling was used, accounting for the random effects of two separate imagers (ORP and 
CBC) and repeated measurements in the same subjects following dobutamine administration. An 
interaction term between group and treatment (dobutamine) was used to determine whether the 
response in treatment differed between groups. For mixed effects modeling, locations were 
viewed as independent and modeled separately. Significance was set at p<0.05. Data were 
analyzed using R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria) and 
GraphPad Prism version 7.0 (GraphPad Software, La Jolla, CA).   
2.4 Results 
2.4.1 3D Maximum Intensity Projections Allowed Consistent Slice Planning Orthogonal 
to Veins 
Coronal and sagittal maximum intensity projections (MIPs) from 3D gradient echo 
sequences using a 12 mm slab enabled consistent slice placement perpendicular to each vessel 
location in all mice (Figure 2.1). We were able to place the gated CINE TOF acquisitions based 
on anatomical markers, such as the renal veins and the iliac bifurcation. In locations where the 
corresponding artery was closely juxtaposed to the vein (infrarenal IVC, iliac, and femoral 
locations), we defined the vessel boundary by manually adjusting the boundaries produced by the 
thresholding technique. 
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2.4.2 Influences of Age and Sex on Vein Area Differ by Location 
For age comparisons, means were adjusted for sex (µS); for sex comparisons means were 
adjusted for age (µA); and for location comparisons, means were adjusted for sex and age (µSA). 
Average body weights increased with age (µS: 24.2±0.4 young vs. 38.1±1.3 old, p<0.001) and 
were greater in young males compared to young females (25.8±0.4 g young male vs. 22.0±0.6 g 
young female, p<0.001). Old males were heavier on average than old females, but the weight 
Coronal MIPs Sagittal MIPs
Jugular
Vein
Suprarenal
IVC
Infrarenal
IVC
Iliac
Vein
Femoral
Vein
Axial Images Analyzed Region
Figure 2.1 Representative maximum intensity projections (MIPs), axial images, and analyzed regions of five locations in the 
murine venous system. Slice planning (dashed line) is shown over coronal and sagittal MIPs. Arrows indicate vein of interest. 
Arrowheads in axial slices indicate corresponding artery. Venous boundaries in the analyzed regions are outlined, with the 
minimum and maximum axes of the vessel demarcated. Typical numbers of voxels across each vessel were: jugular=50, 
suprarenal IVC=62, infrarenal IVC=51, iliac=34, femoral=23. Scale bars in axial images represent 3 mm. IVC: Inferior Vena 
Cava. 
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difference was not statistically significant for our sample size of 25 old mice (39.6±1.3 old male 
vs. 35.8±1.4 old female).  
 
Figure 2.2 Average cross-sectional area across the cardiac cycle (mean ± SEM) at five locations in the venous system of 
C57BL/6 mice (left), and area adjusted to individual gram (g) body weight (right). Significant age differences denoted by *, and 
sex differences by †, p<0.05; young male n=15, old male n=15, young female n=10, old female n=10. IVC: Inferior Vena Cava. 
 
Figure 2.2 shows the average cross-sectional area across the cardiac cycle (left) and the 
same area adjusted for body weight (right) at five locations for the four groups studied. Results 
are summarized in Table 1. The area of the suprarenal IVC increased with age (µS: 1.7±0.1 mm2 
young vs. 2.1±0.1 mm2 old, p<0.001) and was larger in males (µA: 2.1±0.1 mm2 male vs. 
1.6±0.10 mm2 female, p<0.001). Conversely, the area of the femoral vein decreased with age 
(µS: 0.28±0.02 mm2 young vs. 0.21±0.02 mm2 old, p<0.001). Cross-sectional area of the veins 
differed significantly along the vascular network (Table 1). Area, when plotted as a function of 
distance from the heart, decreases linearly from the suprarenal IVC to the femoral vein, with 
larger negative slopes in aged animals (slopes, R2 values: male—young -0.052±0.003, 0.85 vs. 
old -0.067±0.004, 0.83, p<0.001; female—young -0.033±0.002, 0.80 vs. old -0.043±0.002, 0.90, 
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p<0.001). When linear regression of area was performed on individual animals, 10/15 young 
male, 5/15 old male, 5/10 young female, and 9/10 old female mice had slopes significantly 
different from zero. When adjusting for body weight, the average vessel area per gram of body 
weight decreased with age at every location, and the suprarenal IVC was larger in males. 
2.4.3 Veins Show Minimal Circumferential Deformation Across the Cardiac Cycle 
 
Figure 2.3 Cyclic strain values in the venous system typically remained below 10% across the cardiac cycle. (A) Representative 
data from n=15 young male jugular veins. (B) Maximum cyclic strain (mean ± SEM) is plotted at each location. There were no 
significant sex differences. Age differences denoted by *, and location differences by ¥, p<0.05; young male n=15, old male 
n=15, young female n=10, old female n=10. IVC: Inferior Vena Cava. 
The veins showed little circumferential lumen expansion across the cardiac cycle, as 
represented in Figure 2.3A by young male jugular cyclic strain. As shown in Figure 2.3B, the 
maximum cyclic strain across the cardiac cycle remained below 10% with the exception of 
young females in the infrarenal IVC location (11.6±1.8%), and old males and young females in 
the femoral location (11.6±1.2% and 10.0±1.1%, respectively). Even so, in the suprarenal IVC 
location, max strain had a marginally significant decrease with age (µS: 8.5±0.8% young vs. 
7.3±0.7 old, p=0.05). In the infrarenal IVC location, max strain was marginally smaller in males 
(µA: 6.6±0.8% male vs. 8.4±1.3% female, p=0.06) and decreased with age (µS: 8.9±1.1% young 
vs. 5.5±0.9% old, p<0.01). The iliac veins also had marginally decreased max strain with age 
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(µS: 9.1±0.8% young vs. 7.7±0.6% old, p=0.06). Location comparisons and the influence of age 
and sex on maximum cyclic strain are summarized in Table 1.  
Table 1 Summary of main findings by in vivo MRI investigation of the murine venous system. ­ indicates increase, ¯ indicates 
decrease. 
AVERAGE AREA MAXIMUM STRAIN CIRCULARITY 
Locations: 
• Veins > arteries 
• Suprarenal IVC > all 
locations 
• Jugular ≈ Infrarenal IVC > 
iliac, femoral 
• Iliac > femoral 
 
Sex and Age: 
• Suprarenal IVC ↑ with age, 
male > female 
• Femoral ↓ with age 
• Supra IVC to femoral ↓ 
linearly for all groups, > 
linear ↓ with age  
• Normalized to body weight, 
all locations ↓ with age 
 
With dobutamine: 
• Small ↑, in general 
• % ↑ same across locations 
• Iliac greater ↑ due to age 
Locations: 
• Veins < arteries 
• Jugular < suprarenal IVC, 
iliac, femoral  
• Infrarenal IVC < femoral 
 
 
 
Sex and Age: 
• Suprarenal IVC marginal ↓ 
with age (p=0.05) 
• Infrarenal IVC marginal ↓ 
with age 
• Iliac marginal ↓ due to age 
 
 
 
 
With dobutamine: 
• Small ↑, in general (13/16 
measurements) 
• Young male suprarenal 
IVC ↑ 
• Jugular < suprarenal IVC, 
femoral  
• No effects of age, sex, 
location 
Locations: 
• Veins < arteries 
• Jugular most circular 
• Suprarenal, Infrarenal IVC 
least circular 
• Iliac ≈ femoral > 
suprarenal, infrarenal IVC 
 
Sex and Age: 
• Suprarenal IVC marginal ↑ 
with age (p=0.07) 
• Infrarenal IVC ↑ with age 
• Iliac and femoral ↓ with 
age 
• Femoral: female > male 
 
 
 
With dobutamine: 
• Jugular, Infrarenal IVC 
↓ trend (p=NS)  
• Infrarenal IVC in 
young males ↓ 
• Femoral ↑ trend 
(p=NS) 
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2.4.4 Veins Demonstrate Ovular Shapes In Vivo 
Circularity, as calculated from the ratio of minimum to maximum axes lengths of the 
vein, revealed differences across age and sex, as shown in Figure 2.4. The suprarenal IVC 
became slightly more circular with age, although this change did not reach statistical significance 
(µS: 0.61±0.04 young vs. 0.66±0.03 old, p=0.07), and the infrarenal IVC became more circular 
with age (µS: 0.57±0.04 young vs. 0.68±0.03 old, p<0.01). Conversely, the iliac and femoral 
locations were less circular in old mice (µA: 0.76±0.02 young vs. 0.69±0.04 old, p<0.05; 
0.79±0.02 young vs. 0.74±0.03 old, p=0.05, respectively), with female mice having more 
circular femoral veins compared to males (0.74±0.02 male vs. 0.80±0.02 female, p<0.05).  
Circularity varied by location. The jugular vein was the most circular, with circularity 
values significantly greater than all other veins studied (µSA: 0.86±0.02 jugular vs. 0.62±0.04 
infrarenal IVC, 0.63±0.04 suprarenal IVC, 0.73±0.03 iliac, 0.76±0.02 femoral, p<0.0001 
compared to each location). The suprarenal and infrarenal IVC locations were the least circular, 
and were not significantly different in circularity (0.62±0.02 and 0.63±0.02, respectively, p=NS). 
Circularity results are summarized in Table 1. 
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Figure 2.4 (A) Murine veins imaged in vivo tend to have oblong or irregular shapes. (A) Representative images from young and 
old (arrows = vein of interest, filled arrowhead = concomitant artery, open arrowhead in infrarenal IVC = artery-vein proximity 
difference with age). (B) Circularity (mean ± SEM), defined as the ratio of the minimum and maximum axes lengths of the vein, 
is plotted for each vessel location. Significant age differences denoted by *, and sex differences by †, p<0.05; young male n=15, 
old male n=15, young female n=10, old female n=10. Scale bars in A represent 1 mm. IVC: Inferior Vena Cava. 
2.4.5 Dobutamine Has a Small Impact on the Venous System  
Dobutamine infusion resulted in a 17±0.02% increase in heart rate (from resting heart 
rate of 508±43 to 591±15 beats per minute during dobutamine infusion, p<0.0001). There were 
no significant differences in heart rate increase between age and sex groups. The total infusion 
volume accounted for an average of 4.0±0.003% total blood volume (76.8±5.8 µL, assuming 
58.5 mL blood/kg mouse body weight (National Centre for the Replacement Refinement & 
Reduction of Animals in Research, n.d.)). Figure 2.5 shows a representative image of the 
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suprarenal IVC of an old male mouse, with the same slice acquired at baseline (Figure 2.5A) and 
following an increase in heart rate stimulated by dobutamine infusion (Figure 2.5C). The overlay 
of the two vessel segmentations illustrates a small increase in size during the second acquisition 
(Figure 2.5B).  
 
Figure 2.5 Representative images of the suprarenal IVC at baseline (A and B-light) and the same slice during dobutamine 
infusion (C and B-dark) from an old male mouse. When the two images are superimposed, a slight increase in area and circularity 
is apparent (B). IVC: Inferior Vena Cava. 
2.4.6 Dobutamine Effect on Cross-Sectional Area 
The change in area during dobutamine infusion, plotted in Figure 2.6, shows area 
increased during dobutamine-induced cardiac stress in all vessels except for young female 
infrarenal IVC and iliac, and young male femoral veins, which each had either zero or slightly 
negative change in area (a change of ≤ 20 voxels [voxel = three-dimensional pixel]). Significant 
increases in area due to administration of dobutamine were observed in old male jugular veins 
(change in area of 0.19±0.05 mm2 or 76 voxels, p<0.05), old female suprarenal IVCs (change in 
area of 0.31±0.10 mm2 or 124 voxels, p<0.05), and old female infrarenal IVCs (0.19±0.10 mm2 
or 76 voxels, p<0.05). In the iliac vein, the increase in vessel area was greater with age (µS: 
increase of 0.01±0.03 mm2 young [4 voxels] vs. 0.07±0.04 mm2 old [28 voxels], p<0.05), 
Baseline Dobutamine
A B C
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however this age effect was driven by female mice. Comparing across locations, the largest 
increase in vessel area was observed in the largest vessel, the suprarenal IVC, although across 
groups the dobutamine-driven increase in area of the suprarenal IVC was not statistically 
different from any other location. The change in area due to dobutamine in the jugular vein was 
larger than that in the femoral vein (µSA: 0.14±0.06 mm2 jugular vs. 0.02±0.01 mm2 femoral, 
p<0.05). Percentage-wise, however, increases in area due to dobutamine infusion were similar 
across vein locations (µSA: jugular 15±6%, suprarenal IVC 17±14%, infrarenal IVC 10±6%, iliac 
9±7%, femoral 9±6%, p=NS across all location comparisons). The effects of dobutamine on 
average area are summarized in Table 1. 
 
Figure 2.6 Change in area (mean ± SEM) due to dobutamine infusion is plotted for each location across age and sex. Significant 
changes in area under cardiac stress denoted by #, age differences in area response to dobutamine denoted by *, location 
differences in dobutamine response denoted by ¥, p<0.05; baseline measurements: n=5 across all groups. IVC: Inferior Vena 
Cava 
2.4.7 Dobutamine Effect on Maximum Cyclic Strain 
As shown in Table 2, maximum cyclic strain tended to increase slightly during 
dobutamine infusion (13 out of 16 measurements), but this increase was only significant in the 
suprarenal IVC location of young males (8.3±0.6% baseline vs. 11.6±1.1% dobutamine, 
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p<0.05). Neither age nor sex nor vessel location had significant effects on the response to 
dobutamine as measured by the change in maximum cyclic strain. Similar relationships remained 
between locations during dobtuamine infusion, with max strain in the jugular vein significantly 
smaller than that in the suprarenal IVC and femoral vein (µSA: jugular 6.6±1.2% vs. suprarenal 
IVC 9.9±1.3%, p<0.01, femoral 9.6±1.6%, p<0.05). Max strain values in the suprarenal IVC, 
infrarenal IVC, iliac, and femoral locations were not significantly different during dobutamine 
infusion. 
Table 2 Effects of dobutamine on cyclic strain and circularity. Results are presented as mean ± SEM. Bold text indicates 
values that are significantly (p<0.05) different from baseline. Baseline measurements: young male n=15, old male n=15, young 
female n=10, old female n=10; dobutamine measurements n=5 across all groups. 
 Maximum Cyclic Strain Circularity 
Location Group Baseline (%) Dobutamine (%) Baseline Dobutamine 
Jugular 
Young Male 5.49±0.53 ­ 6.51±1.21 0.86±0.02 ¯ 0.79±0.04 
Old Male 4.80±0.60 ­ 5.89±1.29 0.86±0.02 ¯ 0.82±0.03 
Young Female 6.96±0.89 ­ 8.57±1.00 0.82±0.03 ¯ 0.80±0.06 
Old Female 4.79±0.71 ­ 5.30±1.10 0.89±0.01 ­ 0.90±0.02 
Suprarenal 
IVC 
Young Male 8.26±0.62 ­ 11.55±1.12 0.61±0.04 ¯ 0.50±0.07 
Old Male 6.73±0.70 ­ 8.65±1.04 0.68±0.04 ­ 0.73±0.09 
Young Female 8.81±1.02 ­ 10.38±1.30 0.60±0.05 ¯ 0.50±0.08 
Old Female 8.04±0.76 ­ 9.15±1.60 0.64±0.03 ­ 0.65±0.05 
Infrarenal 
IVC 
Young Male 7.21±0.65 ­ 8.03±2.15 0.59±0.03 ¯ 0.47±0.05 
Old Male 5.73±0.94 ­ 7.39±1.89 0.65±0.05 ¯ 0.63±0.09 
Young Female 11.64±1.80 ­ 13.024.53 0.54±0.06 ¯ 0.44±0.09 
Old Female 5.21±0.82 ¯ 4.15±0.81 0.71±0.02 = 0.71±0.02 
Iliac Young Male 8.65±0.85 ­ 11.41±4.50 0.78±0.02 ­ 0.81±0.03 
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Old Male 7.75±0.38 ­ 9.75±0.91 0.66±0.04 ¯ 0.63±0.07 
Young Female 9.60±0.64 ¯ 7.53±1.11 0.74±0.03 ¯ 0.73±0.06 
Old Female 7.58±1.03 ­ 7.78±0.42 0.73±0.03 ­ 0.76±0.05 
Femoral 
Young Male 9.09±1.09 ¯ 7.72±1.55 0.76±0.02 ­ 0.79±0.04 
Old Male 11.56±1.21 ­ 11.93±1.93 0.72±0.03 ­ 0.73±0.02 
Young Female 10.00±1.06 ­ 10.84±1.62 0.82±0.01 ­ 0.84±0.02 
Old Female 7.83±0.45 ­ 7.88±1.20 0.77±0.03 ­ 0.81±0.05 
 
2.4.8 Dobutamine Effect on Circularity 
Also shown in Table 2, dobutamine infusion had mixed effects on vessel circularity. 
Circularity tended to decrease in the jugular and infrarenal IVC locations during dobutamine 
infusion, with significant decreases in the infrarenal IVC of young males (0.59±0.03 baseline vs. 
0.47±0.05 dobutamine, p<0.05). Circularity tended to increase in the femoral location, and a 
heterogeneous response was observed in the suprarenal IVC and iliac locations. Age and sex did 
not have significant effects on the response to dobutamine as measured by change in circularity. 
The same relationships between locations remained during dobutamine infusion, with the jugular 
vein remaining the most circular and the suprarenal and infrarenal IVC the least circular. 
However, during dobutamine infusion the jugular vein was no longer significantly more circular 
than the femoral vein due to a slight decrease in jugular circularity coupled with a slight increase 
in femoral circularity (µSA: 0.83±0.04 jugular vs. 0.79±0.03 femoral, p=NS). During dobutamine 
infusion, changes in circularity in the suprarenal IVC were greater than that in the iliac vein (µSA: 
change of 0.055±0.037 suprarenal IVC vs. -0.009±0.023 infrarenal IVC, p<0.05).  
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2.5 Discussion 
Anatomo-physiology of the venous system in mice has been characterized in this work. 
Using CINE cardiac-gated MRI, we quantified venous geometry and lumen expansion at five 
locations in C57BL/6 mice across age and sex, at rest and during administration of a 
pharmacological surrogate to exercise. To the best of our knowledge, these data represent the 
first such comprehensive in vivo quantification in the murine venous system. We have shown 
that while the structure and function of veins do vary across location, they are consistently larger 
than arteries, deform less than arteries in the circumferential direction across the cardiac cycle, 
and are non-circular. The healthy venous system demonstrated only small changes when 
challenged by the administration of dobutamine. Age, rather than sex, more frequently 
influenced differences in area, maximum strain, circularity, and response to dobutamine infusion 
(Table 1). These methods represent an overall improvement in non-invasively quantifying the 
structure and function of the venous network in the most commonly-used preclinical model. 
Quantifying age and sex differences in normal physiological conditions provides a foundation for 
similar comparisons in disease models.    
Venous research could be impacted by vein size such as the initial size of a vein used to 
host a thrombus in preclinical models. Both C57BL/6 and BALBc wild type mice, the most 
common backgrounds used in research, continue to increase body weight and size throughout 
their lifespan, dissimilar to the sigmoidal growth curve of humans [54], [55]. We quantified the 
influence of age and sex on venous cross-sectional area. In all five locations studied, the veins 
were visibly larger than the corresponding arteries (Figure 2.1 and Figure 2.4A). Without 
adjusting for body weight (Figure 2.2, left), there was a significant increase in vessel area with 
age in the suprarenal IVC. Conversely, there was a significant decrease in vessel area with age in 
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the femoral vein. This finding is consistent with data acquired from human femoral veins using 
ultrasound [56] and may be related to reduced muscle mass in the lower limbs driven by a 
change in the activity levels of aged mice [57], [58]. Overall, four out of five locations studied 
showed either no difference (jugular, infrarenal IVC, iliac) or a reduction (femoral) in cross-
sectional area of the vessel with age, suggesting that while mouse body weight continues to 
increase with age, the cross-sectional area of veins does not parallel this growth. The more rapid 
decrease in vein area from suprarenal IVC to femoral vein in aged animals compared to young 
(differences in regression slopes from data displayed in Figure 2) highlights the development of 
potential imbalances along the network with increasing age.  
For metrics known to scale allometrically, it is common practice in research to adjust raw 
data to body weight when drawing comparisons between different age and sex groups. When 
adjusting for body weight, the area per gram of body weight decreased with age at every 
location. We can speculate that this consistent decrease could be attributable to a decrease in 
musculature coupled with an increase in fat content, which is less metabolically active than 
muscle and therefore demands less blood flow and, hence, less blood return [59]. For sex 
comparisons, males were significantly larger than females in the suprarenal IVC location, 
regardless of adjustments for body weight. This could be attributable to changes in reproductive 
capacity, as the old female mice used in this study were 7-10 months past breeding age 
(C57BL/6 mice typically have a reduced number of oocytes starting at 6 months of age and are 
retired from breeding by 8 months of age). Although the suprarenal IVC was the only location 
studied with significant sex differences in cross-sectional area, the relative difference between 
males and females (either no difference, males larger than females, or females larger than males) 
did not change when adjusting for body weight. This indicates that sex related differences in vein 
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size are proportional to sex differences in body weight. These results suggest that adjusting for 
body weight may be appropriate when comparing across sex, but such adjustments for age 
comparisons could lead to misinterpretations depending on the biological question of interest. 
Rather, we propose that it would be beneficial to normalize data of disease models to baseline 
physiological metrics other than body weight when comparing across age and sex. For example, 
one would measure IVC length and diameter prior to inducing venous thrombosis in the IVC 
murine model. This could occur by gross anatomical measurement at the beginning of surgery or 
by imaging methods such as MRI or ultrasound. 
Arterial pulsatility across the cardiac cycle is understood to be dampened before reaching 
the venous system. Until now, however, there was no in vivo data quantifying the presence or 
absence of luminal changes in the veins of mice across the cardiac cycle. Instead, the 
predominant data acquired with respect to the venous system has been ex vivo and focused on 
elucidating material properties of vessel components under non-physiological conditions 
(lacking tethering, blood flow, and respiration; and sometimes under supra-physiological 
pressures).  
Lumen expansion, quantified using the biomechanical parameter of Green-Lagrange 
cyclic strain, showed minimal change over the cardiac cycle relative to the arterial system, 
maximum strain <10% compared to 19-23% in the suprarenal and infrarenal aorta [37]. This 
difference is one example of how quantifying in vivo venous cyclic strain provides baseline data 
to inform investigations of other disease states, such as arterio-venous fistula models. The 
jugular vein demonstrated the smallest lumen expansion across the cardiac cycle, which may be 
related to blood flow and pressure regulation associated with the central nervous system, even 
though valves are present at this location [60]. Although maximum strain in the femoral vein was 
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only significantly different from the infrarenal IVC across age and sex groups (Figure 2.3), 
maximum strain values were consistently highest at the femoral location. This may be due to the 
fact that the femoral vein has valves that contribute to blood flow control and alter forces on the 
vein wall that would be relevant to measurements of circumferential cyclic strain. Alternatively, 
the proximity of the femoral artery may influence venous strain extraluminally. It is important to 
note for the femoral location, in particular, that the calculation of cyclic strain becomes more 
sensitive to subtle changes as vessel size decreases and the resolution limit of MRI is 
approached. Due to the size of the veins, this is likely less of a confounder as we were still able 
to achieve 23 voxels across the femoral vein. Additionally, the coefficients of variation for 
maximum strain did not vary significantly between locations (µSA: 0.43 jugular, 0.34 suprarenal 
IVC, 0.45 infrarenal IVC, 0.29 iliac, 0.36 femoral, p=NS). Interestingly, the young female 
infrarenal IVC group had both the largest cyclic strain and was the least circular vessel of all 
groups across locations (Figures 3 and 4). This could be attributable to the reproductive veins in 
young female C57BL/6 mice draining into the infrarenal IVC [61]. Circumferential strain in the 
arteries has been shown to be scale independent [62], and therefore venous strain is not 
normalized to body weight here. 
At locations where the artery and vein are closely juxtaposed (infrarenal IVC, iliac, and 
femoral locations, Figure 4A, young images), the proximity of the corresponding artery and its 
changes in geometry over the cardiac cycle may impinge on the neighboring vein externally. As 
such, for locations where the artery abuts the vein, arterial conditions such as hypertension and 
atherosclerosis could potentially alter this effect. Understanding such factors is important to the 
overall health and performance of the venous system. For example, coronary artery bypass 
grafts, typically supplied by the saphenous vein, are prone to stenosis and thrombosis, which 
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may be in part caused by the extraluminal biomechanical forces of the myocardium compressing 
the vein graft which does not have sufficient wall thickness to contest such forces [63].  
Abnormal vein shape can be indicative of an underlying pathology, thus understanding 
the normal shape of veins is important for interpreting pathological vs. physiological geometries. 
We observed that the veins are typically oval, which is in part related to low pressure in the 
venous system. Differences in circularity between locations were evident. The jugular vein was 
the most circular, followed by the femoral vein. This is not surprising as pressure increases more 
distal from the heart, thus non-trunk veins are expected to have higher pressure relative to trunk 
veins. Higher pressure contributes to a more circular shape, as was observed here. Interestingly, 
the jugular and femoral locations are also the unique veins in this system that have valves which 
help regulate pressure to maintain venous return in the horizontal position (here in an 
anesthetized quadruped). We can speculate that venous valves contribute to circularity. Although 
comparable geometric comparisons along the venous network in humans is incomplete, the 
consistencies with human vein geometry we do see, which is dependent on the presence of 
valves and volume-pressure relationship [42], is noteworthy to observe in quadrupeds while 
under anesthesia. 
Our quantification of shape again highlights the potentially under-appreciated influences 
of neighboring arteries in the infrarenal IVC, iliac, and femoral locations (Figure 2.4A, young 
images). Similar to how this intimate juxtaposition of structures may have an influence on cyclic 
strain, it appears to contribute to reduced circularity as well. The effect appears greatest on the 
infrarenal IVC of young mice, where the vessels are so closely juxtaposed that the infrarenal 
aorta appears ‘nested’ into one side of the IVC (Figure 2.4). The external influence of the 
infrarenal aorta on the concomitant IVC is reinforced by the fact that circularity of the infrarenal 
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IVC increased with age. Our images clearly show that while the aorta and infrarenal IVC vessels 
were directly next to each other in all young animals, there was a visible separation between 
these vessels in 13/20 old mice (Figure 2.4A, open arrowhead; 7/10 males, 6/10 females). This 
separation, which could be due increased fat content around the vessels often observed during 
surgical procedures in old mice, appears to have lessened the impact of the aorta on venous 
shape thus contributing to the increase in circularity with age at this location. These data suggest 
that a highly circular vein—particularly in the core vasculature—could be indicative of an 
underlying pathology. For example, in vivo studies using infrarenal IVC murine models of DVT 
show that in the presence of a thrombus, the IVC is greatly distended and becomes highly 
circular at peak thrombus size [64]. This dramatic change in vessel shape can be propagated 
distally into the iliac veins. Conversely, irregular vein shape in vessels that are physiologically 
more circular, such as the jugular or femoral veins, could be indicative of a mass such as a tumor 
producing changes in vessel shape. Understanding physiological conditions of vein shape 
provides an important reference for mouse models of disease.   
Dobutamine is used clinically and preclinically as a surrogate for exercise to reveal 
functional arterial deficits. We used dobutamine to address whether response to cardiac stress 
alters the venous system, and whether those effects vary based on age and sex. Increasing cardiac 
output through dobutamine infusion had a relatively small impact on the venous system, whether 
measured by area, cyclic strain, or circularity (Figure 2.6, Table 2). While some groups of mice 
did see an increase in vessel area during dobutamine infusion (old male jugular, old female 
suprarenal IVC, and old female infrarenal IVC, Figure 2.6), this is likely attributable to a multi-
factorial volume effect. During exercise, increased demand for oxygen in the muscles pulls more 
blood into active circulation, initially recruited from the unstressed venous reserve [65]. 
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Dobutamine, however, stimulates ß1 receptors which increases cardiac output without 
stimulating skeletal muscles, thus we do not expect a decrease in venous cross-sectional area 
during dobutamine infusion. It is notable that the 4% increase in blood volume during 
dobutamine infusion did not result in significant changes in the iliac or femoral veins, across age 
and sex groups. This finding is consistent with the decreased compliance of veins in the 
extremities relative to splanchnic veins, diminishing their role as a blood reservoir [66]. The 
largest changes in vein area were observed in the suprarenal IVC, suggesting their important role 
as a reservoir in the murine venous system. Larger variability was observed in male mice, which 
could be due to the upstream variation in lateral branches draining into the IVC in C57BL6 mice. 
While the ovarian veins in female mice consistently drain into the infrarenal IVC, there is a large 
variability in the lateral branching patterns of male mice [67]. As such, mice with a bilateral 
infrarenal IVC branch phenotype may see variable downstream volume effects due to 
dobutamine compared to mice with no lateral infrarenal IVC branches. These results indicate that 
across age and sex, increasing cardiac output alone does not have a large impact on the healthy 
venous system. While a cardiovascular stressor such as dobutamine has been used to reveal 
subtle phenotype difference in cardiomyocyte-specific knockout mice [53], whether it can play 
the same role in murine models of venous disease will need to be evaluated. 
Our study was not without limitations. First, the non-circular geometries and vessel 
curvature, particularly in the suprarenal IVC location, made image planning perpendicular to the 
vessel more challenging, and presents a source of uncertainty in the data. As such, complex 
vessel curvature could introduce partial volume effect biases in the cross-sectional area 
measurements. However, the imaging parameters optimized for this work adjusted for slower 
blood flow velocities, enabling us to reproducibly visualize branching structures and anatomical 
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landmarks that led to consistency in measurements between two independent imagers (O.R.P. 
and C.B.C). Second, future studies of vessel pathology may require additional optimization of 
MRI parameters, as the bright signal intensity in TOF imaging can be influenced by blood 
velocity and T1 relaxation time. Thus, changes in blood velocity due to stasis or narrowing of a 
vessel, or changes in T1 relaxation due to the accumulation of red blood cells and 
methemoglobin concentration could confound TOF imaging in pathological conditions. 
Third, in locations where the artery abuts the vein, manual segmentation for analysis was 
sometimes needed when thresholding alone was not adequate to segment the vein from the 
adjacent artery. Finally, irregular venous shapes were more sensitive to changes in vessel 
perimeter, used to determine cyclic strain.  
To our knowledge, this is the first time that the structure and function of the murine 
venous system has been characterized non-invasively, at multiple locations across age and sex, 
and during application of a cardiovascular stressor. The results demonstrate that there are 
differences in size, luminal expansion across the cardiac cycle, and shape along the venous 
network and relative to the arterial system. Furthermore, location, age, and sex are relevant to 
consider when drawing conclusions from disease models. Our data can provide physiologically-
relevant parameters to computational models and ex vivo studies. Although comparable venous 
data in humans is incomplete, there is harmonization of our results with available data. Being 
able to quantify structural and functional differences along the venous network in quadrupeds 
under anesthesia suggests the methodology we have developed could provide sensitive 
measurements of the venous system in the most commonly used preclinical rodent model. With 
ultrasound data in humans demonstrating marked decreases in femoral vein flow with age [56] 
due to a combination of reduced diameter and flow velocity, future work incorporating pressure 
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measurements and flow velocity profiles would be useful for examining stress-strain properties 
and luminal biomechanical forces such as wall shear stress in vivo. We believe this work could 
be used as a benchmark for investigations of a variety of physiological and pathophysiolgoical 
conditions of the venous system. Finally, in vivo quantification of structure and function can 
inform ex vivo studies on the relevant physiological conditions in murine models as well as 
computational fluid dynamic models of the venous system, hopefully leading to a greater 
understanding of the biomechanics of venous diseases. 
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Mouse Models of Venous Thrombosis: Research-Based Model-Selection Algorithm 
3.1 Common Mouse Models of Venous Thrombosis 
Several animal models have been developed to mimic DVT. A major preclinical approach 
for understanding the biology of VT and testing new therapeutics is the use of murine models, as 
they provide an accessible model with the availability of genetically modified strains. Many of 
these models have shown utility in discriminating a number of factors that can influence 
thrombosis—from genetic effects to therapeutic interventions—leading to a better mechanistic 
understanding of VT development and resolution. 
The murine system has several relatively large and accessible veins.  The most popularly 
used vein for hosting thrombosis is the IVC distal to its junction with the left renal vein. This 
region should not be confused with the more proximal region of the vena cava which lies just 
below the heart and is only accessible via thoracotomy. The IVC yields sample sizes sufficient 
for the study of both vein wall tissue and thrombus. The absence of valves in the IVC is a 
drawback of IVC models when comparing to venous thrombi in humans. The other easily 
accessible large veins are the jugular, the femoral and the saphenous veins. The jugular vein is 
less commonly used for thrombosis models in mice because of its highly branching anatomy, 
variable diameter with dissection or manipulation, and because it is rarely the site of VT in 
humans.  Both the femoral and saphenous veins are directly accessible with a simple skin 
incision and can be used without any dissection, leaving the vein essentially in its natural bed. 
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Other venous systems that have been used in thrombosis research are the venules of thin-tissue 
structures, such as the cremaster muscle, the mesenteric microvasculature, and the ear. Although 
much has been gained from these venule models, they are qualitatively different, and are not 
categorically large veins.  
 
Figure 3.1 Choosing a Mouse Model of Venous Thrombosis. Representative schematic overview of common mouse models of 
venous thrombosis. 
Thrombosis is induced by altering/stopping blood flow, or by free radical endothelial cell 
activation. Thrombus size is commonly used as a metric for understanding the phase of 
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thrombogenesis, thrombus amplification, recanalization, and eventual thrombus resolution. It is 
important to note that these models have almost 100% survival, and to our knowledge none of 
the models cause pulmonary embolism. A summary of the well-characterized models is 
presented in Table 1, with suggested guidelines for validation of surgical technique. 
Table 3 A listing of the Well-Characterized Murine DVT Models, Guidelines for Surgical Validation, and Their Advantages and 
Disadvantages 
Model Brief Description 
Incidence 
of 
Thrombus 
Induction 
Thrombus Size 
(Coefficient of 
Variation); Guidelines 
for Validating 
Surgical Technique 
Advantages Disadvantages 
Stasis Model 
(Ligation 
Model) 
Lateral 
branches 
ligated, 
posterior 
branches 
cauterized. 
The IVC is 
ligated with a 
nonreactive 
suture placed 
just distal to 
left renal vein 
95-100% Large (<10% 
variation); In 9 to 10-
week-old male 
C57BL/6 mice 
weighing 25 grams, 
thrombus weights (IVC 
+ thrombus at harvest) 
should be 
approximately 33 mg at 
day 2, 29 mg at day 6, 
and 18 mg at day 14. 
Highly 
consistent 
thrombus 
size 
Lack of blood 
flow may 
inhibit maximal 
effect of 
administered 
systemic 
therapeutics; 
thrombus forms 
against 
direction of 
blood flow 
St. Thomas 
Model 
Partial ligation 
of IVC, lateral 
branches 
interrupted, 
vascular 
clamp applied 
to IVC in two 
locations 
Strain 
dependent
— Balbc 
>90%; 
C57BL6 
75-80% 
Moderate to large (20% 
variation); In a 25g 
male BALB/C mouse, 
thrombus weight 
should be 
approximately 20 mg at 
24 hours with a volume 
of 18 mm3. C57BL/6 
mice produce slightly 
smaller thrombi 
Thrombus 
develops in 
the presence 
of blood 
flow, 
combines 
stasis and 
endothelial 
injury 
Induction 
incidence is 
strain 
dependent; 
relevance of 
clamp injury is 
unclear; 
thrombus forms 
against 
direction of 
blood flow 
Stenosis 
Model 
Modifications  
Partial ligation 
of IVC 
without an 
endothelial 
damage step 
40-100%  
(variable) 
Small to large (85% 
variation) 
Thrombus 
develops in 
the presence 
of blood 
flow; 
variability 
mimics that 
seen in 
humans 
Variable 
incidence of 
induction; large 
variation in 
thrombus size; 
variation of 
branching 
phenotype 
introduces 
variability if 
branches are 
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left open 
Electrolytic 
IVC Model 
(EIM) 
Small (≤250 
µA) direct 
current 
applied to 
copper wire 
with the end 
inserted into a 
25-g needle 
placed inside 
IVC on 
anterior wall 
for ≤15 min. 
Lateral 
branches 
ligated. 
100% Current and time 
dependent – moderate 
to large (<10% 
variation); 10-week-old 
25 g C57BL/6 mice 
show approximate 
thrombus weights 
(IVC+thrombus at 
harvest) of 17 mg at 2 
days, 12 mg at 6 days, 
and 8 mg at 14 days 
when induced with 250 
µA for 15 min. 
Thrombus 
forms in 
direction of 
blood flow; 
highly 
consistent 
thrombus 
size; ability 
to modify 
current or 
application 
time to fit 
research 
question 
Longer surgery 
time required 
(~30+ minutes) 
IVC Ferric 
Chloride 
(FeCl3) 
Model 
A piece of 
filter paper 
satured in a 
solution of 
FeCl3 is placed 
on the IVC 
100% Concentration and time 
dependent—Small 
(20% variation); In 20-
25g male C57BL6 
mice, wet thrombus 
weight (separated from 
the IVC in saline) 
should be 
approximately 1.3 mg 
at 30 min following 
induction with 3.5% 
FeCl3 for 3 min. 
Thrombus 
forms in 
direction of 
blood flow; 
ability to 
modify 
conc. or 
application 
time  
Only early time 
points (≤1 
hour) can be 
studied; small 
thrombus size 
requires 
microbalance 
and may not be 
adequate for 
biochemical 
assays 
Femoral Vein 
Electrolytic 
Model 
A 1.5 to 3-volt 
direct current 
is applied to 
the exposed 
but un-
dissected 
femoral vein 
(standard 
application of 
30 seconds; 
modifications 
can range 
from 1s up to 
2 min) 
100% Current and time 
dependent—Small 
(25% variation); In 12-
16 week old male 
C57BL6 mice, 
thrombus 
histomorphometric 
volume should be 0.015 
mm3 at day 1 when 
induced with 1.5V for 
30 seconds, or 0.140 
mm3 at day 1 when 
induced with 3V for 90 
seconds. 
Presence of 
valves in 
femoral 
vein; 
thrombus 
forms in 
direction of 
blood flow; 
ability to 
modify 
current or 
application 
time; vein 
un-dissected  
Small thrombus 
size may not be 
adequate for 
biochemical 
assays 
 
The work in this dissertation used the ligation (stasis) model and the electrolytic IVC 
model (EIM). However, I had the opportunity to work with leading experts in the field on a 
consensus of mouse models of VT. As part of my contribution, I developed a model selection 
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algorithm to assist researchers in selecting a model appropriate for a given research question. 
Seven models, shown in Figure 3.1 were included based on their use and thorough 
characterization to enable reproducibility between laboratories.  
3.1.1 Ligature Based IVC Models 
Ligature models, which include stasis and stenosis models, involve the placement of a 
ligating or stenosing ligature around the IVC just caudal to the left renal vein to achieve stasis or 
low flow induction of thrombosis, respectively. The selection of this site and the various 
manipulations are based on the capacity to generate a sizable thrombus that can be weighed with 
a standard micro-balance and subsequently evaluated with Western blotting or ELISA, or 
processed for histology or immune-based detection of specific antigens. Surgery can be 
performed in 20-30 minutes, with limited surgical setup (anesthesia machine and surgical 
microscope). In ligature-based models, the thrombus forms in the upstream distal direction, 
whereas clinical VTs are generally seen to form downstream from a nidus, such as a valve 
pocket. This reverse direction of growth may not be trivial and requires more investigation. 
However, resulting thrombi have been shown to be structurally similar to human thrombi [68]–
[71]. 
Stasis Model 
The stasis model, also known as the ligation model, seeks to achieve complete stasis in 
the IVC, mimicking the clinical scenario of an occlusive thrombus. Any lateral or lumbar 
branches draining into the IVC between the left renal vein and the iliac bifurcation are 
interrupted, and the IVC is completely ligated. This total stasis leads to a severe vein wall 
reaction and nearly a 100% incidence of thrombosis. This widely used and well-characterized 
model produces thrombi highly consistent in size, with 10% variability [72]. A consolidated 
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thrombus (with consistency transitioning between liquid and solid) is observed beginning 2 hours 
post ligation, with reported outcomes extending to 28 days in most mouse strains. It has proven 
valuable in the study of interactions between the vein wall and thrombus during the progression 
from acute (first 2-3 days) to chronic inflammation and remodeling of the vein wall [73], [74]. 
Retraction of fibrosed thrombus into the vessel wall is observed as a consequence of a total vein 
wall/thrombus retraction at chronic time points, specifically 21 days post thrombosis or further. 
Avoiding interruption of side and/or back branches, even due to surgical challenge, significantly 
reduces thrombus size and introduces variation in thrombus size between mice [67].  
St. Thomas Stenosis Model 
The St. Thomas stenosis model, named for its development and standardization at St. 
Thomas Hospital in London, involves a combination of reduced blood flow and endothelial 
damage (two out of three components of Virchow’s triad) [75]. Posterior branches are left intact, 
while lateral branches are ligated, if present. The ligature, placed immediately distal to the left 
renal vein, is tied over a spacer such as a small length of 5-0 Prolene, which is subsequently 
removed to generate a ~95% reduction in blood flow. A neurovascular clamp is then applied to 
the vena cava wall at two locations in the upstream area for 15-20 seconds on each location 
sequentially, which causes apparent “bruising” and an additional thrombogenic stimulus to the 
vein. This model results in formation of a thrombus under low flow conditions with 90% 
incidence in the Balb/c mouse strain, with moderately lower rates of 75-80% incidence for the 
C57BL/6 strain (unpublished observational data).  
Stenosis Modifications 
The St. Thomas stenosis model has been subjected to several surgical modifications that 
are all broadly recognized under the stenosis model. Modifications avoid the endothelial damage 
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step, and further vary in their treatment of side branches as well as the chosen spacer. One 
variation leaves all branches open and uses a 0.36 mm wire spacer [70], while other variations 
interrupt side branches and use either a 30-gauge needle spacer [69], [76]–[79], or a 0.26 mm 
wire spacer [80]. Experts in the field have noted that these modifications which avoid the 
endothelial damage step open a different and often unpredictable thrombotic process in the 
model. The incidence and size of the resulting thrombus is largely dependent on the variation 
used; ligating side branches draining into the IVC between the left renal vein and iliac 
bifurcation can increase incidence of thrombus induction, and the spacer used has a direct effect 
on the degree of stenosis. Stenosis models result in thrombi that are smaller than those induced 
with the stasis model. The variability of this model mirrors the variability seen in humans and 
this may be useful in translating findings to the clinic. Variations on the stenosis model may be 
useful for studying pro-thrombotic conditions [81]. This model has been used to study early 
thrombotic events based on the apparent simulation of the clinical low-flow risk state [70]. 
Up to today, models performed with stenosis in the IVC have been collectively known as 
“stenosis models” despite the large degree of variation in surgical technique. Due to the amount 
of variation combinations, it is difficult to provide independent names for each surgical 
technique. Therefore, when using a stenosis model, it is imperative to specify either “St. Thomas 
Stenosis Model” or “Stenosis Model” with a detailed description of the surgical technique in the 
methods section of the publication. This will clarify to the field the actual surgical approach and 
serve as a comparative tool between laboratories. We also encourage reviewers to ensure 
thorough descriptions of the specific surgical modification used in addition to citing previous 
papers. Importantly, thrombus variability among mice subjected to the same surgical procedure, 
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as is common in the variations of the stenosis model, are welcomed if the research question 
involves variability in thrombus size, but should be reported. 
3.1.2 Free Radical Thrombosis Models 
Murine models of free radical induced thrombosis are achieved by either application of 
ferric chloride to the surface of the vein, or an electrolytic application of free radicals using non-
injurious direct current to deposit metal cations (ferric ions) onto or within the vein. Importantly, 
free radical models induce thrombus formation in the direction of blood flow, as is observed in 
humans. Additionally, the surgical procedures are not as technically difficult compared to 
ligature-based models as no dissection is required between the IVC and aorta. 
Ferric Chloride Model 
Free radical induced thrombosis may be performed chemically, using the ferric chloride 
(FeCl3) model. This model has been widely used in murine carotid artery models, and has been 
adapted for the IVC. A small piece of filter paper soaked in a solution of 3.5% ferric chloride by 
weight in water is applied to the IVC for 3 minutes [82]. This model may only be used to study 
very early time points (<1 hour), as the mouse cannot be safely recovered with the presence of 
FeCl3 in the abdominal cavity. If used in the jugular or sapheno-femoral vein, however, chronic 
time points may be studied if the site of application is thoroughly irrigated [83]. The FeCl3 
applied to the IVC induces a thrombus that is typically very small, requiring an ultrasensitive 
micro-balance (error of measurement should be < 0.05 mg on the balance, as the thrombi are 
typically 1-2 mg) and offering little thrombus material for evaluation. 
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Femoral Vein Electrolytic Model 
The femoral vein electrolytic model was designed to combine a simple method of 
thrombus induction commonly used in arterial models with intravital fluorescence microscopy. A 
1.5-volt direct current is delivered to the surface of the exposed but un-dissected femoral vein for 
30 seconds. Modifications in time—as short as 1-2 seconds and as long as 90 seconds—as well 
as current—up to 3 volts—can be used if a smaller or larger thrombus is desired, respectively. 
Thrombus can be studied in both acute and chronic time points, with resolution extending out to 
28 days in larger thrombi [84]. The size of the thrombus is generally too small for weight 
measurements or subsequent protein analysis. The advantage is that the relatively small diameter 
(~0.6 mm) allows application of intravital fluorescence microscopy imaging for quantitative 
analysis of the development of a variety of thrombotic elements at the site of thrombus induction 
[85]. Additionally, the murine femoral vein has valves, which are thought to play an important 
role in human thrombogenesis. 
Electrolytic IVC Model (EIM) 
The electrolytic IVC model (EIM) induces thrombosis by constant current application to a 
copper wire inserted into the IVC [86]–[88]. This generates free radicals in the wire which 
activate endothelial cells without injuring or destroying them. Prior to needle insertion, lateral 
branches are ligated while posterior branches remain open. Thrombi develop quickly, forming in 
the direction of maintained blood flow (without causing occlusion), with consistent size which 
can be evaluated for weight and subsequent protein/cellular composition [88]. Electrolysis does 
not alter intravascular temperature, but does require a longer operative time for current 
application and some damage to the vein wall at the needle insertion site. It is important to note 
that the needle insertion causes a 0.5 mm tear in the endothelial layer, which represents 14% of 
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the vessel perimeter [89]; insertion of the needle without current application does not induce 
thrombosis [88]. The EIM is recommended for the study of anti-thrombotic, thrombolytic agents 
or any new agents in VT treatment and prophylaxis. Recently the EIM application was expanded 
for the study of pro-thrombotic conditions [90], [91]. Further, imaging studies recently 
demonstrated the consistent thrombus size is both current and time dependent, enabling 
researchers to modify these parameters to create thrombi of consistent size to study both pro-
thrombotic and anti-thrombotic phenotypes, supporting the modification introduced in 2015 [92]. 
Additionally, a new approach was recently introduced to address lack of equipment availability 
and high cost, following the same principles but significantly reducing equipment cost [92].  
3.1.3 Recurrent Model of Venous Thrombosis 
Among VT patients, 30% will suffer a recurrent episode within ten years, with 45% 
occurring in the ipsilateral leg leading to an increased risk of post thrombotic syndrome. The 
IVC recurrent VT model was thus developed to investigate this biology by producing two 
episodes of VT in the same animal. Because of the high rate of recurrent thrombosis in humans, 
this model is a novel and direct application to the human condition. The initial thrombus is 
induced using the electrolytic IVC model (EIM), and a secondary episode is induced 21 days 
later using either the EIM or a ligature-based model. At the time of induction of the secondary 
episode, the primary thrombus has become incorporated into the vein wall and the lumen has 
been recovered. Using EIM as the primary insult allows for continuous blood flow and the 
opportunity to induce a second episode without needing to remove any ligature. This clinically 
relevant model has proven valuable in the study of recurrent VT biology [93]. 
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3.1.4 Comparison and Critique of the Models 
An ideal model would recapitulate the disease onset and pathology that are seen 
clinically.  Because of our relative lack of understanding about VT development and progression, 
current animal models represent our “best guess”, and thus, may lack critical features of clinical 
VT.  A likely scenario for VT development, frequently presented by many in the field, is a low-
flow or stasis state within the vein, often in a valve pocket, which can be compounded by genetic 
or acquired systemic prothrombotic propensity, an inflammatory state, or other factors that may 
enhance thrombogenesis. As such, none of the models mimic thrombogenesis in its natural form, 
but we can use them to study the stages of VT once a thrombus has formed. 
Each model has its own unique benefits and limitations. For example, ligature-based 
models use slow flow or an occlusion to generate the thrombus. This is an opposite scenario to 
clinical VT development, for which the thrombus generates occlusion of the vein, with the 
exception of May-Thurner syndrome and portions of thrombus that develop distally following 
total occlusion. The free-radical-based models induce rapid thrombus growth and are more 
attuned to testing acute thrombogenesis. The maintained flow in the vein, with the possibility of 
thrombus regression or embolization, provides a level of relevance not available with the 
ligature-based models. It should be noted that while stenosis models are often thought of as 
blood flow models, the resulting thrombus often leads to full stasis as the thrombus occludes the 
site of stenosis.  
While most models may be used to study both pro-thrombotic and anti-thrombotic 
phenotypes, the research question may lead investigators to consider the sensitivity required for 
detecting differences between experimental groups. For example, the IVC stasis (ligation) model 
creates a close to peak growth in control conditions, so it is mostly relevant for evaluating anti-
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thrombotic phenotypes, i.e. experimental conditions expected to reduce thrombus size. In the 
case of pro-thrombotic phenotypes, a large effect should be expected for adequate sensitivity 
when using the stasis model [71], [94]. In contrast, the stenosis model variations have a lower 
thrombus incidence and smaller thrombus size under control conditions, so these may be applied 
to pro-thrombotic phenotypic testing, with attention paid to rates of incidence between 
experimental groups. The EIM produces thrombi sufficiently large to test anti-thrombotic 
therapeutics, and may also be adjusted (decreasing the current or duration of current application) 
to study pro-thrombotic conditions [90]. 
It is of the utmost importance that publications give clear and detailed descriptions of the 
model with justification of any modifications used in the materials and methods section. 
Additionally, for rigorous science we recommend reporting data regardless of whether a 
thrombus developed in all mice, as variation in thrombus incidence could have important 
research implications. Further, robust end-point measures should be taken into consideration 
dependent on the model chosen during experimental design [95]. Researchers should continually 
strive to balance accurate and rigorous science with the highest standards of animal care, with the 
principles of the 3Rs (refinement, replacement and reduction) firmly in mind. Increasing the 
number of animals to match a representative or significant number should absolutely be avoided, 
unless this is highly justified towards a specific research question. An initial power calculation 
should be carried out based on the variability of the endpoint measure chosen in order to 
determine how many mice will be required [96]. 
3.1.5 Choosing a Model Based on the Research Question 
There is no single “best” model to represent this complex disease in all its stages. 
Therefore, the choice of model should be based on the specific research question. Investigators 
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should consider the clinical scenario the model should represent, including relevant time points, 
what outcomes will be measured, the strain of mouse that will be used, and available resources. 
All surgical models require a surgical microscope and anesthesia. Given the faster metabolic rate 
of mice compared to humans, thrombi ≤ 3 days old are considered acute, and the thrombi 
naturally resolve and become incorporated into the vein wall by day 28. When studying chronic 
VT, it can become increasingly difficult to remove the thrombus from the vein wall from 14 days 
following induction, which can hamper analysis. 
Once a research question has been clearly defined, Figure 3.2 may provide an aid in 
model selection. Because a clear “best murine model” for simulating VT does not exist, a 
practical and more generalizable approach to experimental investigations of VT is to apply two 
or more different models under similar conditions, such as in evaluating new 
transgenic/knockout mouse lines or novel pharmaceutical therapies [79].  By using multiple 
mechanisms for inducing thrombus growth in a vein, a broader representation of thrombogenesis 
is presented for testing a potential phenotype. Relevant options for secondary models are listed 
under each model in Figure 3.2. The selected models should have a response range that is 
commensurate with the anticipated or hypothesized response.   
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Figure 3.2 Model Selection Algorithm. This flow chart may serve as a starting point for considerations in model selection. No 
single model is adequate to capture the complexity of VT; thus, we recommend alternatives and secondary model options below 
each model. Mouse strain and sex should also be considered in model selection, as induction rates are strain dependent in stenosis 
models, and lateral branches draining into the IVC (common in mice from a C57 background) may not be interrupted in female 
mice. 
Anatomic Considerations & The Use of Female Mice 
In choosing a mouse strain, it is important to note the anatomical differences between 
mice from BALBc vs. C57BL/6 backgrounds. BALB/c mice have very few if any lateral 
branches compared with C57BL/6. Although posterior branches in BALB/c mice are increased 
in number, they are of a smaller caliber than in C57BL/6 mice. Thrombus size is generally larger 
and less variable in BALBc compared to C57BL/6 mice. There are, however, far more 
genetically-modified mice available on a C57BL/6 background. 
An important note for any model requiring the interruption of lateral branches is that in 
female mice from the C57BL/6 background, the right uterine vein commonly drains into the 
IVC, with ligation resulting in necrosis of the reproductive organs [61]. Thus, if an IVC model is 
being used, either the stenosis model variation that does not interrupt branching vessels or the 
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use of BALB/c mice (which typically do not present lateral branches) is recommended to study 
VT in females. If mice from the C57BL/6 background are used, the branching phenotype should 
be noted as a variable influencing thrombus size and larger numbers of animals may be required. 
In conclusion, there is no single “best” model to study VT, as areas of peri-thrombus blood flow 
and total stasis occur in human deep vein thrombosis. Model selection should be determined by 
the specific research question, and an additional model should be implemented to examine the 
experimental conditions under more than one setting. While no single mouse model can capture 
the complexity of VT, this method brings us closer to a rigorous understanding of the disease. 
3.2 Importance of Interrupting Side Branches 
Variation in thrombus size is a current concern that limits the ability to detect small 
differences between experimental groups. In the IVC ligation model, there has been debate over 
whether to interrupt branching vessels draining into the IVC [80], [97]. Leaving branches 
uninterrupted has been shown to significantly decrease thrombus burden and increase variability 
in thrombus size [67]. We aimed to understand the mechanism of this variation. We 
hypothesized that thrombus size variability results from altered flow dynamics involving venous 
branches. Using MRI, we investigated the path of blood flow in the murine IVC ligation model. 
VT was induced in 11-15-week-old C57BL/6 mice (n=9) via IVC ligation with either 
interruption of all venous branches (IB), or all branches left open (OB). Mice were imaged by 
MRI 2 days post ligation to examine IVC patency and/or presence of thrombus.  Venous flow 
was saturated to determine venous branching phenotype and flow direction, which was compared 
to pre-surgical MRI. Then, axial slices were acquired from the renal to iliac vessels to quantify 
thrombus volume. Finally, thrombus weight (TW) was quantified at harvest. 
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Thrombus volumes were larger in IB mice compared to OB mice (Figure 3.3, 38.0 ± 4.6 
mm3 IB vs. 11.3 ± 8.3 mm3 OB), with greater variability in OB mice (variation coefficient 12% 
IB vs. 73% OB). Open branches had great impact on reducing TW due to reversed flow 
direction, increasing thrombus size variability. IB mice showed flow compensation through the 
vertebral veins and collateral vessels. At harvest, TWs confirmed MRI findings (Figure 3.3, 34.5 
± 3.8 mg IB vs. 15.7 ± 9.8 mg OB; variation coefficient 11% IB vs. 62% OB). The OB mouse 
with the highest TW had 2 side branches, whereas the other OB mice had 1 right branch only.  
 
Figure 3.3 Thrombus length and volume (measured by MRI) and thrombus weight (IVC + thrombus) 2 days following IVC 
ligation in IB and OB mice. * indicates p<0.05.  
Using saturation bands in a plane perpendicular to branching vessels, we observed a clear 
reversal of blood flow at day 2 compared to pre-surgical imaging (Figure 3.4). All of the distal 
back branches reversed direction, whereas only 3 of the 5 proximal back branches reversed 
direction (Figure 3.5). The branches where flow reversal was not detected were all occluded by 
the thrombus. 
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Figure 3.4 Sagittal MRI slices with saturation bands placed to saturate either outflow (veins bright) or inflow (outflow bright). 
Back branches flowing into the IVC prior to thrombus induction (A and B) reversed direction 2 days following IVC ligation 
when branches were left uninterrupted (C and D). 
 
Figure 3.5 Schematic representation of blood flow reversal in branching vessels. None of the mice in this study had left 
branches. Four mice had right branches, in which two reversed blood flow direction. All mice had two back branches; all distal 
back branches reversed blood flow direction, three of five proximal back branches reversed blood flow direction. 
Thrombus size variability increased when branches were not interrupted. Blood flow 
dynamics detected by MRI were critical for understanding the “flow escape phenomenon” from 
the IVC that occurs through branches when they are left open. This study supports that the 
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anatomical branching pattern affects blood flow in the IVC. Non-invasive MRI brings to light 
the important role of venous branches inducing thrombus variability in VT models.  
The thrombus-venous interface is important in understanding the mechanisms involved in 
venous thrombosis. Thrombus size has a direct impact on venous wall remodeling, thus 
variability in thrombus size changes the impact on the vein wall. Moreover, thrombus size 
variability in control groups can make experimental comparisons difficult, particularly in 
therapeutic intervention studies. This study noninvasively explains the thrombus size variability 
observed when branches are uninterrupted in a venous thrombosis model. It supports the need to 
interrupt all venous branches in studies requiring a comparison of thrombus size between groups. 
By understanding the sources of variability in our preclinical models, we can control for them. 
This will improve conclusions derived from therapeutic studies, potentially expediting decisions 
to advance or reject therapeutic candidates. 
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A Cost-Effective Flexible Pre-Clinical Tool for Studying the Fibrinolytic System in Venous 
Thrombosis: An Update on The Electrolytic IVC Model (EIM) 
 
4.1 Abstract 
We chose to use the EIM as one of the models in this work to represent the clinical 
scenario of a non-occlusive thrombus. However, the equipment used to induce thrombosis in the 
original model description was expensive and had since been discontinued. Further, the 
fibrinolytic system had not been previously studied in the EIM. Thus, I developed an equipment 
alternative using a voltage to current converter powered by a direct current power supply, 
providing an added benefit of significantly reducing costs. Additionally, we further characterized 
the model through mapping the current and time dependency of thrombus resolution dynamics, 
and investigated the fibrinolytic system from acute to chronic VT. The current and time 
dependency of thrombus volume dynamics was assessed by MRI, demonstrating the flexibility 
of the EIM to investigate both pro-thrombotic and anti-thrombotic conditions. Additionally, the 
fibrinolytic system was characterized in EIM. Centripetal distribution of plasminogen was 
observed over time, with peak staining at day 6 post thrombus induction. Both active circulating 
plasminogen activator inhibitor-1 (PAI-1) and vein wall gene expression of PAI-1 peaked at day 
2, coinciding with a relative decrease in tissue plasminogen activator and urokinase plasminogen 
activator. 
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4.2 Introduction 
The EIM was developed to simulate VT in the clinical scenario of a non-occlusive 
thrombus. By applying a small constant current to a copper wire inserted into the IVC, free 
radicals are released which activate endothelial cells and initiate the thrombotic process in the 
constant presence of blood flow. These conditions mimic the clinical scenario of a non-occlusive 
thrombus (Figure 4.1)[86]–[88]. This method produces a thrombus that is highly consistent in 
size. The EIM has been used in the United States and beyond to study VT in both anti-
thrombotic and pro-thrombotic conditions, demonstrating the flexibility of the model [90], [91]. 
 
Figure 4.1 A) Schematic representation of the EIM. Any lateral branches draining into the IVC distal to the left renal vein are 
ligated, and a 250 µA current is applied to a copper wire placed within the IVC against the anterior wall. The right lymph node, 
consistently located near the bifurcation, serves as an anatomical reference for placement of the 25-gauge needle containing the 
copper wire. B) Gross anatomy images of the thrombus and vein wall at day 2 harvest; line markings denote mm. References: 
EIM – electrolytic inferior vena cava model, IVC – inferior vena cava. 
Since the initial development of the EIM in 2010, several changing circumstances have 
driven a need for an update on the model. First, the originally described stimulator equipment 
was expensive and has since been discontinued. Second, the dependence of thrombus size on 
current and time were assumed, but had not previously been demonstrated. Third, increasing 
interest in targeting the fibrinolytic system for treatment of VT and the results of the ATTRACT 
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trial emphasize a need for basic science evidence on the fibrinolytic system of thrombi in the 
presence of blood flow [98], [99]. The EIM provides a favorable environment for such 
therapeutic targets due to the sustained blood flow access to the thrombus. However, the 
fibrinolytic system had not previously been investigated in the EIM. In this communication, we 
addressed all three of these important updates; we developed an equipment alternative to the 
previously described system, investigated the current and time dependency of thrombus size, and 
characterized the fibrinolytic system in the EIM. 
4.3 Methods 
4.3.1 Mice and EIM Surgical Procedure 
All experiments were performed at the University of Michigan with approval from the 
University of Michigan’s Institutional Animal Care and Use Committee and conducted in 
accordance with The Guide for the Care and Use of Laboratory Animals [100]. Male C57BL/6 
mice aged 10-12 weeks were anesthetized with 2% isoflurane, placed in dorsal recumbency, and 
a midline laparotomy was performed. The IVC was exposed, any lateral branches were ligated 
using 7-0 Prolene suture (Ethicon, Inc., Somerville, NJ), and back branches remained patent. A 
30-gauge silver coated copper wire (KY-30-1-GRN, Electrospec, Dover, NJ, USA) with exposed 
copper wire at the end was attached to a 25-gauge needle and inserted into the IVC and 
positioned against the anterior wall (anode). Another needle was implanted subcutaneously at the 
proximal end of the laparotomy incision, completing the circuit (cathode). A detailed video 
demonstrating the surgical technique is available [87].  
A constant current of 250 µA was applied for 15 minutes for standard procedures [87]. 
To investigate the current and time dependency of the EIM, either the current or time was 
modified to 100 µA or 7.5 minutes, respectively. The current was supplied by either the 
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previously described Grass S48 square wave stimulator and constant current unit (Grass 
Technologies, Astro-Med, Inc., West Warwick, RI), or by the voltage-to-current converter, 
described below (Figure 4.2). The direct current results in the release of free radicals within the 
IVC, which in turn activate endothelial cells and initiate a thrombogenic environment in the 
constant presence of blood flow. The needle was then removed and the abdomen closed in two 
layers; the muscle and peritoneum was closed with 5-0 Vicryl (Ethicon, Inc., Somerville, NJ), 
the skin closed with Vetbond (3M, St. Paul, MN). 
 
Figure 4.2 The EIM was developed using a square wave stimulator and constant current unit (C, Grass Technologies), both of 
which are discontinued. Construction of a standard voltage-to-current converter (VIC) – circuit diagram shown in A and 
constructed circuit with standard DC power supply shown in B – provide a cost-effective alternative. The VIC was validated on 
the benchtop and then in vivo by thrombus weights at days 2, 6, and 11 to the Grass S48 system (n=5 per group, mean ± SEM, 
D). References: EIM – electrolytic inferior vena cava model, VIC – voltage to current converter, DC – direct current, NS – not 
statistically significant. 
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Mice not undergoing magnetic resonance imaging (MRI) were euthanized at specific 
time points post thrombosis in order to analyze thrombus weight and perform histology, PCR, or 
ELISA. True controls (TC), surgically naïve mice, were utilized for baseline molecular assays. 
4.3.2 EIM Equipment 
EIM was performed either with the previously described discontinued stimulator and 
constant current unit, or with a voltage to current converter (VIC), as pictured in Figure 4.2. The 
AD620 operation amplifier may be used in conjunction with a second operational amplifier, such 
as the AD705 (DigiKey, Thief River Falls, MN). A 40 kΩ resistor (R1) was used with an input 
voltage of +5 and -5 volts, but the desired resistor and/or voltage may be calculated based on the 
input current as follows: 
𝐼< = 𝑉>𝑅1 = [(𝑉ABC) − (𝑉ABD)]𝐺𝑅1 																																																						(2) 
where IL is the current applied to the load, typically 250 µA, R1 is the resistor used, VIN is the 
positive and negative input voltage, and G is the gain. A gain resistor (RG) is not needed for this 
application, so the gain (G) remains at 1. The circuit was powered by a DC power supply 
(Agilent E3630A, KeySight Technologies, Santa Rosa, CA). Prior to surgery, a sample load 
resistor (e.g. 100 Ω) was connected to the circuit and a multimeter was connected in series to 
fine tune the supplied voltage to deliver 250 µA (or desired current) to the load. 
4.3.3 Validation and Characterization 
In vivo validation of the VIC was performed by comparing thrombus weights at days 2, 6, 
and 11-post thrombus induction against thrombi produced using the stimulator and constant 
current unit. Following validation, the vein wall was isolated for qRT-PCR analysis, and 500 µL 
of blood was collected for circulating plasminogen activator inhibitor (PAI)-1 activity assay. 
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EIM was performed in a separate group of mice for immunohistochemistry at the same time 
points.  
Additionally, to investigate the current and time dependency of the EIM, thrombus was 
induced in three groups: standard, 250 µA for 15 min; reduced current, 100 µA for 15 min; and 
reduced time, 250 µA for 7.5 min. Thrombus volume was followed over time using MRI, 
described below. 
4.3.4 Thrombus Weight 
At the time of euthanasia, the IVC and the associated thrombus were removed and 
weighed for wet thrombus weight. The IVC was separated from the aorta and surrounding tissue, 
and a segment from just below the left renal vein to the iliac bifurcation was removed for 
weighing. The lymph nodes were removed from the IVC prior to weighing. After determining 
thrombus weight, the vein wall was separated from the thrombus for subsequent assessment by 
qRT-PCR. 
4.3.5 Thrombus Volume Assessment by MRI (in vivo) 
The current and time dependency of the EIM was investigated in three groups of mice 
(standard, reduced current, or reduced time). Thrombus size was monitored in vivo by MRI at 
days 1, 2, 4, 6, 9, 11, and 14 following thrombus induction. Mice were anesthetized using 2% 
isoflurane and imaged supine on a preclinical 7 Tesla MRI scanner. Respiration was monitored 
with a respiratory pillow (SA Instruments, Inc., NY), and a PID controller was used to maintain 
the animal’s temperature at 37±1ºC via warm air circulation through the bore of the magnet. To 
assess thrombus volume, 2D time-of-flight gradient echo axial slices were acquired from the 
renal vessels to the iliac vessels (18 contiguous slices, each 1 mm thick; repetition time 15 ms, 
echo time 4.9 ms, field of view 30 mm x 30 mm, flip angle 20º, matrix 256 x 256 zero-filled to 
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512 x 512, in-plane resolution 58.6 µm x 58.6 µm, number of excitations 3, imaging time 4 
minutes). Thrombus volume was assessed by summing thrombus area in each axial slice 
(MRVision, Winchester, MA).   
4.3.6 Quantitative Real-Time Polymerase Chain Reaction 
Ribonucleic acid (RNA) was isolated from the IVC wall by homogenizing in TRIzol 
reagent (Invitrogen, Carlsbad, CA) per the manufacturer’s protocol. Gene expression of PAI-1, 
tissue plasminogen activator (t-PA), and urokinase plasminogen activator (u-PA) were 
determined by qRT-PCR using commercially available primers (mouse PAI-1: PPM03093C, 
mouse t-PA PPM03855B, mouse u-PA PPM03095D) and SYBR master mix (SA Bioscience, 
Frederick, MD) in a Rotor-Gene 3000 thermocycler (Corbett Life Science, San Francisco, CA), 
as previously described [7], [72]. Gene expression was normalized to β-actin (mouse β-actin: 
PPM02945B) levels for each specimen. 
4.3.7 Immunohistochemistry 
Harvested IVC samples containing thrombus were formalin fixed for 2 hours, dehydrated 
in alcohol, paraffin embedded, and cut into 5 µm longitudinal sections. Nonspecific sites were 
blocked with normal serum, and sections were incubated with primary antibodies to Plasminogen 
(1:500, Genetex, Inc.; Catalog number GTX102877, Irvine, CA.) A species-specific ABC 
peroxidase kit (Vector Laboratories Inc., Burlingame, California) was used according to the 
manufacturer’s instructions for the corresponding secondary antibody and subsequent steps. 
Color development was performed with diaminobenzidine (DAB). Mosaic images were created 
via light microscopy (Nikon, Tokyo, Japan) under 40x magnification and quantification of 
percent positive staining was performed as previously described [101]. 
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4.3.8 PAI-1 Activity Assay 
500 µL of blood was collected by cardiocentesis at harvest using a syringe with 0.05 mL 
of sodium citrate, and active and total PAI-1 was determined as previously described [102]. In 
brief, to measure active murine PAI-1 concentrations in plasma samples, human u-PA 
(rheotromb) was coupled to carboxylated beads (Luminex, Austin, TX) and used to capture 
active PAI-1. A standard curve was generated using known concentrations of murine PAI-1 in 
PAI-1 depleted mouse plasma (Molecular Innovations, Novi, MI). The assay was performed by 
adding 25 µL of either the standards or samples to a 96 well plate filter plate (Millipore, 
Billerica, MA). Each well then received 25 µL PBS-1% BSA and 5000 beads in 30 µL of PBS-
1% BSA. The wells were incubated overnight in the dark at 4°C. The solution from each well 
was removed by vacuum suctioning and each well was washed twice with 200 µL PBS-0.05% 
Tween-20. The beads were mixed with continuous shaking in the dark at room temperature for 2 
hours with 50 µL of 2µg/mL biotin-labeled rabbit anti-mouse PAI-1 (Molecular Innovations, 
Novi, MI). The wells were vacuum washed and 25 µL of 4 µg/mL streptavidin-R-phycoerythrin 
(Molecular Probes, Eugene, OR) was added to each well, and the mixture incubated in the dark 
with continuous agitation at room temperature for 30 minutes. Finally, the solution was removed 
from each well by vacuum suctioning, the beads were washed three times with 200 µL of PBS-
0.05 % Tween-20, and 150 µL of sheath fluid was added for 5-10 minutes. The beads were then 
read with a Luminex 100 (Luminex, Austin, TX), median setting, 100 µL sample size, 100 
events/bead. 
4.3.9 Statistical Analysis 
All statistical analyses were completed using GraphPad Prism 7 (GraphPad Software, San 
Diego, CA). Comparison of thrombus weight between the VIC and Grass S48 was performed 
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using an unpaired t test with Welch's correction. A two-way ANOVA analysis using the Tukey's 
multiple comparison test was performed between VIC groups for the current and time 
dependency investigation as well as comparison of immunohistological plasminogen expression 
between time points. Relative expression of t-PA, u-PA, and PAI-1 in the vein wall as well as 
active circulating PAI-1 was compared to true controls for each time point using two-way 
ANOVA with Dunnett’s multiple comparison test. A p value of ≤ 0.05 was considered 
significant. Data was reported as mean ± standard error of the mean (SEM). 
4.4 Results 
4.4.1 Voltage-to-current circuit provides cost-effective system for performing EIM 
We constructed a voltage-to-current converter (VIC) powered by a common DC power 
supply to offer an equipment alternative to perform the EIM. The development of the VIC 
provided an added benefit of a significant cost reduction (Table 4). In vivo validation of the VIC 
was performed by comparing thrombus size by wet weight at days 2, 6, and 11 post thrombus 
induction to thrombi produced using the Grass S48. Thrombus weights were not significantly 
different between the VIC and Grass S48 at any of the time points studied (Figure 4.2). 
Table 4 Equipment required and price ranges for the previously described system compared to the VIC. Sample product numbers 
are provided for each component for reference. References: VIC – voltage to current converter. 
Previously Described System 
Stimulator: $2000-$5000 
• Grass S48 Square Wave Stimulator [86] 
• Nihon Kohden SEN-3401 [90] 
Compatible Constant Current Unit $200-$2100 
• Grass CCU1 [1] 
• Nihon Kohden SS-203J [90] 
VIC 
DC Power Supply $500 
• Agilent E3630A 
VIC Circuit – 2 operational amplifiers, 1 resistor $10 
• AD620, AD705 
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4.4.2 Thrombus Size in EIM is both Current and Time Dependent 
The dependence of thrombus size on the supplied current and duration of application in 
the EIM was assessed by MRI from day 1 to 14 post-thrombosis to enable tracking of thrombus 
size (via volume) in the same mouse over time. Time-of-flight imaging confirmed continuous 
blood flow at peak thrombus size, day 2 post-thrombus initiation (Figure 4.3). Reduction of 
either current or time resulted in significantly smaller thrombus volume across time points 
compared to standards (at day 2: 20.5±1.3 mm3 standard vs. 5.88±0.7 mm3 reduced current vs. 
5.93±0.6 mm3 reduced time, p<0.05) (Figure 4.3). Interestingly, no statistical differences were 
found between the two modified groups. Importantly, thrombus size within each group was 
highly consistent between mice (coefficient of variation at day 2: controls 11%, reduced current 
20%, reduced time 19%).  
 
Figure 4.3 A) Contiguous axial MR images were used to quantify thrombus volume. Axial sections at the approximate midpoint 
of the thrombus at day 2 are shown for each group. Blood flow is visible surrounding the thrombus in all groups. The IVC is 
outlined in blue, the thrombus in green, and the aorta in red. Schematic representation of the thrombus is shown to the right of the 
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MR images to highlight the thrombus size at day 2. B) Modifications to the model demonstrate the current and time dependency 
of thrombus size (n=3 per group, mean ± SEM) in the EIM, as measured by MRI. Time points were compared across groups, 
*p<0.05. References: MR(I) – magnetic resonance imaging, IVC – inferior vena cava. 
4.4.3 The Fibrinolytic System is Suppressed in Acute VT 
 
Figure 4.4 A) Representative composite longitudinal images of thrombus stained for plasminogen at days 2, 6, and 11 post 
thrombus induction. B) Analysis for positive staining as a percentage of total thrombus area. 
The fibrinolytic system was investigated in the EIM at days 2, 6, and 11. Qualitatively, 
positive immunostaining for plasminogen was initially found along the perimeter day 2, with 
distribution throughout the thrombus at days 6 and 11. Maximum staining was measured at day 6 
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(Figure 4.4). Active circulating PAI-1 was significantly increased compared to true controls at 
days 2 and 11, with peak concentration at day 2 post thrombus induction (day 2: 2764±120 
pg/mL, day 11: 1775±292 pg/mL vs. controls: 1063±140 pg/mL, p<0.05) (Figure 4.5). 
Interestingly, active circulating PAI-1 at day 6 was not different from true controls, indicating a 
dynamic process of thrombus burden with changing thrombus composition. PAI-1 expression in 
the IVC wall paralleled active circulating PAI-1 expression (Figure 4.5). Vein wall PAI-1 
expression peaked at day 2, with a down-regulation trend of t-PA and u-PA at the same time 
point (p=NS). The opposite PAI-1 to t-PA and u-PA relationship was observed at day 11 (Figure 
4.5).  
 
Figure 4.5 Dynamics of fibrinolytic system markers tissue plasminogen activator (t-PA), urokinase plasminogen activator (u-
PA), and plasminogen activator inhibitor 1 (PAI-1) from the vein wall were assessed by qRT-PCR (left axis). Active circulating 
PAI-1 was assessed by ELISA (right axis). Data presented as mean ± SEM. TC – true controls (naïve animals). References: TC – 
true control (surgically naïve mice), qRT-PCR – quantitative real time polymerase chain reaction. 
4.5 Discussion  
Animal models provide critical insight to understanding the mechanisms of VT. However, 
there is no single model that can replicate the complexities of deep vein thrombosis. Moreover, 
model selection should be driven by the specific research question. Thus, a deep understanding 
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of each available animal model including detailed characterization is necessary for choosing the 
appropriate model for a given research question. The EIM is the only currently available mouse 
model that provides both thrombus size consistency and maintained blood flow in the IVC and 
around the thrombus independently of the time point investigated, which is favorable for 
systemically administered therapeutic investigations.  
The EIM was originally described using a stimulator and constant current unit from Grass 
Technologies to follow the procedures used by Luchessi and collaborators [103] in their canine 
coronary artery thrombosis model. This equipment was expensive and has since been 
discontinued. Alternative compatible stimulator and constant current units are difficult to find, 
but products from a Japanese company Nihon Kohden have been used [90]. This equipment also 
can be expensive, amounting to several thousands of dollars (Table 4).  Thus, the high cost and 
discontinuation of the originally described equipment warranted an update to improve 
accessibility and characterization of the EIM.  
Induction of thrombosis in EIM is accomplished by application of a very small constant 
current. In the original model description, this was regulated by the constant current unit (CCU1, 
Grass Technologies), which was powered by a compatible stimulator providing a very high 
voltage (150 V). The unit required this high voltage input to achieve accuracy in delivering 250 
µA. Alternative current sources, however, do not require high voltage sources, eliminating the 
need for a high-voltage stimulator. Other constant current sources sold typically do not provide a 
range sufficiently low for this application. We chose to implement an operational amplifier 
constant current source for cost effectiveness, which we powered with a common DC power 
supply that many labs will have readily available. The VIC was validated on the bench using a 
multimeter and in vivo by comparing thrombus weight at days 2, 6 and 11, yielding results that 
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were not statistically different from the stimulator and constant current unit. Thus, the model 
may be implemented at costs comparable to other murine models which only require a surgical 
scope and anesthesia machine. 
Recently, a Japanese group presented a modification to the original EIM description to 
study a pro-thrombotic phenotype [90]. Typically, maximum thrombus burden is observed at day 
2 with a thrombus-to-lumen ratio of 3:1 making this method very suitable to study “thrombus 
reduction”, an attractive option when it comes to drug development and testing the potential role 
of pharmaceutical compounds for VT. Banno et al. adapted the original EIM by modifying the 
time (10 minutes instead of 15 minutes) and the current (200 µA instead of 250 µA), resulting in 
a smaller initial thrombus size for control mice, allowing them adequate sensitivity to detect 
larger thrombi in pro-coagulant mice. Their modification relied on the current and time 
dependency of the model, but also opened the question of how individual modifications of these 
variables would influence the dynamics of thrombogenesis and resolution. 
Taking advantage of MRI to follow each mouse over time, we performed EIM with the 
original descriptive technique and in two experimental groups—one with a reduced current of 
100 µA and one with reduced time to 7.5 minutes. The results of this experiment demonstrated 
thrombus size in this model is current and time dependent, and that these modifications still 
produce highly consistent thrombus size. These results corroborate the flexibility of the EIM to 
fine tune the model to a desired thrombus size for a specific research question. Of note, 
modifications served to decrease either current or time rather than increase. This is because in 
our experience with the development of this methodology, we concluded that 250 µA was the 
highest safe current without inducing off-target pathology (we observed lower limb paralysis 
with currents beyond 250 µA, independent of the time of application; observational data).  
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The recently completed ATTRACT trial investigated the impact of prompt thrombus 
removal via pharmacomechanical catheter directed thrombolysis (PCDT) on post thrombotic 
syndrome [104]. PCDT involves both mechanical and chemical lysing of the thrombus from a 
catheter-based device embedded within the thrombus. Currently, there are no fibrinolytic drugs 
with FDA approval for the treatment of VT [105]. However, the use of t-PA as a chemical lysing 
agent is commonly used in endovascular procedures (“off-label” use). Its mechanism of action is 
conversion of plasminogen into plasmin, which breaks down fibrin. Thus, studying plasminogen 
content in this VT model provides a platform for further investigations from both a biological 
and therapeutic perspective. The continuous blood flow channel in the EIM at all time points 
provides the possibility of direct drug access to the thrombus, even with systemically delivered 
therapies. However, before we move to therapeutics, the fibrinolytic system should be 
characterized in each animal model, as we did for this methodology (EIM). Our experiments 
addressed plasminogen concentration at different time points, gene expression of markers of the 
fibrinolytic system (PAI-1, u-PA and t-PA) in the vein wall directly in the area where the 
thrombus occurred, and active circulating PAI-1.  
Plasminogen, the inactive precursor of the enzyme plasmin which degrades fibrin, is 
activated by t-PA and u-PA. Interestingly, the immunohistochemistry for plasminogen showed 
higher total concentrations at day 6, with plasminogen arranged from the thrombus perimeter 
(day 2) towards the center of the thrombus over time. This centripetal integration suggests that 
blood flow access to the thrombus may play an important role in the fibrinolytic process. 
Understanding plasminogen dynamics may provide basic science insights that could lead to a 
better understanding of therapeutic efficacy at different stages of VT. 
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PAI-1, one of the key inhibitors of t-PA and u-PA, was measured by gene expression in the 
vein wall and in its active circulating form. Total circulating PAI-1 correlated with PAI-1 gene 
expression in the vein wall, and interestingly, the peak of PAI-1 was observed at day 2, 
coinciding with the decreased expression of t-PA and u-PA. Taken together, this information 
supports that there is an impairment of the fibrinolytic system activity at day 2 (acute VT) 
favoring the development of a thrombus. This is aligned with previous work demonstrating that 
PAI-1 levels peaked at day 2 in the total IVC ligation model, which is considered a blood stasis 
model [102]. The impairment of the fibrinolytic system during acute VT suggests that VT is not 
only attributable to coagulation processes, but also a decrease in the fibrinolytic system, 
regardless of blood flow conditions. This insight not only improves our knowledge of the model 
but also increases our understanding of VT and is aligned with previous human VT publications 
[106]. 
In conclusion, we have demonstrated that the EIM can be performed using a VIC with the 
added benefit of reduced cost. Thrombus size in the EIM is both current and time dependent. We 
characterized the dynamics of thrombus resolution in reduced current and time of application 
experiments, further confirming the flexibility of this model to study both anti-thrombotic and 
pro-thrombotic conditions. Regardless of the current and time of application used, this model 
generates thrombi that are highly consistent in size, as was demonstrated previously with 
thrombus weight and ultrasound [88], and now by MRI. Additionally, the EIM can be used to 
investigate the fibrinolytic system under flow conditions. The functionality of the fibrinolytic 
system increases over time as t-PA and u-PA are up-regulated and plasminogen disseminates 
throughout the thrombus, providing insights for improving future therapeutic approaches. Hence, 
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the EIM provides a cost-effective, flexible pre-clinical tool for studying the fibrinolytic system in 
venous thrombosis. 
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Collateral Vein Pathways of C57BL/6 Mice: Comparative Analysis with Human Anatomy 
5.1 Abstract  
Unlike arteriogenesis, prolific collateralization in the venous system has been associated 
with more severe disease. However, there is a scarcity of information on venogenesis, and little 
is understood regarding the relevance of the most common preclinical model—the mouse—for 
studying venous collateralization. Thus, we aimed to characterize collateral vein development 
and progression in two murine models of deep vein thrombosis by using multiple overlapping 
thin slice acquisition (MOTSA) MRI. VT was induced in 12-14-week-old male C57BL/6 mice 
using either the IVC ligation model (n=5) or the electrolytic IVC model (n=5). Mice were 
imaged at 7-T on days 2, 6, 14, and 21 following VT induction. 2D time-of-flight (TOF) images 
with and without saturation bands to distinguish venous flow for collateral cross-section 
measurements at the midpoint of the thrombus and assess thrombus volume, respectively. 
MOTSA was optimized for collateral imaging and used to assess collateral pathway. MOTSA 
enabled tracking of collateral veins ³200 µm in diameter. Collateral patterns were influenced by 
pre-existing anatomy; mice with bilateral IVC branches showed a predominant superficial 
collateral pathway (superficial and internal epigastric veins), whereas mice with no lateral 
branches exhibited a strong intermediate collateral pathway (gonadal and periureteric veins) and 
were less likely to develop ascending lumbar collaterals. The degree of venogenesis showed a 
positive correlation with thrombus volume (R2=0.64, p<0.0001). MOTSA enables quantification 
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of murine venogenesis following IVC obstruction. Venous collateral patterns in C57BL/6 mice 
are consistent with those described in humans, are influenced by pre-existing anatomy, and 
correlate with the degree of obstruction.  
5.2 Introduction 
Vascular obstruction creates physical forces that promote the remodeling and maturation 
of pre-existing arterioles/arteries or venules/veins known as arteriogenesis and venogenesis, 
respectively. While arteriogenesis and therapies augmenting collateral arterial flow restore 
function in cases such as peripheral artery disease [107] and cerebral ischemia [108], collateral 
veins typically do not have valves and cannot fully compensate for impaired venous function 
[109]. As such, while prolific arterial collateralization reduces clinical symptoms, excessive 
venous collaterals are unable to restore function [109], [110] and indicate more severe disease 
[111], [112]. Additionally, when venous obstruction is treated by stenting, competitive flow in 
large collaterals increases the risk of thrombotic stent occlusion [110], making collateral size 
assessment an important consideration for stenting procedures.   
Four collateral pathways resulting from vena cava obstruction in humans have been 
identified [113]–[116]. The deep pathway is the most commons in humans, involving 
enlargement of the azygos-hemiazygos system and/or ascending lumbar veins. The intermediate 
pathway involves the gonadal veins and periureteric veins, which drain into the renal veins or 
IVC, and is most common in humans with occlusion in the infrarenal segment of the IVC [117]. 
The superficial pathway involves the superficial and internal epigastric veins, also known as the 
external and internal mammary veins, which originate from the femoral and iliac veins and drain 
into the cephalic and brachiocephalic veins, respectively. The portal collateral pathway makes up 
the fourth pathway, with several subtypes identified following portal obstruction or hypertension. 
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 Unlike arteriogenesis which has been extensively studied, venogenesis is poorly 
understood in part due to a paucity of preclinical studies. Collateral veins have been noted but 
not characterized in a porcine model of venous thrombosis [118] and a rat model of varicose 
veins [119]. A retrospective veterinary study of dogs with caudal IVC obstruction or increased 
flow resistance found collateral pathways similar to those reported in humans [117]. 
Additionally, a study using a non-human primate model of ilio-femoral venous thrombosis 
showed collateral veins persistent through day 21 but absent in treatment and prophylaxis groups 
[6]. To our knowledge, little is understood regarding the relevance of the most common 
preclinical model—the mouse—for studying venous collaterals.  
MRI has been used to examine collateral vessels both clinically [110], [120], [121] and in 
preclinical models [6], [122]–[124]. Non contrast-enhanced angiography methods are 
increasingly desirable as safety concerns of gadolinium-based contrast agents have risen [125]. 
Additionally, bolus gadolinium contrast enhancement holds limited application in mice as 
administered contrast agents rapidly perfuse tissue, resulting in an inability to temporally 
separate the arterial pass from the venous pass of the contrast agent, as well as an inability to 
image for longer times before contrast becomes ineffective. Multiple overlapping thin slab 
acquisition (MOTSA) is a commonly used non contrast-enhanced angiography method that 
reduces signal saturation while maintaining good signal to noise ratios [126], [127], enabling 
visualization of collateral vessels. The purpose of this work was to characterize collateral vein 
development and progression in two murine models of deep vein thrombosis using high-
resolution, time-of-flight (TOF) MOTSA. 
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5.3 Materials and Methods 
All experiments were performed with approval of the University of Michigan 
Institutional Animal Care and Use Committee. Adult male C57BL/6 mice weighing 27 ± 2g 
were used in the study.  
5.3.1 MOTSA Optimization 
 The tail arteries of naïve mice were used for optimization of MOTSA parameters because 
their diameter (~350 µm) is comparable to previously reported peripheral artery collateral vessels 
(318±20 µm) [128]. Starting values for the 3D-TOF datasets were chosen based on literal values 
of collateral imaging performed at 4.7 T [122]. The RF excitation thicknesses tested were 
prescribed as a percentage of the thin slab, with the goal of optimizing small vessel conspicuity 
while minimizing total imaging time for a complete volume. Because TR and FA are the most 
influential parameters in determining the contrast-to-noise ratio (CNR) in TOF MR angiography 
of blood vessels, quantitative optimization of these parameters was performed. To optimize TR, 
the TR was varied from 10 to 50 ms in 5-10 ms increments, while holding FA constant at 20°. 
Similarly, FA was optimized by holding TR constant at 30 ms, and varying FA from 10° to 90° 
in 5° increments.  
Tail artery voxels were manually segmented from 2D axial slices derived from the 3D-
TOF optimization datasets. Because a region of interest (ROI) based CNR calculation, i.e. taking 
the average CNR over an ROI, is sensitive to under/over segmentation when there are a small 
number of voxels across the object of interest (10-14 voxels for the tail artery), the maximum 
contrast-to-noise ratio (CNRmax = MAX[(signal intensityvessel – signal intensitytissue)/σ noise]) was 
determined for each slice. The average CNRmax and 95% confidence interval (CI) was calculated 
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from ~55 axial slices (covering ~7 mm of resolvable vessel) for each dataset acquired for TR or 
FA and compared across TR or FA values. 
5.3.2 Mouse Models 
Two models of VT were used to represent total or partial venous occlusion. Mice were 
anesthetized using 2% isoflurane, their abdomen shaved, placed on a heating pad and a 
laparotomy was performed. The intestines were exteriorized and placed between saline-soaked 
gauze pads. In the total occlusion cohort, VT was induced by IVC ligation immediately distal to 
the left renal vein using 7-0 Prolene (Ethicon, Inc., Somerville, NJ), including ligation of any 
lateral branches and cauterization of both posterior branches emanating from the IVC between 
the left renal vein and the iliac bifurcation. In the partial occlusion cohort, VT was induced using 
the electrolytic IVC model (EIM), which produces an ~80% occlusion while maintaining blood 
flow. For EIM procedures, the stripped end of a 30G copper wire (approximately 3 mm exposed 
length, KY- 30- 1- GRN, Electrospec, Dover, NJ) was placed in the blunted end of a 25G needle 
cut to 5 mm in length. Following ligation of any lateral branches draining into the IVC, the 
needle with copper wire was inserted into the IVC at the level of the lymph node just proximal to 
the iliac bifurcation, and a second wire was inserted subcutaneously (at proximal end of incision) 
to complete the circuit. A voltage to current converter was used to supply a constant current of 
250 µA for 15 minutes, releasing free radicals in the copper wire and activating endothelial cells 
within the IVC [92]. Following current application, sterile saline was applied to the IVC and the 
needle was carefully removed. The intestines were then placed back into the abdominal cavity 
and the muscle was closed with continuous sutures using 5-0 Vicryl (Ethicon, Inc., Somerville, 
NJ). The skin was closed with Vetbond (3M, St. Paul, MN, USA). 
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5.3.3 MRI 
All mice were imaged on a 7 Tesla small animal MRI scanner at days 2, 6, 14 and 21 post 
VT induction. Mice were anesthetized with 2% isoflurane, 1 L/min O2 carrier gas. Respiration 
was monitored with a respiratory pillow and maintained at 60-100 breaths/min (SA Instruments, 
Inc., NY). A PID controller was used to maintain the animal’s temperature at 37±1 ºC via warm 
air circulation through the bore of the magnet. Mean total imaging time was 1.25 hours. 
Collateral vessels were imaged using the optimized MOTSA parameters: TR/TE: 30/2.84 
ms, FA 25°, FOV: 34 x 34 x 17 mm, matrix: 128 x 128 x 64 zero-filled to 256 x 256 x 128, in-
plane resolution (132 µm)3, NEX 2, 8 slabs each 6 mm thick with 50% overlap, imaging time 3m 
25s per slap with a total of 8 slabs. Using an in-house MATLAB script (Mathworks; Natick, 
MA), Thin slabs were overlapped and aligned using the spatial coordinates of each dataset and 
merged into a single continuous 3D volume. In areas of overlap between two adjacent thin slabs, 
voxel pairs were evaluated individually and the highest intensity voxel was assigned to the final 
volume. 3D volumetric renderings of the MOTSA were used to count and classify collateral 
vessels. 
To assess thrombus volume, 2D TOF gradient echo axial slices were acquired from the 
renal to iliac vessels (18 contiguous slices, each 1 mm thick; TR/TE: 15/4.9 ms, FA 20°, FOV: 
(30 mm)2 x 30 mm, matrix 256 x 256 zero-filled to 512 x 512, in-plane resolution (58.6 µm)2, 
NEX: 3, imaging time 4 minutes). Thrombus volume was assessed by manual segmentation 
(MRVision, Winchester, MA). Cross-sectional area of collateral veins was quantified at a slice 6 
mm proximal to the iliac bifurcation (the approximate midpoint of the thrombus) using 
thresholding. To distinguish venous flow (i.e. flow directed in the superior direction), an 
acquisition with saturation bands placed either proximal to (saturating arterial flow) or distal to 
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(saturating venous flow) the slice of interest was used: TR/TE: 20/4.9 ms, FA 20°, FOV: (30 
mm)2, matrix: 256 x 256, NEX 6, saturation band thickness 5 mm, imaging time 30 s.  
5.3.4 Statistical Analysis 
Data were analyzed using GraphPad Prism version 8.0 (GraphPad Software, La Jolla, 
CA). A repeated measures one-way ANOVA was used to compare collateral numbers and cross-
sectional area across time points within each model. An unpaired two-tailed t-test was used to 
compare the two models. All data are plotted as mean ± standard error (SEM). Significance was 
set at p < 0.05. 
5.4 Results 
5.4.1 Multiple overlapping thin slice acquisition reveals collateral vein pathways 
Collateral vessels were visualized using MOTSA optimized for imaging collateral 
vessels. Despite collateral tortuosity, previous studies of collateral veins have shown primarily 
longitudinal alignment [6], [113], [115]–[117]. Therefore, we reduced the FOV in the axial 
direction (thin slab direction) by half to minimize saturation effects of blood passing through the 
imaging volume. The matrix size was also halved to maintain isometric resolution and thus 
increase the changes of resolving venous collaterals in any anatomical plane. TR and FA 
optimization was performed on the tail arteries of naïve mice to balance high CNR with 
acquisition time. As shown in Figure 5.1A, a TR of 30 ms provided a comparable CNRmax to that 
of 50 ms (TR 30: 23.3 ± 3.9 vs. TR 50: 26.4±2.9) with a 40% reduction in acquisition time, 
while significantly improving CNRmax compared to a TR of 20 ms (19.5±3.4, p<0.01). Flip angle 
was quantitatively optimized over the same anatomical region as TR, holding TR constant at 30 
ms. As anticipated, higher flip angles resulted in a higher CNRmax, but a lower median CNR 
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(horizontal marks) along the length of the vessel due to TOF saturation effects as blood passes 
through the volume. A final flip angle of 25° was chosen because it had the greatest number of 
CNRmax measurements (78.2%) above a selected CNR value of 10, and nearly the highest 
median CNR (Figure 5.1B). The optimized MOTSA parameters using 50% overlap of successive 
acquisitions enabled visualization of collateral vessels as small as 200 µm in diameter.  
 
Figure 5.1 2D axial slices from single slab 3D-TOF acquisitions the tail artery of a naïve mouse were used to optimize repetition 
time (A) and flip angle (B). Asterisks represent the chosen parameter. 
3D renderings of the stitched volume enabled tracking of the collateral vessel path. 
Collaterals in the extraperitoneal space showed a tortuous pattern, whereas gonadal and 
superficial epigastric veins took a nearly straight path (Figure 5.2, green arrowheads and blue 
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arrows, respectively). Internal epigastric and periureteral veins showed a corkscrew pattern 
(Figure 5.2, white arrowheads and red arrows, respectively).   
 
Figure 5.2 Representative coronal MIPs from MOTSA of two mice at days 2, 6, 14, and 21 following A) inferior vena cava 
ligation (total IVC occlusion) or B) electrolytic induced IVC stenosis (partial IVC occlusion). Green arrowheads: superficial 
epigastric veins; white arrowheads: internal epigastric veins; orange arrows: gonadal veins; red arrows: periureteric veins. 
Vertebral veins not visible in coronal images. C) Number of collateral veins over time following two models of caval thrombosis. 
Collateral vessels were most prominent at early time points following thrombus induction 
(Figure 5.2). In both models, the number of collaterals peaked at day 6, although none of the 
time points studied were significantly different from one another (Ligation—D2: 6.8±0.9, D6: 
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7.4±0.8, D14: 5.8±1.0, D21: 4.6±0.8; EIM—D2: 5.2±1.0, D6: 5.4±0.9, D14: 4.0±0.6, D21: 
3.0±0.5). While total vessel occlusion via ligation had more collateral vessels compared to partial 
occlusion induced by EIM at every time point, there was no significant difference in total 
number of collaterals between the models.  
 
Figure 5.3 Schematic representation of the superficial (green), intermediate (purple), and deep (dark blue) collateral vein 
pathways in C57BL/6 mice following inferior vena cava obstruction. 
Three of the four collateral vein pathways described in humans were observed in mice 
(Figure 5.3). Both models exhibited the deep, intermediate, and superficial collateral pathways 
(Figure 5.4). Deep collaterals (ascending lumbar veins, Figure 5.4A, black arrowhead) were 
observed in 4/5 ligation and 3/5 EIM mice, most commonly rejoining the IVC via a lumbar vein 
proximal to the thrombus (Figure 5.4A, white arrowhead). Interestingly, for the mice with 
thrombus induced by EIM exhibiting ascending lumbar collaterals, this deep collateral pathway 
 82 
persisted across time points, whereas in the ligation model only one of the three mice with the 
deep collateral pathway continued to show visible ascending lumbar collaterals beyond day 2 
(Figure 5.4A). The intermediate collateral pathway was observed in all mice (Figure 5.4B). The 
superficial collateral pathway, also observed in all mice, was more prevalent in the ligation 
model (Figure 5.4C, p<0.05). 
 
Figure 5.4 Number of collaterals in each collateral pathway with corresponding MOTSA data, inverted color scale for clarity: 
deep collaterals (A), ascending lumbar veins noted by black arrowhead, white arrowhead denoting the rejoining with the IVC 
through the lumbar vein; intermediate collaterals (B) with gonadal (blue arrows) and periureteral (red arrows) veins; and 
superficial collaterals (C) with superficial (green arrowheads) and internal (teal arrows) epigastric veins. 
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5.4.2 Collateral pattern is influenced by pre-existing vascular anatomy 
The pattern of collateral vessels showed consistent trends depending on the pre-existing 
anatomical pattern of branching vessels draining into the IVC (Figure 5.5). C57BL/6 mice have 
four anatomical patterns of branching vessels draining into the IVC: no branches – 21%, right 
branches only – 34%, left branches only – 20%, and bilateral branches – 25%. [67] Any lateral 
branches that drain into the IVC between the left renal vein and iliac bifurcation are interrupted 
during thrombus induction for both models used. Interestingly, mice with no lateral branches 
tended to predominantly rely on the intermediate collateral pathway (Figure 5.5A), whereas mice 
with bilateral side branches predominantly exhibited the superficial collateral pathway, with 
some involvement of the periureteral but not gonadal veins from the intermediate pathway 
(Figure 5.5C). When unilateral branches were present, the side with the interrupted branch 
followed the superficial collateral pathway, while the contralateral side took an intermediate 
collateral pathway (Figure 5.5B).  
 
Figure 5.5 Representative coronal MIPs from MOTSA showing collateral vessel patterns in mice 6 days post thrombus induction 
grouped by anatomical patterns of branches draining into the IVC, which are interrupted during thrombus induction. 
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5.4.3 Collateral veins correlate with degree of stenosis 
Measurements of collateral cross-sectional area in a slice 6 mm proximal to the iliac 
bifurcation (approximately the midpoint of the thrombus) were made on axial time-of-flight data 
using thresholding. As shown in Figure 5.6A-C, a saturation band placed first proximal then 
distal to the slice of interest was used to verify venous flow for measurements. Cross-sectional 
area of collateral vessels following total IVC occlusion by ligation was more than double that of 
partial occlusion by EIM (Figure 5.6D, D2: 2.3±0.6 mm2 ligation vs. 0.8±0.4 mm2 EIM, D6: 
2.5±0.6 mm2 ligation vs. 0.8±0.3 mm2 EIM, D14: 1.2±0.5 mm2 ligation vs. 0.4±0.2 mm2 EIM, 
D21: 1.1±0.5 mm2 ligation vs. 0.2±0.1 mm2 EIM, ligation vs. EIM overall p<0.05). The cross-
sectional area peaked at day 6 following thrombus induction in both models. In the ligation 
model, cross-sectional area of collaterals at days 14 and 21 were significantly smaller than at day 
6 (p<0.01). In the EIM, cross-sectional area of collaterals at day 21 was significantly smaller 
than at day 6 (p<0.05).  
In both VT models, the thrombus naturally resolves over time, with peak thrombus 
burden at day 2. To determine whether the blood volume diverted to collateral vessels correlated 
with the degree of IVC obstruction at the same time point, a linear regression of collateral cross-
sectional area vs. thrombus volume from both models across time points was performed (Figure 
5.7). The cross-sectional area of all collaterals at a slice approximately 6 mm proximal to the 
iliac bifurcation showed a significant correlation with thrombus volume (R2=0.64, p<0.0001). 
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Figure 5.6 Representative axial time-of-flight image at baseline (A), saturating arterial flow to show venous collaterals (B), and 
saturating venous flow to show arteries (C). D) Collateral vein cross-sectional area from a cross-section taken 6 mm proximal to 
the iliac bifurcation. * denotes difference from the same model at day 6, p<0.05. 
   
 
Figure 5.7 Collateral cross-sectional area correlates with the degree of vessel occlusion (R2 = 0.64, p<0.0001). Data is from two 
models of inferior vena cava thrombosis (partial or total occlusion) at days 2, 6, 14, and 21 following thrombus induction. 
5.5 Discussion 
Using two well-established mouse models of VT, we have quantified the endogenous 
venogenic response to IVC thrombosis through high resolution MOTSA. Three of the four 
collateral pathways previously reported in humans were observed in mice. As in humans, the 
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degree of collateralization correlated with the amount of obstruction [110], [111]. The ligation 
model, which produces a total stasis environment in the IVC and larger thrombi than the EIM, 
had larger collateral vessels at all time-points compared to EIM. In mouse models of VT, the 
thrombus size peaks at day 2 and then gradually decreases as the thrombus resolves and IVC 
blood flow is restored. The number and size of collateral vessels parallels the thrombus 
resolution process, with decreasing collateral presence at days 14 and 21. However, the presence 
of a thrombus permanently alters the vein wall, leading to increased vein wall intimal thickness 
and fibrosis [7]. Thus, restoration of flow attenuates collateral presence but does not eliminate it; 
at least 2 collateral vessels continued to be visible through day 21 in all mice. 
Interestingly, the peak collateral cross-section following total IVC obstruction was more 
than double that of pre-surgical IVC cross-sectional area previously reported in male C57BL/6 
mice of the same age (collaterals: 2.5±0.6 mm2 vs. baseline IVC: 1.12±0.04 mm2) [89]. 
Conversely, peak collateral cross-sectional area following partial IVC obstruction (0.8±0.3 mm2) 
accounted for roughly 70% of baseline IVC cross-sectional area [89]. 
The tortuous path of collateral vessels combined with slower blood flow in veins 
typically makes visualization with non-contrast enhanced MRI challenging. MOTSA overcomes 
some of the challenges of MR angiography by enabling imaging of longer extents of blood 
vessels [126]. The stitching of overlapping slices results in venetian blind artifacts which are due 
to a combination of the Gaussian radiofrequency pulse profile, the motion of blood between 
excitation and echo, and vessel geometry that may be other than the cranial-caudal direction. 
However, our efforts to minimize these artifacts using a slab thickness of 6 mm with 50% 
overlap, optimizing TR and FA for CNR, and acquiring isometric voxels enabled us to resolve 
both small vessels and vessels following a tortuous path. 
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The deep collateral pathway was observed in 7/10 mice via enlargement of the ascending 
lumbar veins. However, the deep collateral pathway in mice reconnected to the IVC through a 
lumbar vein proximal to the thrombus in all cases rather than extending to the azygos and 
hemiazygos veins, a preferential collateral pathway in humans with superior vena cava 
obstruction [113]. C57BL/6 mice consistently have 2 lumbar veins draining into the IVC 
between the left renal vein (which sits lower than the right in mice) and iliac bifurcation. These 
lumbar veins are cauterized in the ligation model, but remain patent in the EIM. As such, the 
deep collateral pathway presents less flow resistance in the EIM compared to the ligation model, 
which supports the observed persistence of this pathway over time in the EIM.  
Interestingly, the deep collateral pathway was present in all mice with at least one lateral 
branch, whereas only 1 of 4 mice with no lateral branches exhibited deep collaterals. Likewise, 
mice with no lateral branches displayed less prominent superficial collaterals. In the anatomical 
variation with no lateral branches, the right gonadal vein connects with the IVC at or proximal to 
the left renal vein, while the left gonadal vein connects with the left renal vein. The gonadal 
veins are the largest pre-existing vessels of the collateral pathways, making venogenesis via the 
intermediate pathway the most prevalent when the anatomical variant did not necessitate their 
interruption during thrombus induction. Conversely, mice with bilateral branches (both gonadal 
veins draining into the IVC between the left renal vein and iliac bifurcation) displayed the most 
prominent superficial collaterals, persisting through day 21 in the ligation model and day 14 in 
EIM (Figure 5.2A-B, green arrowheads). As expected, the portal collateral pathway was not 
observed in these models because the thrombus in both the ligation model and EIM do not 
extend beyond the renal veins, thus the portal vein was not obstructed. The phenotype of a 
possible portal collateral pathway in mice remains to be investigated.  
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Female mice were not used in this study due to an anatomical challenge in C57BL/6 
females; ligation of the right uterine vein, necessary for both models as it drains into the 
infrarenal IVC, leads to necrosis of the reproductive organs [61]. Thus, we would not be able to 
humanely study chronic time points in female C57BL/6 mice. This limitation may be overcome 
through the use of mice from the BALBc background, which often do not have lateral IVC 
branches but rather increased lumbar branches. Differences in collateral patterns between mouse 
strains and the presence and relevance of BALBc collateral pathways to humans remains to be 
investigated.  
In conclusion, three-dimensional renderings of MOTSA data enabled tracking of small 
tortuous veins, and revealed that collateral pattern is influenced by pre-existing anatomy. These 
data support that murine models are relevant tools to study venogenesis, and support the use of 
MOTSA as a tool of choice with which to study this process. Importantly, we have shown that 
the collateral pathways in mice are consistent with those described in humans. Additionally, 
similar to humans, collateralization in mice correlates with the degree of obstruction. This work 
represents the first characterization of the collateral pattern following IVC obstruction in mice, 
which is critical for understanding the pathophysiology in preclinical modeling. This mapping 
may be helpful for researchers to make observations of potential therapeutic effects in mouse 
models. 
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Thrombus Composition by Multiparametric MRI 
6.1 Introduction 
Clinical response to current DVT therapies has large variability due to variation in the 
composition and age of a thrombus. The use of MRI has mainly been limited to diagnosis when 
ultrasound or contrast venography is contraindicated, however, the vast information readily 
attainable by MRI can go beyond diagnosis to provide patient specific information regarding 
thrombus composition, which could be used to model and eventually predict susceptibility to 
different types of treatments.  
The potential of MRI as an interventional tool for DVT is just beginning to be realized. 
One hospital in the Netherlands recently developed their own qualitative classification of 
thrombus age based on gadolinium-enhanced MR venography (MRV) [129]. Their preliminary 
data showed that thrombi they defined as acute by MRV lysed within just over 24 hours by CDT, 
sub-acute thrombi lysed in just under 48 hours, and chronic thrombi showed little or no lysis 
after 3 days [21]. While promising, their qualitative classification is highly subjective; to be used 
as an interventional tool, quantitative metrics are needed.  
Another group applied multiparametric MRI to post mortem human thrombi samples 
imaged ex vivo to compare acute VT to acute/chronic PE and sedimented clots (formed post 
mortem) using T2 and apparent diffusion coefficient (ADC) values. They showed distinct ADC-
T2 2D distributions between the different groups of thrombi, demonstrating the potential of MP-
MRI to assess thrombus structure [130]. However, this study had major limitations such as long 
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scan time (>5 hours), lack of heterogeneity consideration, and they did not show feasibility for 
the in vivo setting where the thrombus is surrounded by blood flow, inflammation, and 
extravascular structures. Further, another study showed similar ADC values in RBC-rich thrombi 
and collagen-rich thrombi [131], which would therefore only enable distinction of subacute 
thrombi and not be clinically informative.  
Saha et al showed that a short T1 is associated with fibrin in the St. Thomas stenosis 
murine VT model, and thrombi with the shortest T1 had the greatest percentage of lysis 
following t-PA administration, as measured by phase contrast MRI [131]. However, similar to 
ADC, the transient nature T1 attenuation limits its potential as a single metric for thrombus 
aging. Perhaps the most promising metric tested to date is magnetization transfer rate, which is 
shown to increase with increasing fibrin and collagen content [64]. When used in combination 
with ADC, which peaks at day 14, Phinikaridou et al showed a sensitivity of 87.5% and a 
specificity of 83.3% at identifying intermediately aged murine thrombi (days 7 and 14).  
These methods share a common limitation – they treat the entire thrombus as a 
homogenous entity with one single identifiable disease stage. On the contrary, thrombi are 
known to be highly heterogenous both spatially within a given patient and longitudinally 
between patients. Multiparametric MRI, commonly used in tumor imaging [132], [133], offers 
the possibility of identifying heterogeneities that are not fully discernible in single-parametric 
assessments.  
6.2 Study Design 
6.2.1 Mouse Models 
DVT was induced in male C57BL6 mice aged 10-12 weeks by either total IVC ligation 
(n=15), or by the EIM (n=15). Each model group was divided into 3 time points of interest: day 
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2, 6, or 14, n=5 each. Mice were imaged at 7T on days 2, 6, or 14 using TOF imaging and 
multiparametric MRI (MP-MRI). TOF imaging enabled distinction of a clear boundary between 
thrombus (filling defect—hypo-intense) and flowing blood (hyper-intense) during thrombus 
recanalization. Mice were sacrificed and thrombi were harvested for histology immediately 
following imaging. Thrombi were harvested with surrounding tissue to maintain anatomical 
landmarks, and fixed sections were cut into proximal, middle, and distal slices for pairing with 
MRI (Figure 6.1). 
 
Figure 6.1 A: Representative MR images of the same location. Dotted white line – thrombus; solid line – aorta (A). B: Following 
imaging, mice were harvested, the thrombus was fixed, and 5 µm sections from 3 blocks were used for histology. 
6.2.2 Multiparametric MRI Methods 
T2*-, T2-, and T1-weighted acquisitions enable the distinction of spatial heterogeneities 
across a thrombus. We decided to use T1-, T2-, and T2*-weighted imaging for three reasons. 
First, these scans are readily translatable to the clinic. Second, contrast agents cannot be used in 
patients with chronic kidney disease, which is becoming more prevalent with the rise of diabetes 
and hypertension, so by not relying on contrast agents we ensure that this method can be used in 
all patients. Third, weighted scans are much faster than proper mapping.  
All MP-MRI acquisitions were acquired with a FOV of 302, a matrix of 2562 zero-filled to 
5122, and 1 mm slice thickness. We used a fast spin echo for the T2-weighted acquisition that is 
sensitive to fluid such as edema and unorganized thrombus (TR/TEeffective 1500/20ms, echo 
spacing 10ms, echo train length 2, NEX 3, ~10min). For T2*-weighting we used gradient echo 
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with a short TE that’s sensitive to structured material and blood products (TR/TE: 200/6 ms, FA 
20º, NEX 4, 3 min 25 sec). For T1-weighting we used a fast spin echo with a short TR that is 
sensitive to trapped proteins such as platelet aggregates which appear bright on T1-weighted 
imaging (TR/TEeffective 200/12 ms, NEX 8, 6 min 50 sec). Red blood cell rich regions also appear 
bright on T1-weighting, but this signal is lost as the red blood cells die and release iron. 
We expected fibrin to appear dark on T2- and T2*-weighted scans due to its highly 
structured nature. As the thrombus remodels to a collagen-rich scar, platelets and RBCs are 
cleared and we expected remaining thrombotic regions to appear dark on T2-, T2*-, and T1-
weighted scans. Platelets form tight aggregates mimicking solid tissue structure, with an 
accumulation of cellular proteins released by the activated platelets and trapped in the platelet 
plug. The trapped proteins shorten the spin-lattice relaxation times causing platelet aggregates to 
appear bright on T1-weighted scans [134]–[136]. RBC-rich regions also demonstrate T1 
shortening due to the accumulation of paramagnetic Fe3+, however the lack of extracellular 
serum in platelet aggregates outweighs the spin-lattice relaxation for clots with hematocrit levels 
up to 60% [135]. As such, there may be differences in signal intensity for RBC-rich regions 
depending on the model used (stasis model compared to EIM blood flow model) as well as the 
organization of the thrombus over time. In high enough concentrations, we expected iron from 
RBCs to result in loss of signal in T2*-weighted images.  
6.2.3 Histology 
Excised thrombi with surrounding tissue were formalin fixed overnight, dehydrated in 
alcohol, paraffin embedded, and cut into 5 µm longitudinal sections. Sections were stained for 
gross anatomy (Hematoxylin & Eosin), collagen (Masson’s Trichrome), and fibrin/red blood cell 
content (Martius Scarlet Blue – MSB). Stained sections were photographed via light microscopy 
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(Nikon, Tokyo, Japan) under 40x magnification. Regions of interest containing the thrombus and 
vein wall were manually traced in ImageJ (NIH) and quantification of each component was 
assessed through color threshold values as previously described [101]. 
6.3 Analysis Methods & Preliminary Findings 
6.3.1 Manual Thresholding of MP-MRI 
First, thresholding techniques were used to assess the individual MRI signals for 
similarities/differences across animals and between models (Figure 6.2), focusing on low T2* 
signal as an indicator of highly structured material and/or the potential entrapment of 
deoxygenating RBCs (average signal intensity in a region of dark thrombus + 2 standard 
deviations = maximum threshold) and high T2 signal as an indicator of fluid related to edema 
(average signal intensity in a region of bright thrombus + 2 standard deviations = minimum 
threshold). 
Thrombus composition varied spatially and temporally. Low T2* signal, indicating 
structured material such as a fibrin mesh or deoxygenating RBCs, was most prevalent at day 2 in 
both models (Figure 6.2 left). Interestingly, thrombi developed under stasis conditions saw a 
sharp decrease in regions of low signal intensity in T2* at days 7 and 14 (Figure 6.2A left), 
whereas thrombi developed under flow saw a more gradual decrease in the amount of low T2* 
signal intensity regions with time (Figure 6.2B left). Thrombi from the blood flow model showed 
low intensity T2* regions through day 14, centered on the site where current was applied to 
activate the endothelium. This suggests that totally occlusive thrombi may begin to remodel 
more quickly compared to thrombi in the presence of blood flow, via deposition of disorganized 
collagen eventually forming a collagen-rich scar. Regions with high T2 signal were more 
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prevalent in the stasis model across time points (Figure 6.2 right), indicating an increased 
inflammatory response in occlusive thrombi. 
 
Figure 6.2 A: Contiguous axial slices were acquired using T2* and T2 MRI. Thrombi (dashed line), shown adjacent to the aorta 
(‘A’, solid line) displayed heterogeneity in signal intensity. B & C: Representative gross anatomy images for each model are 
shown in the center. For each axial slice along the thrombus, the area of low signal intensity in T2* MRI (left) and high signal 
intensity in T2 MRI (right) was measured by thresholding techniques for both the stasis model (B) and the blood flow model (C). 
Time points were compared using two-way ANOVA, * p<0.05. 
6.3.2 Unsupervised Classification 
Rather than assessing each MP-MRI acquisition separately, more information can be 
gained from combining the signals to form a tissue composition map informed by the signal 
 95 
signature from each MP-MRI scan. Thus, we implemented unsupervised classification 
techniques to assign each voxel a classification based on its signal signature from the T1-, T2-, 
and T2*-weighted acquisitions. Thrombi were manually traced with a paired TOF scan to aid in 
defining the boundary between the thrombus and blood flow. Signal intensities from each scan 
were normalized to a mean of 0 and a standard deviation of 1 to enable comparison between 
signals. Normalizing the entire MRI signals from each scan to a uniform mean and standard 
deviation is more objective and consistent than the commonly used method of normalizing to an 
internal reference tissue. A reference tissue, typically back musculature, introduces some level of 
subjectivity based on the size and location of the region chosen for normalization. This would 
also become a time-consuming process with 11 slices x 3 images = 33 regions of interest for 
normalization to be defined per mouse. Additionally, the signal intensities in the three scans are 
vastly different from one another, thus there is a benefit to also normalizing the signal intensities 
to standard deviation of 1, which would not be achieved by normalizing to a reference tissue.  
K Means Clustering 
Initially, a k-means clustering algorithm was used to classify voxels within the thrombus 
into three populations based on the T2 and T2* MP-MRI. Tissue classification by k-means 
clustering further supported that blood flow conditions affect thrombus composition (Figure 6.3). 
The drawback of k-means clustering is that it gives a hard assignment, and updates the 
classification assignment using only the points in the same class with an equal distribution of 
data points in each cluster. Therefore, we decided to move to a different unsupervised 
classification algorithm. 
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Figure 6.3 Representative T2* and T2 MR images (windowed and leveled individually) used for classification in two murine 
models of venous thrombosis at day 2 post induction. Thrombus – green, aorta – white dashed line, scale bar 1 mm. 
Gaussian Mixture Model 
We chose a Gaussian Mixture Model (GMM) because it uses soft classifications and 
updates the classification using all points in the population, which helps express uncertainty. The 
GMM fits a finite number of Gaussian distributions to a set of data, where the outcome is not 
known a priori. In our case, the objective was to fit the model to the MRI intensities to identify 
underlying features and determine whether such features correlated to known composition by 
histology. An expectation-maximization statistical algorithm is used to maximize the likelihood 
that each intensity pair belongs to one of a user-defined number of total clusters.  
We used the Akaike information criterion, or AIC, to determine the appropriate number 
of clusters to use. The AIC is an estimate of the relative quality of a statistical model given the 
data, with a lower the score indicating a better fit. Figure 6.4 shows the AIC score for a given 
number of clusters. There is a clear elbow point at 3 clusters, beyond which there is not much 
improvement in the model thus risk of overfitting the data. Thus, we chose to use 3 clusters for 
probabilistic tissue classification.  
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Figure 6.4 Akaike information criterion (AIC) parameter search scores for the first 15 clusters to reduce the relative information 
lost in the Gaussian mixture model. The circle indicates good options for minimizing AIC without overfitting the model.  
The GMM was applied to n=5 mice per 3 time points (day 2, 6, or 14) in 2 models 
(ligation or EIM), with roughly 11 axial slices through each thrombus for a total of 330 data sets. 
Following GMM classification, a color was assigned for each tissue class and a classified tissue 
map was generated for each slice (Figure 6.5). Stacking the 2D slices in a 3D representation of 
the thrombus emphasize the spatial heterogeneity along the thrombus. Proximal, middle, and 
distal histological sections were manually paired with their approximately corresponding MRI 
slice. It is important to note that the histology is 5 µm thick, whereas each MRI slice is 1 mm 
thick (200x thicker). Hence, the MRI represents an average of what is going on in the general 
region of each histological slice. Despite this limitation, qualitative comparison shows promising 
co-localization. MRI from each time point with the corresponding martius scarlet blue (MSB) 
staining is shown in Figure 6.6. 
 98 
 
Figure 6.5 Schematic representation of GMM workflow. Voxels are classified using a GMM and mapped back to the thrombus 
to form a classified tissue map for each axial slice. 3D stacks of 2D images for the ligation model at days 2, 6, and 14 are shown 
at the right.  
6.4 Results 
The MP-MRI revealed clear differences between the ligation and EIM models. This is 
consistent with ex vivo findings that thrombus composition is dependent on the blood flow 
conditions under which it has formed and resolved. Total stasis resulted in a bulls-eye pattern 
that resolved radially inward, whereas partial occlusion resulted in a binary distribution between 
the site of origin and the (slightly younger) tail of the thrombus. The proximal (tail) end of the 
EIM thrombi more closely resembled the ligation thrombi. 
We observed that the blue tissue class was more prevalent at chronic time points, the red 
tissue class was most prevalent at day 2, and the green tissue class decreased over time. Based on 
this hypothesis, we hypothesized that the blue tissue class may correspond to organized thrombus 
(characterized by collagen content, blue on MSB), red to RBCs (yellow on MSB), and green to 
fibrin (pink on MSB). 
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Figure 6.6 Representative MP-MRI and resulting GMM with paired MSB histology for each time point. 
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Figure 6.7 Ligation and EIM correlation of GMM with histological staining for RBCs (A, D), fibrin (B, E) and collagen (C, F). 
Based on these hypotheses, we assessed the correlation between %GMM tissue class with 
the corresponding composition as a % positive MSB staining across the thrombus and vein wall 
across time points. Although this correlation ignores spatial localization, we found a significant 
correlation in every case. The red tissue class correlated with thrombus rich in RBCs, shown as 
yellow in MSB histology (Ligation: R2=0.35, p<0.01, Figure 6.7A; EIM: R2=0.12, p<0.03, 
Figure 6.7D), while green correlated with fibrin, shown as red in MSB (Ligation: R2=0.17, 
p<0.05, Figure 6.7B; EIM: R2=0.16, p<0.01, Figure 6.7E). The blue tissue class, characterized by 
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MR signals indicating structured material, correlated with collagen content (blue in MSB, 
Ligation: R2=0.14, p<0.05, Figure 6.7C; EIM: R2=0.15, p<0.01, Figure 6.7F). 
6.5 Conclusions 
The MP-MRI framework provides a novel approach to non-invasively determine thrombus 
composition with readily available imaging techniques. This methodology does not require 
contrast agents or long scan times. Classification of the data showed thrombus organization and 
evolution, validated by correlation with histology. This approach provides foundational 
methodology that could eventually be used clinically to provide patient-specific treatment 
planning for DVT, which would improve patient quality of life and reduce the risk of adverse 
events from treatment, including death. An example the application of this methodology to 
treatment planning is shown in Figure 6.8. 
 
Figure 6.8 Schematic of treatment options. Currently, the thrombus age is inferred from the patient’s recollection of symptom 
onset. Treatment selection based on thrombus composition would reduce the risk to the patient. 
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Effects of Spontaneous Exercise on Murine Model of Venous Thrombosis 
7.1 Introduction 
Exercise has tremendous cardiovascular health benefits that have been indicated to be 
safe and beneficial in patients with DVT, yet we lack an understanding of how exercise affects 
thrombus formation and resolution. Exercise and ambulation in patients with DVT have been 
controversial given the historical but never empirically tested narrative that ambulation could 
cause PE. This narrative has since been discredited [137]–[140]. Several recent studies suggest 
that early walking does not increase the risk of PE, may reduce the risk of extensions of proximal 
DVT shortly after diagnosis, and may be associated with less severe post thrombotic syndrome 
[141]–[144]. Given the significant bleeding risks associated with the standard treatment of 
anticoagulation and large variation in response to treatment, understanding the impact exercise 
may play on DVT could open a new avenue of treatment and/or inform treatment practice in the 
case of an athlete or highly active person with DVT.  
In humans, it is well established that the effects of exercise are dependent on duration and 
intensity. Regular moderate exercise is associated with beneficial health effects, whereas 
strenuous prolonged exercise such as in endurance athletes can induce negative physiological 
disturbances. In rodents, studies using forced exercise (treadmill with a motivator such as electric 
shock) have been shown to cause significant stress that may outweigh the benefits of exercise. 
These effects were emphasized in studies of the gastrointestinal microbiome, which showed 
increased inflammatory gene expression, increased morbidity (diarrhea) and increased mortality 
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in mice undergoing forced exercise, while the opposite effect was observed in mice undergoing 
voluntary running wheel exercise [145], [146]. Inflammation plays a key role in VTE, thus stress 
induced exercise could exacerbate the inflammatory response and misrepresent the effects of 
exercise in humans. Therefore, we chose to use spontaneous exercise in the form of in-cage 
running wheels to investigate whether exercise, alone and in combination with standard 
treatment, impacts thrombus composition and resolution.   
7.2 Methods 
All experiments were performed with approval of the University of Michigan’s 
Institutaional Animal Care and Use Committee. 
7.2.1 Experimental Groups and Spontaneous Exercise 
10-12-week old C57BL6 male mice divided into four groups outlined in (Figure 7.1): true 
controls (CC) were not given access to an in-cage running wheel and received no 
pharmacological intervention, exercise controls (EC) were given access to in-cage running 
wheels starting 2 weeks prior to and continuously following VT induction but received no 
pharmacological intervention, the non-running heparin group (CH) received 6mg/kg low 
molecular weight heparin twice daily via subcutaneous injection beginning 4 hours after VT 
induction but had no access to a running wheel, and the exercising heparin experimental group 
(EH) received the same LMWH treatment with running wheel access beginning 2 weeks prior to 
and continuously following VT induction. Mice exposed to a running wheel were singly housed 
to enable individual monitoring of exercise activity. A 2-week acclimation period prior to VT 
induction was chosen because this time period has been demonstrated to induce vascular 
conditioning in wheel-running mice [147]. Because we hypothesized that exercise would lead to 
a reduction in thrombus size (leading to non-occlusive thrombi in humans) and a reduction in 
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circulating inflammatory cytokines, we chose to use the EIM model to enable continuous blood 
flow access to the thrombus.  
 
Figure 7.1 Schematic representation of experimental groups. Exercising mice (EC and EH) had continuous access to an in-cage 
running wheel beginning 2 weeks prior to and continuously following VT induction by EIM. Mice with pharmacological 
intervention (EH and CH) received subcutaneous injections of low molecular weight heparin (LMWH). Within each 
experimental group, mice were separated into three time points of interest (day 2, 6, and 14 following VT induction, n=5 each). 
Day 2 and 6 mice were imaged on days 2 and 6, respectively, prior to harvest. Day 14 mice were imaged at days 2, 4, 6, 11, and 
14 prior to harvest. At harvest, blood was collected via exsanguination, and the IVC with surrounding tissue was collected for 
histology. 
7.2.2 Magnetic Resonance Imaging 
Within each of the four experimental groups, mice were separated into three time points 
of interest representing the harvest time point: day 2 (acute), 6 (sub-chronic), or 14 (chronic) 
following VT induction, n=5 per time point within each group. Day 2 and 6 mice were imaged 
on days 2 and 6, respectively, prior to harvest. For longitudinal data on thrombus resolution in 
the same mice over time, day 14 mice were imaged at days 2, 4, 6, 11, and 14, followed by 
harvest at day 14. 2D contiguous axial TOF images and MP-MRI was acquired as described in 
Chapter 6.2.2.  
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7.2.3 Histology and Immunohistochemistry 
The IVC containing thrombus was harvested with surrounding tissue to maintain 
anatomic landmarks for orienting with image data. Samples were formalin fixed overnight, 
dehydrated in alcohol, paraffin embedded, and cut into 5 µm axial sections at three locations 
along the thrombus: proximal, middle, and distal. Sections were stained by using hematoxylin 
and eosin (H&E) for anatomic detail, Masson’s Trichrome for collagen content, and Martius 
Scarlet Blue for RBC and fibrin content. Percent RBC, fibrin, and collagen content was analyzed 
by thresholding as in a modification of the previously described method [101].   
For immunohistochemistry, non-specific sites were blocked with normal serum. Sections 
were incubated with primary antibodies to Ly6G (1:2000, BD Pharmingen, Catalog # 551458, 
Franklin Lakes, NJ), FSP-1 (1:2000, Millipore, Catalog # 07-2274, Burlington, MA), CD68 
(1:100, Bio-Rad, Catalog # MCA1957, Hercules, CA), or CD41 (1:100, Santa Cruz, Catalog # 
Sc-6602, Dallas, TX). A species-specific ABC peroxidase kit (Vector Laboratories Inc., 
Burlingame, CA) was used according to the manufacturer’s instructions for the corresponding 
secondary antibody and subsequent steps. Color development was performed with 
diaminobenzidine (DAB). Images were captured using light microscopy (Nikon, Tokyo, Japan) 
under 40x magnification and quantification of percent positive staining was performed as 
previously described [101]. 
7.2.4 Circulating Inflammatory Cytokines 
At harvest, blood was collected via exsanguination by cardiac puncture and incubated 
undisturbed at room temperature for at least 20 minutes. Samples were then centrifuged at 4 °C 
for 10 min at 3000 rpm, and blood serum was extracted and stored at -80 °C. Standard enzyme-
linked immunosorbent assays (ELISAs) for IL-6 (from Abcam, Cambridge, MA), IL-1b, TNFa, 
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and CRP (from R&D Systems, San Diego, CA) were used to measure blood serum levels of each 
circulating inflammatory cytokine according to manufacturer’s instructions.  
7.3 Results 
7.3.1 Exercise Reduces Thrombus Size 
Of the 37 mice exposed to an in cage running wheel, 6 did not engage in any spontaneous 
exercise activity. These mice were assigned to non-exercise groups. Mice that did use the in-cage 
running wheel averaged just under 1 km of running per day in the 2 weeks before VT induction, 
and 300 m per day following VT induction (Figure 7.2). We were initially unsure whether mice 
would run at all following surgery, so although they had reduced activity, these results show 
promise for the use of spontaneous exercise as a therapeutic following VT induction.  
 
Figure 7.2 Average daily exercise activity in 31 mice before and following VT induction. 
 Exercise reduced thrombus size at initiation and throughout thrombus resolution (Figure 
7.3). As expected, thrombus volume was significantly reduced compared in mice treated with 
LMWH (CH and EH) compared to those receiving no pharmacological intervention (CC and 
EC) across time points. Interestingly, there was a trend of decreased thrombus volume across 
time points with exercise compared to the non-exercising control group. Exercise significantly 
reduced thrombus volume at day 11 compared to non-running controls (EC vs CC, p<0.05). 
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Further, from day 6 onwards, thrombus volume in EC mice were not significantly different from 
the CH group, indicating that by chronic time points, exercise approaches the effectiveness of 
LMWH at reducing thrombus volume. EH mice had a smaller thrombus volume compared to CH 
mice across time points, although these groups were not significantly different from one another.  
 
Figure 7.3 Thrombus volume measured by MRI. AT day 11, thrombus volume was significantly reduced with exercise, p<0.05. 
CC – true control; EC – exercise; CH – low molecular weight heparin (LMWH); EH – exercise + LMWH. Day 2, 11, and 14 
have n=5 per group; days 2 and 6 have n=10 per group.  
7.3.2 Impact of Exercise on Thrombus Composition 
Neutrophils are the main leukocytes observed in acute VT, with a transition to monocytes 
in chronic VT. Neutrophils were observed in all groups at day 2. We found that exercise reduced 
neutrophil recruitment in acute VT in mice not receiving LMWH (Figure 7.4). Neutrophil 
content was not different in mice treated with LMWH (with and without exercise) compared to 
true controls.  
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Figure 7.4 Neutrophil content as measured by Ly6g immunohistochemistry (IHC) with representative IHC and binary image of 
positive staining from each group. Binary images are enhanced for clarity – positive stain regions appear larger than the true 
amount. CC – true control; EC – exercise; CH – low molecular weight heparin (LMWH); EH – exercise + LMWH. * = p<0.05. 
At day 2, the thrombus is largely composed of fibrin and entrapped RBCs. Exercise 
alone, but not coupled with anticoagulants, increased fibrin content in acute VT (Figure 7.5A). 
RBC content did not differ between groups (Figure 7.5B). At day 6, exercise tended to increase 
fibrin content in both treated and untreated groups, although this effect was not statistically 
significant (Figure 7.6A). LMWH alone decreased RBC content compared to CC and EC, but 
was not reduced in exercising LMWH treated mice (Figure 7.6B). 
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Figure 7.5 Day 2 percent fibrin (A) and red blood cell (B) content as measured from Martius Scarlet Blue stain and 
representative histology images from each group. Fibrin is stained pink, RBCs yellow, and collagen blue. CC – true control; EC – 
exercise; CH – low molecular weight heparin (LMWH); EH – exercise + LMWH. * = p<0.05. 
 
Figure 7.6 Day 6 percent fibrin (A) and red blood cell (B) content as measured from Martius Scarlet Blue stain and 
representative histology images from each group. Fibrin is stained pink, RBCs yellow, and collagen blue. CC – true control; EC – 
exercise; CH – low molecular weight heparin (LMWH); EH – exercise + LMWH. * = p<0.05.  
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 In chronic VT, the thrombus organizes into a collagen rich thrombus that becomes 
incorporated into the vein wall. At day 6, collagen content in the vein wall and thrombus was 
greatest in non-exercising mice treated with LMWH (CH mice, Figure 7.7A-C). However, the 
opposite trend was observed in the thrombus at day 14 (Figure 7.7F), suggesting that LMWH 
hastens thrombus organization causing sub-chronic thrombi to resemble chronic thrombi. 
However, exercising mice receiving LMWH did not differ from true controls in collagen content 
at either time point. The groups did not differ in vein wall thickness, taken as the average of five 
measurements of the vein wall (data not shown).  
 
Figure 7.7 Percent collagen content in thrombus and vein wall (A, D) or thrombus only (C, F) with representative histology 
images from each group (B, E) at days 6 and 14 as measured from Masson’s Trichrome stain (collagen = blue). CC – true 
control; EC – exercise; CH – low molecular weight heparin (LMWH); EH – exercise + LMWH. * = p<0.05, *** = p<0.001. 
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 Fibroblasts are the precursor to collagen. We measured fibroblast content by fibroblast-
specific protein-1 (FSP-1) IHC. At day 6, FSP-1 expression tended to decrease with exercise 
compared to the control group under the same treatment conditions, although this decrease was 
not significant (Figure 7.8A). At day 14, the opposite trend was observed, although again not 
significant (Figure 7.8B). LMWH decreased fibroblast expression in both CH and EH groups 
compared to EC, but not compared to CC mice.  
 
Figure 7.8 Fibroblast content as measured by immunohistochemistry (IHC) for FSP-1 at day 6 (A) and 14 (B) with representative 
IHC from each group. CC – true control; EC – exercise; CH – low molecular weight heparin (LMWH); EH – exercise + LMWH. 
* = p<0.05, *** = p<0.001. 
7.3.3 Impact of Exercise on Circulating Inflammatory Cytokines 
TNFα, CRP, and IL-6 are inflammatory cytokines known to be elevated in DVT [7], [19], 
[148], but decreased in healthy patients undergoing an exercise regimen [149]. We hypothesized 
that exercise would lead to a reduction in circulating inflammatory cytokines. At day 2, TNFα 
was elevated in EH mice compared to CH (p<0.05), but tended to decrease at days 6 and 14 
(Figure 7.9A). In the untreated groups, TNFα tended to increase with exercise across time points, 
although this trend was not significant. LMWH groups had significantly decreased TNFα at day 
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6 compared to both non-treated groups. No significant trends were observed with CRP (Figure 
7.9B). LMWH decreased serum IL-6 expression in CH mice compared to CC and EC mice at 
day 2 (p<0.01), in both LMWH groups compared to CC and EC groups at day 6, and in both 
LMWH groups compared to EC at day 14 (Figure 7.9C). 
 
Figure 7.9 A) Circulating tumor necrosis factor alpha (TNFα) was elevated with exercise at day 2, but showed a decreasing trend 
with exercise at day 6 in both control and LMWH treatment groups and the LMWH group at day 14. B) Circulating C reactive 
protein (CRP) was not significantly different between groups at any time point. C) Interleukin-6 (IL-6) was significantly reduced 
with administration of LMWH but was not significantly different with exercise. CC – true control; EC – exercise; CH – low 
molecular weight heparin (LMWH); EH – exercise + LMWH. * = p<0.05. Significance bars only shown comparing exercise 
group to its treatment control group (i.e. CC vs EC and CH vs EH); all other comparisons denoted with asterisk colored by group 
of comparison.   
7.4 Discussion 
We have quantified the impact of spontaneous exercise—alone and coupled with standard 
anticoagulation treatment—on thrombus resolution and composition in a preclinical blood flow 
model of VT. Exercising mice showed a trend of reduced thrombus size across time points, with 
significantly reduced thrombus volume at day 11 in non-treated exercising mice compared to 
true controls. In chronic time points, thrombus volume in non-treated exercising mice was not 
significantly different from mice treated with LMWH, indicating that exercise has beneficial 
effects on thrombus resolution.  
Exercise in non-treated mice attenuated local inflammation (neutrophil content), but not 
circulating inflammatory cytokines. However, due to limitations in the amount of blood collected 
from cardiac puncture, preliminary results of circulating inflammatory cytokines are limited by 
small numbers in some cases and will require further studies to determine significance. Exercise 
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alone increased acute fibrin content and reduced sub-chronic collagen content. Together, this 
indicates the exercising individuals may respond better to thrombolytic therapy when timed 
appropriately. However, this effect was reversed in chronic thrombi, where the remaining 
thrombus in LMWH treated mice had significantly less collagen content compared to treated 
exercising mice. Increased fibroblast content compared to LMWH treated mice at day 14 
indicates that untreated mice will become more collagen rich at more chronic time points, 
although differences with exercise were not observed.  
The large variability in exercise activity between mice serves as a major limitation of this 
work. Exercising mice in our study ran slightly less compared to a previous study in which 
C57BL/6 males of the same age ran average of 2-3 km per day on the same type of setup [150]. 
Another study reported significantly more running activity (averaging 8-10 km per day) with an 
angled running track instead of a running wheel [151]. Future studies may benefit from 
switching to an angled running track for increased running activity, particularly following 
exercise. Due to the shape of the running wheel, mice must arch their back, a position which 
increases tension on their incision site (see Figure 7.10). Therefore, the angled running track (in 
which the mice maintain a neutral spine) may be more comfortable for post-surgical mice to use.   
 
Figure 7.10 Picture of a mouse using the in-cage running wheel. White line shows curvature of the spine required to use the 
wheel, which increases tension on incision site. 
If post-surgical activity increased with this method, it may be possible to parse out 
differences in prophylactic exercise compared to therapeutic exercise. We were not able to 
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separate the two in this study due to the time needed for mice to acclimate to the running wheel 
and significantly reduced activity following surgery. To account for the large variation in 
exercise activity, further studies could separate mice into running performance groups based on 
pre-surgical exercise to allow comparison between mice from different time point groups. 
Classifications could consist of high performance (>20 km), medium performance (10-20 km), 
and low performance (<10 km).  
In conclusion, this work represents the first basic science study of exercise on VT. We 
found that exercise reduces thrombus size and contributes to thrombus resolution. Additionally, 
exercise increases acute fibrin content, attenuates local but not systemic inflammation, and 
decreases sub-chronic collagen content in pharmacologically treated mice. Understanding the 
impact exercise may play on DVT could open a new avenue of treatment and/or inform 
treatment practice in the case of an athlete or highly active person with DVT. These findings 
support clinical findings that exercise is beneficial rather than harmful to patients, and provides 
insights on the compositional changes that result from exercise activity. 
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Conclusions 
8.1 Scientific Contributions 
This work provides five contributions to the field of venous thrombosis research. The first 
three contributions directly impact preclinical model research, which are critical to advancing 
our understanding of DVT and the development of new treatment approaches and therapeutics. 
The third and fourth contributions have translational implications, with the potential to contribute 
to patient-specific treatment planning in DVT.  
8.1.1 First In Vivo Characterization of the Murine Venous System 
Previous studies of the venous system had focused on ex vivo measurements under supra-
physiological conditions. Using MRI, we noninvasively quantified the cross-sectional area, 
cyclic strain, and circularity of the venous system in young and old, male and female C57BL/6 
mice at five locations (PMID: 28865773). This work provided a foundation for drawing age and 
sex comparisons in disease models, provided physiologically relevant parameters to inform 
computation models, and represents the first in vivo characterization of the murine venous 
system at rest and during the application of a pharmacological exercise surrogate. These results 
are important for providing a greater understanding of the biomechanics of the venous system. 
8.1.2 First Model Selection Algorithm 
Prior to 2019, researchers hoping to use a mouse model of VT had no set of guidelines 
for selecting or implementing an appropriate model. Variation in surgical technique and major 
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modifications to existing models confounded comparisons between labs and created ambiguity 
for investigators, manuscript reviewers, and grant reviewers alike. I had the opportunity to work 
with the American Venous Forum’s Animal Model Task Force on developing the first consensus 
on mouse models of VT (PMID: 30786739). After compiling information on each animal model 
and gathering statistics and metrics for surgical technique validation, I developed the first model 
selection algorithm to guide researchers in selecting a model appropriate for their specific 
research question, which also suggests relevant secondary models to explore the research 
question in more than one setting. With the help of Dr. Diaz, the proposed algorithm was readily 
supported by the co-authors, all experts in animal models of VT. This tool will help 
investigators, manuscript reviewers, and grant reviewers understand the most appropriate 
primary and secondary model options for basic science investigations of VT.  
8.1.3 Improvements to VT Model Surgical Equipment and Characterization 
The EIM was originally developed in 2009, using equipment that was subsequently 
discontinued. Thus, when I began preparing to implement the EIM, I encountered a problem that 
had prevented several other researchers from moving forward with this valuable model. The only 
options in the U.S. were to purchase old equipment off eBay (which I and others have tried and 
found to be unreliable). Therefore, I developed an equipment alternative by constructing a 
standard voltage to current converter circuit powered by a direct current power supply, which 
offered the added benefit of significantly reducing costs. This validated method, along with a 
characterization of the current and time dependency of the EIM and natural history of the 
fibrinolytic system under flow conditions, offered a much-needed update on the EIM (PMID: 
30046728). Since publishing this update, I have helped three other labs implement this 
equipment, enabling broader use of the EIM.  
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Characterization is fundamentally important for both consistencies in preclinical models 
and outlining the translational ability of a given model. MRI enabled two important 
characterization insights that would not have been possible with ex vivo or ultrasound studies. 
First, I demonstrated that leaving branches uninterrupted causes blood flow reversal, the cause of 
thrombus size variability in a proposed modification to the IVC ligation model. Second, I used 
high resolution MOTSA to quantify the endogenous venogenic response to IVC occlusion in two 
models of VT. This study showed that collateral vein patterns are influenced by pre-existing 
anatomy, collateralization correlates with the degree of occlusion, and importantly, venous 
collateral patterns in C57BL/ mice are consistent with those observed in humans.  
8.1.4 Foundational Methodology for Determining Thrombus Composition 
Successful treatment of DVT depends on the components present in the thrombus at the 
time of treatment, a composition which changes significantly over time. Currently, thrombus 
composition is inferred from the duration of symptoms, a metric that is inherently unreliable and 
is not able to account for heterogeneity within the thrombus or differences between patients. We 
developed a multiparametric MRI approach using readily translatable sequences that shows 
correlation with RBC, fibrin, and collagen content – important components for determining 
susceptibility to thrombolysis. This work provides a foundational methodology that could 
eventually enable physicians to determine regions amenable to thrombolysis, which would 
improve patient quality of life and reduce the risk of adverse events from treatment, including 
death.  
8.1.5 First Basic Science Study of Exercise in VT 
There is growing interest on the use of exercise as a treatment for cardiovascular disease, 
punctuated by the recent approval of supervised exercise therapy as a treatment for peripheral 
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artery disease. Small clinical trials have shown exercise to be safe and beneficial to patients with 
DVT, yet little is known regarding how exercise affects thrombus formation and resolution. We 
conducted what is to our knowledge the first basic science study of the impact of exercise on VT. 
Our study looked at exercise alone, and in the clinically relevant scenario of exercise coupled 
with the standard treatment of LMWH. Using an in-cage running wheel, our results show that 
spontaneous exercise – both alone and in combination with standard treatment – reduces initial 
thrombus size and contributes to thrombus resolution. We found that exercise increases acute 
fibrin content, attenuates local inflammation but not circulating inflammatory cytokines, and 
decreases sub-chronic collagen content in pharmacologically treated mice. These findings 
support clinical findings that exercise is beneficial rather than harmful to patients, and provides 
insights on the compositional changes that result from exercise activity. 
8.2 Future Directions 
We found that age and sex impact the naïve murine venous system, but did not have the 
chance to investigate the role of age and sex on thrombus composition and treatment response. 
Age is a known risk factor for DVT, and studies have shown that thrombus resolution is 
impaired in aged mice [152]. Additionally, there are known sex differences in risk factors for 
DVT, yet preclinical studies focus almost exclusively on male mice. One study found that male 
mice had increased thrombotic potential [61], but this study was crucially flawed. As discussed 
in Chapter 3.1.5, interrupting the right uterine vein in female mice leads to necrosis of the 
reproductive organs. To avoid necrosis, the authors of this study interrupted all side branches in 
male mice but left branches open in female mice. I have shown that leaving branches 
uninterrupted is the source of thrombus size variability, thus the results of this paper may solely 
be the result of the sex-based modification of the model rather than true sex differences. Sex-
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based differences in preclinical models remain uncertain. The limitation of branching vessels in 
female mice could be overcome by the use of the BALBc strain, in which males and females 
have more back branches but no side branches in the segment of the IVC between the left renal 
vein and the iliac bifurcation. Understanding potential sex differences in thrombus composition 
could have important clinical implications in the treatment of DVT. 
The study of aged mice may be especially important for understanding the impact of 
exercise because the majority of DVT patients are over the age of 50. Mice continually add body 
weight as they age, thus exercise studies on aged mice would need to switch to an angled running 
track because the larger old mice cannot readily fit inside a running wheel (see Figure 8.1). 
Studies have shown young C57BL/6 mice run significantly farther on angled running wheels, 
and this increased activity without the arched back tension on the incision site may enable 
studies on exercise as a therapeutic compared to a prophylactic.  
 
Figure 8.1 An aged mouse (over 1 year old) checking out the in-cage running wheel. Aged mice become too large to be able to 
fit onto an in-cage running wheel. 
 The exercise studies were conducted using the EIM. Basic science findings are strongest 
when supported by data from more than one model. Repeating this study using the ligation 
model may show stronger differences between groups, particular in fibrosis and vein wall 
thickness as the vein wall is much more involved in the thrombotic process in the ligation model. 
Additionally, MP-MRI was performed on all mice in the exercise study, thus future studies could 
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use this data to test the GMM framework on detecting composition differences under different 
treatment conditions.  
8.3 Translational Potential 
We have designed a method for non-invasive determination of thrombus composition to 
facilitate ease of clinical translation. The MP-MRI sequences are readily available and thus 
avoids potential issues of dealing with specially coded sequences on different scanner systems. 
The MP-MRI is faster than parameter mapping and does not require the use of contrast agents, 
thus is accessible to all patients able to undergo MRI scanning. Our GMM results have shown a 
general correlation with known composition, but this correlation does not consider spatial 
localization of each component. We are working on developing co-localization techniques to 
ensure the validity of this correlation. If successful, this method could be implemented in human 
studies.  
The impact of exercise on DVT has two potential translational implications. First, basic 
science evidence can provide information on the mechanisms under which exercise influences 
thrombus resolution, which helps to counter the historical resistance to ambulation following 
diagnosis. Second, composition differences in exercising subjects could implicate a modified 
treatment regimen for athletes or people undergoing regular cardiovascular exercise diagnosed 
with DVT.  
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Appendix 1:  Detailed Surgical Procedures 
1.1 Surgical Preparation and Approach 
Mice are anesthetized in a small anesthetic induction chamber using isoflurane at 5% and 
an oxygen flow rate of 500 mL/mn. Once the animal is at a respiration rate of approximately 1 
breath every second, it is removed from the chamber, weighed, and the animal’s abdomen hair is 
shaved and/or removed using a hair removal lotion (I prefer to use both methods). Then the 
animal is transferred to a nose cone atop a heating pad, in a dorsal recumbent position, and the 
oxygen flow is reduced to 200 mL/mn at 2%. The animal’s shaved abdomen is wiped (cranially 
to caudally) with appropriate cleaning solutions (such as chlorhexidine or betadine in 
combination with alcohol wipes).  A midline laparotomy is performed using iris scissors—not a 
blade—to ensure that only the skin is incised. The muscle layer is opened along the linea-alba to 
reduce pain/bleeding, and a Fine Science Tools (FST) retractor system or small internal 
abdominal retractor/eyelid retractor is placed to keep the abdominal cavity opened. To allow for 
easy visualization of the IVC, the intestines are exteriorized and placed on a sterile saline 
moistened 2x2 inch gauze pad to the animal’s left, with an additional moistened gauze pad 
placed over the bowel. The surgery should then proceed as follows depending on the model. 
1.2 Ligation Model 
The fascia tissue on either side of the IVC is dissected using straight jeweler’s forceps. 
Dissection is performed carefully, as grabbing the IVC alone may result in puncture. Small, 
controlled movements should be utilized when dissecting. Once visualized, all lateral branches 
are ligated with nonreactive 7-0 Prolene suture, slightly away from the IVC (approximately 1-2 
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mm), taking caution to avoid damaging the nerves that run parallel to the IVC on either side. 
Using a cotton swab to roll the IVC if accessing from animal’s right side (usually more 
accessible), or straight forceps if accessing from animal’s left side, posterior venous branches are 
cauterized using a Bovie low temperature fine tip cautery pen (MFI Medical Equipment, Inc; San 
Diego, CA). Slight compression with the cotton swab should be applied to collapse the posterior 
branches prior to cauterization to prevent bleeding. Gentle maneuvers when handling the IVC are 
strongly recommended. 
Dissection between the IVC and aorta is then performed immediately below the left renal 
vein, usually within a window of 1-3 mm below where the left renal vein enters the IVC. The 
gap between the IVC and aorta is used to create a path underneath the IVC, and a 7-0 Prolene 
suture is passed through and tied down onto the IVC as close as possible to the left renal vein. 
Silk or nonreactive nylon/polyprolene sutures sized 4.0-7.0 may also be used. Dilation of the 
IVC is immediately observed. After the retractors are removed, the intestines are moistened and 
placed back into abdominal cavity. The abdomen is then closed with a continuous stitch using 3-
0 Vicryl for the muscle layer, and the skin is closed with tissue glue.  
1.3 EIM 
1.3a Supplies Needed 
If using the voltage to current converter described in Chapter 4, the following provides a 
list of equipment needed for the surgery and for construction of the voltage to current converter. 
Sample vendors and product numbers are provided as one option, however, other vendors or 
products could also work. 
General surgery equipment 
• Microscope & micro-surgical instruments 
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• Heating pad 
• 7-0 Polyprolene for ligating side branches 
• 5-0 Vicryl for closing the muscle (and skin if not using Vetbond) 
• Vetbond for closing the skin 
• Eye ointment to protect mouse’s eyes during surgery 
• Sterile saline   
• Magnetic fixator retractor system – Fine Science Tools, Catalog No. 18200-20 
Supplies for making EIM needle 
• 30-gauge insulated copper wire – DigiKey, Part No. K617-ND 
• 25-gauge needles – Fisher, Catalog No. 14-826AA 
• Alice Clamp 
• #11 blade  
VIC-specific equipment 
• Triple output DC power supply – Bell Electronics, E3630A 
• Multimeter that can read µA – Lowe’s Item # 447115 (cheaper option) or Digikey part 
No. 614-1042-ND 
o Alligator clips to connect multimeter to circuit (ensure compatibility with your 
mulitimeter leads) – Amazon Part No. a15042900ux0086 or AliExpress Model 
No. sh-255  
• Operational amplifiers – need one of each (total of 2 op amps) but can order larger 
quantities for replacements. I’ve found the circuit to last 2 years. 
o AD620 - DigiKey, Part No. AD620BN-ND 
o UA741CP (DigiKey Part No. 296-11107-5-ND) or AD705  
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• Breadboard - Digikey Part No 1286-1062-ND 
• Banana plug probe cables (4 cables total, so buy n=2 sets) - Grainger Item No. 4XKX1 
• Resistors – as most resistors can only be bought in bulk (1000 or more), we recommend 
buying a kit – Amazon Model No. Top-cofrLD008 
o 40 kΩ resistor (somewhere close to this range will suffice) 
o 100 Ω resistor (somewhere close to this range will suffice) 
1.3b Surgical Preparation 
Prior to surgery, equipment should be prepared as follows. The EIM needle is prepared 
by cutting a 25-gauge needle to a length of 0.5 cm using a #11 blade and scoring the needle 
completely around until it is broken cleanly (no sharp edges and without decreasing the lumen of 
the needle). A 30-gauge silver-coated copper wire is measured to a length of approximately 20 
cm, and the coating is stripped off on each end (0.3 cm off one end, approximately 2 cm of the 
other end). The 0.3 cm stripped wire end is inserted into the blunt end of the 0.5 cm 25-gauge 
needle, which is held in place using alligator forceps. A needle holder is used to clamp the needle 
onto the wire to secure it. The 2-cm end of the stripped wire is attached to a positive anode of a 
constant current machine. The needle is bent, bevel facing up, at 60-70° from the wire (less than 
90° to avoid slipping out of the IVC, so that upon insertion the needle will be angled upwards 
along the anterior vein wall). A second piece of copper wire of the same length is prepared with 
the shorter stripped end bent into a small hook to be inserted into subcutaneous tissue. This 
second wire is connected to the negative terminal of the constant current source. 
1.3c Surgical Procedure 
Mice are prepared and surgery is initiated as described above. If lateral branches draining 
into the IVC are present, the immediately surrounding fascia tissue should be carefully dissected 
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and a nonreactive 7-0 Prolene suture used to ligate the lateral branches. Care should be taken to 
avoid damaging the nerves that run parallel to the IVC on either side. To better visualize the iliac 
bifurcation, a moistened cotton tip broken off a cotton swab (without any rough edges) may be 
used as a laparotomy pad for bladder and seminal vesicles, held in place with FST retraction to 
keep these tissues from touching the IVC during the procedure. The copper wire is bent into an 
upside down “U” shape and taped such that the needle lies directly on top of the distal IVC, with 
care taken to avoid poking the IVC with the needle. The hook end of the second wire is inserted 
into subcutaneous tissue near the proximal end of the abdominal incision.  
Next, the EIM needle connected to the anode is inserted into the IVC at the level of the 
lymph node just proximal to the iliac vein bifurcation. To accomplish this, a cotton swab is used 
to press on the IVC just below the left renal vein prior to needle insertion in order to dilate the 
IVC to prevent sticking the needle through the back of the IVC. A needle driver or forceps is 
used to hold the wire by the base of the needle to insert into the IVC, keeping the needle parallel 
to the vessel, taking care not to insert the needle all the way to where the needle meets the wire 
(insert approximately 90%) as this can increase the risk of bleeding. The inserted needle is 
elevated in order to contact the ventral surface of the IVC. This elevation can be accomplished 
by taping to a fixed structure such as the microscope, or through construction of a stable hook. 
A direct current of 250 µA is applied over 15 minutes, which will produce a large 
thrombus from the iliac bifurcation extending to approximately the left renal vein by day 2. If 
modifying current or time to achieve a different thrombus size, these modifications should 
decrease one or both of these parameters, as higher current or longer application may result in 
paralysis. 
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The direct current generates free radicals in the copper wire, which results in endothelial 
cell activation. Saline is intermittently dripped into the abdomen while the current is being 
applied, and the brightness of the microscope is reduced to diminish tissue desiccation. Dark 
spots should become visible surrounding the needle during current application, indicating 
successful thrombus formation. Following electrolysis, the negative wire is removed first, and 
sterile saline is applied to the IVC around the anode needle to ease the removal process. While 
gripping the wire with a needle driver, small up and down motions should be used to release the 
needle from the anterior IVC wall before removal. Light or minimum pressure is applied to the 
insertion site without compressing the IVC following removal of the EIM needle. A laminar 
thrombus (visible during current application) forms immediately with maintenance of a flow 
channel and a solid thrombus can be harvested beginning at 2 hours following induction, 
depending on the mouse strain. The cotton tip is removed from the bladder area, and the 
intestines are moistened and placed back into the abdominal cavity. The muscle layer is closed 
with a continuous stitch using 3-0 Vicryl, and the skin is closed with tissue glue. 
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Appendix 2:  Harvest Procedures 
2.1 Harvest for Histology 
The surrounding tissue, including the back musculature and aorta, serve as valuable 
anatomical landmarks in histology. As such, when harvesting for histology, it is most useful to 
harvest a block of tissue rather than only the infrarenal segment of the IVC. With the mouse 
under deep anesthesia, use scissors to cut a line parallel to either side of the IVC into the back 
musculature, approximately 3 mm on either side of the IVC. It is best to cut the sides first so that 
you can see where you are cutting before the cavity fills with blood. Next cut horizontally across 
the iliac veins, approximately 2 mm below the bifurcation (or where you guess the bifurcation to 
be), and hold onto that bottom part of the IVC with forceps (so you don’t lose it in the pool of 
blood) while you make a horizontal cut near the left renal vein. If harvesting a thrombus from the 
ligation model, the top cut is straightforward – above the ligature site. If harvesting a thrombus 
from the EIM, be sure that you capture the top of the thrombus, which may extend a bit farther 
proximal from the left renal vein, in which case I like to angle the scissors to snip both the left 
renal vein and the segment of the IVC with thrombus at once.  
While still holding the distal end of the thrombus/back muscle in your forceps, carefully 
cut underneath the thrombus to release the back musculature, keeping the scissors as close to the 
spine as you can. Once the block of tissue is entirely cut loose from the mouse, place it in 
formaldehyde (Formalin) overnight, followed by ethanol.  
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2.2 Harvest for Thrombus Weight 
When harvesting for thrombus weight, the IVC must be carefully separated from the 
aorta and surrounding tissues. Separating the IVC from the aorta can be very difficult, especially 
at chronic time points. It is easiest to start by separating the IVC from the back musculature by 
passing forceps underneath both the IVC and aorta and opening the forceps slowly, moving 
proximal/distal to separate the entire infrarenal segment of the IVC from back musculature. The 
lumbar veins may need to be snipped if this process does not separate them by itself. If the 
lumbar veins are enlarged, wait to snip until after separating the aorta so that you can see what 
you’re doing. Next, separate the lymph nodes that sit on the IVC near the iliac bifurcation. The 
lymph nodes may be separated following IVC removal, but it is often easier to do while still in 
the body.  
Next, clasp the aorta with forceps, and using separate forceps, poke and open another pair 
of forceps on the fascia between the two vessels. Once a window is created between the aorta 
and IVC, pass closed forceps through and let them open, moving proximal/distal to widen the 
window. Once separated, cut the IVC with thrombus out by making a horizontal cut just distal to 
the iliac bifurcation, and another at the proximal end of the thrombus (above ligature for ligation 
model, at left renal vein or just above where thrombus ends if it extends farther proximal in the 
EIM). If harvesting a thrombus from the ligation model, the ligature may be used as a grabbing 
point to hold onto the IVC for separation procedures (although use caution because sometimes it 
comes off). If the aorta breaks in half during separation (common), carefully peel it away from 
the vessel however possible (before or after cutting the IVC) out. 
Once removed, weigh the IVC (with thrombus) on a microscale capable of reading ~3-60 
µg. This weight is referred to as the thrombus weight. The thrombus may be subsequently 
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separated from the IVC for separate weighing or for q-RT PCR analysis. To separate at acute 
time points, clasp one end of the IVC with one forceps, and use another closed bent forceps to 
squeeze the thrombus out of the IVC. At chronic time points, the IVC may need to be carefully 
cut open under a microscope for scraping removal of the thrombus (very difficult).  
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Appendix 3:  Note on Leg Edema in Murine Models 
 
Leg edema is a primary indicator of DVT in humans, yet the presence or potential 
importance of leg edema in quadruped models had not previously been considered. Nonhuman 
primates are the only semi-upright model available for studying VT, but there are significant 
disadvantages of nonhuman primates including ethical considerations, cost, and the need for 
highly trained personnel. Lower limb edema is used as a clinical indicator of deep vein 
thrombosis, yet edema had not been a focus in animal models. We examined lower limb edema 
over time in the ligation model to address whether quadrupeds exhibit leg edema as a clinical 
feature.  
Multiple axial slices were acquired through the lower limbs using a fast spin-echo 
sequence (TR: 2700 ms, TEeff: 20 ms, FOV: (40 mm)2, matrix 2562 zero-filled to 5122 for an in-
plane resolution of (78 µm)2, NEX: 3, slice thickness: 1 mm). Three consecutive axial slices of 
the calf located 4 mm below the knee were used to quantify calf volume using a threshold value 
of half the signal intensity in muscle (MRVision, MA). Over the same segment of leg, changes in 
the MRI signal itself were quantified using identical sequence parameters but with a 180° 
inversion preparation RF pulse (TI: 300 ms) to eliminate the signal from fat and highlight fluid 
accumulation in the musculature of the lower limbs. In this case, images were quantified using a 
threshold value of three standard deviations above mean muscle signal intensity (Figure A.1). 
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Figure A.1 Multiple 1 mm contiguous axial slices were acquired to encompass the calf region (A and B) using a fast spin-echo 
sequence. A 180° inversion preparation RF pulse was used to highlight fluid accumulation, measured using a threshold of three 
standard deviations above mean muscle signal intensity (C, blue). 
The calf volume decreased at days 2 and 4 post-surgery (Figure A.2, line; pre-surgical 
volume 154.3 ± 13.5 mm3; day 2 134.7 ± 15.8 mm3, p<0.05; day 4 135.8 ± 13.7 mm3, p<0.05) 
and returned to pre-surgical volume by day 7. VT-associated lower leg edema was observed in 3 
of the 5 mice, displaying the most edema between days 1 and 4 (Figure A.2, bar). By day 14, the 
MRI signal associated with edema was consistently smaller than pre-surgical values, but this 
difference did not reach statistical significance. Reduction in leg volume may be attributable to a 
loss of muscle mass associated with weight loss and decreased activity following surgery. Mice 
that did not demonstrate leg edema may have a larger network of collateral vessels develop early 
on. Interrupting the largest abdominal vein (IVC) resulted in leg edema in 3 of 5 mice. This 
confirms for the first time that quadruped models can display clinical features of venous 
thrombosis, but that lower limb edema is not consistent in this population size as is observed in 
humans.  
 
A B
 
C 
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Figure A.2 Murine calf edema (bar) and total calf volume (line) as measured by MRI before surgery, and days 1, 2, 4, 7, and 14 
following induction of VT using the IVC ligation model (n=5; mean, standard deviation; * denotes differences from pre-surgical 
volume of p<0.05). 
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